


On the epigenetic ageing clock in humans



Daniel Elías Martín Herranz

European Bioinformatics Institute (EMBL-EBI)
University of Cambridge

This dissertation is submitted for the degree of
Doctor of Philosophy

Churchill College

April 2019

I would like to dedicate this thesis to my loving parents ...

Declaration

I hereby declare that except where specific reference is made to the work of others, the contents of this dissertation are original and have not been submitted in whole or in part for consideration for any other degree or qualification in this, or any other university. This dissertation is my own work and contains nothing which is the outcome of work done in collaboration with others, except as specified in the text and Acknowledgements. This dissertation contains fewer than 65,000 words including appendices, bibliography, footnotes, tables and equations and has fewer than 150 figures.

Daniel Elías Martín Herranz
April 2019

Acknowledgements

And I would like to acknowledge ...

Abstract

This is where you write your abstract ...

Table of contents

List of figures	xiii
List of tables	xvii
Abbreviations and acronyms	xxiii
1 Introduction	1
1.1 The biology of ageing	1
1.1.1 A brief introduction to ageing theory	1
1.1.2 The genetic basis of ageing	5
1.1.3 A few notes on mammalian ageing	7
1.1.4 Studying the ageing process in humans	10
1.2 Epigenetics of ageing	13
1.2.1 A brief introduction to epigenetics	13
1.2.2 Fundamentals of DNA methylation	16
1.2.3 Epigenetic changes during mammalian ageing	16
1.3 Epigenetic ageing clocks	17
1.3.1 Measuring the ageing process	17
1.3.2 The emergence of epigenetic clocks	18
1.3.3 The landscape of epigenetic clocks	18
1.3.4 What do we know about the epigenetic ageing clock so far?	19
2 Statistical aspects of the epigenetic clock	21
2.1 Analysing the blood methylome to study human ageing	21
2.1.1 Building a DNA methylation dataset from public data	21
2.1.2 Main DNA methylation data pre-processing pipeline	24
2.1.3 Accounting for blood cell composition changes during ageing	29
2.1.4 Identifying differentially methylated positions during ageing	37
2.1.5 Shannon methylation entropy	41

2.2	Behaviour of Horvath's epigenetic clock during ageing	42
2.2.1	Calculating epigenetic age using Horvath's epigenetic clock	42
2.2.2	Horvath's epigenetic clock measures physiological ageing	46
2.2.3	Correcting for batch effects in the context of the epigenetic clock .	49
2.3	Behaviour of other epigenetic clocks during ageing	52
2.3.1	Hannum's epigenetic clock	52
2.3.2	Epigenetic mitotic clock: <i>epiT</i> OC	53
2.4	Additional methods	55
3	Biological aspects of the epigenetic clock	59
3.1	Background	59
3.2	Screening for genes that accelerate the epigenetic clock	59
3.3	Sotos syndrome accelerates epigenetic ageing	63
3.4	Comparing Sotos syndrome and physiological ageing	65
3.5	Methylation Shannon entropy and the epigenetic clock	69
3.6	Discussion	71
3.7	Additional methods	77
4	Technological aspects of epigenetic clocks	83
4.1	Background	83
4.2	Restriction enzyme digestion as a tool for genomic enrichment	85
4.3	cuRRBS: customised Reduced Representation Bisulfite Sequencing	86
4.4	Running cuRRBS in different biological systems	89
4.5	Experimental validation of cuRRBS	91
4.6	Conclusions and future directions	93
4.7	Additional methods	95
Appendix		103
S.1	Statistical aspects of the epigenetic clock	103
S.2	Biological aspects of the epigenetic clock	112
S.3	Technological aspects of epigenetic clocks	133
References		141

List of figures

1.1	Theoretical framework to conceptualise the ageing process	4
2.1	Chronological age distribution in the healthy individuals	22
2.2	Main DNA methylation data pre-processing pipeline	26
2.3	Effect of BMIQ normalisation on the β -value distribution	28
2.4	Benchmarking of the cell-type deconvolution strategies in blood: <i>RMSE</i> and <i>MAE</i>	34
2.5	Predictions obtained for each blood cell type using the optimal deconvolution strategy	35
2.6	Changes in blood cell composition during human ageing	36
2.7	Changes in the blood methylome during human ageing	39
2.8	Changes in the β -values of four different aDMPs	40
2.9	Relationship between the β -value and the Shannon entropy at a given CpG site	42
2.10	Genome-wide methylation Shannon entropy during physiological ageing . .	43
2.11	Transforming chronological age in Horvath's model	45
2.12	Horvath's epigenetic clock measures physiological ageing	48
2.13	Correcting for batch effects in the context of the epigenetic clock	51
2.14	Causes of deviation from the expected EAA distribution in the control model	52
2.15	Behaviour of Hannum's epigenetic clock in the healthy individuals	54
2.16	Behaviour of the epigenetic mitotic clock (<i>epiT</i> OC) in the healthy individuals	56
3.1	Chronological age distribution in the individuals with developmental disorders	60
3.2	Overview of the analyses performed in Chapter 3	61
3.3	Screening for epigenetic age acceleration (EAA) in developmental disorders	64
3.4	Sotos syndrome accelerates epigenetic ageing	66
3.5	Comparing DNA methylation changes in Sotos syndrome and physiological ageing	68
3.6	Landscape of Horvath's epigenetic clock CpGs in Sotos syndrome	70

3.7	Methylation Shannon entropy during physiological ageing and in Sotos syndrome	72
3.8	Proposed model that highlights the role of H3K36 methylation maintenance on epigenetic ageing	75
4.1	The landscape of restriction enzyme motifs	85
4.2	Restriction enzyme digestion as a tool for genomic enrichment	87
4.3	cuRRBS overview	90
4.4	Running cuRRBS in different biological systems	92
4.5	Experimental validation of cuRRBS	94
S1.1	Effects of <i>noob</i> background correction on the array fluorescence intensities.	103
S1.2	Quality control (QC) strategy to identify outlier samples.	104
S1.3	M-value distributions in the GSE41273 batch	104
S1.4	Cell-type deconvolution strategies that were benchmarked	105
S1.5	Benchmarking of the cell-type deconvolution strategies in blood: R^2	106
S1.6	Table showing the top 100 aDMPs	109
S1.7	Impact of the absence of background correction on the predictions from the epigenetic clock	109
S1.8	Correcting for batch effects: control model without cell composition correction	110
S1.9	PCA on the array control probes captures batch effects: cases	111
S1.10	Variance explained by the different principal components during batch effect correction	111
S2.1	Table showing information for the individuals with developmental disorders	121
S2.2	Effect of changing the median age of the controls when performing the screening	122
S2.3	Screening for epigenetic age acceleration (EAA) in developmental disorders: additional scatterplots	125
S2.4	Enrichment for the categorical (epi)genomic features in Sotos and ageing: genome-wide	126
S2.5	Distributions of scores for the continuous (epi)genomic features in Sotos and ageing: genome-wide	127
S2.6	Scores for the continuous (epi)genomic features in the Horvath's epigenetic clock CpGs	128
S2.7	Enrichment for the categorical (epi)genomic features in Sotos and ageing: Horvath's epigenetic clock	129

S2.8 Distributions of scores for the continuous (epi)genomic features in Sotos and ageing: Horvath's epigenetic clock	130
S2.9 Methylation Shannon entropy acceleration	131
S2.10Batch effects in the methylation Shannon entropy for the epigenetic clock sites	131
S2.11Information for the continuous (epi)genomic features	132
S3.1 Scatterplot of fragment length distributions for the isoschizomer families . .	133
S3.2 Genomic features that overlap with restriction enzyme cleavage sites	134
S3.3 Comparison of studies using restriction enzymes for genomic enrichment .	135
S3.4 Additional insights into cuRRBS	136
S3.5 Additional results of running cuRRBS in different biological systems	137
S3.6 Effect of experimental errors during size selection in cuRRBS predictions .	138
S3.7 cuRRBS computational efficiency	139

List of tables

2.1	Overview of the blood DNA methylation dataset from healthy individuals	23
3.1	Overview of the developmental disorders that were included in the screening	62
4.1	Flexible user-defined cuRRBS parameters	97
S2.1	Additional information for the developmental disorders dataset	112

Abbreviations and acronyms

27K	Illumina Infinium HumanMethylation27 array
450K	Illumina Infinium HumanMethylation450 array
5mC	5-methylcytosine
aDMPs	Differentially methylated positions during ageing
AMP	Adenosine monophosphate
AMPK	Adenosine monophosphate-activated kinase
ASD	Autism spectrum disorder
ATP	Adenosine triphosphate
ATR-X	Alpha thalassemia/mental retardation X-linked syndrome
aVMPs	Variably methylated positions during ageing
B	CD19 ⁺ B cells
BMIQ	Beta-mixture quantile normalisation
bp	Base pairs
CCC	Cell composition correction
CD4T	CD4 ⁺ T cells
CD8T	CD8 ⁺ T cells
CG	5'-cytosine-phosphate-guanine-3'
CGI	CpG island
CHG	5'-cytosine-phosphate-H-phosphate-guanine-3', where H corresponds to adenine, thymine or cytosine
CHH	5'-cytosine-phosphate-H-phosphate-H-3', where H corresponds to adenine, thymine or cytosine

ChIP-seq	Chromatin immunoprecipitation and sequencing
CP/QP	Constrained projection/quadratic programming
CpG	5'-cytosine-phosphate-guanine-3'
CPU	Central processing unit
CRF	Cost Reduction Factor in cuRRBS
cSEA	Shannon entropy acceleration for the Horvath's epigenetic clock sites
CTCF	CCCTC-binding factor
cuRRBS	customised Reduced Representation Bisulfite Sequencing
DHS	DNase Hypersensitive Sites
DHS-DMCs	In cell-type deconvolution strategies, reference probes identified using information from differential methylation and chromatin accessibility
DMCs	Differentially methylated cytosines
DMCTs	Differentially methylated cytosines in individual cell types
DMPs	Differentially methylated positions
DMRs	Differentially methylated regions
DMV	DNA methylation valley
DNA	Deoxyribonucleic acid
DNAmAge	DNA methylation age i.e. epigenetic age calculated with Horvath's epigenetic clock
EAA	Epigenetic age acceleration
EPIC	Illumina Infinium MethylationEPIC array
epiTOC	epigenetic Timer of Cancer (i.e. the epigenetic mitotic clock)
EV	Enrichment Value in cuRRBS
EWAS	Epigenome-wide association studies
FDR	False discovery rate
FN	False negatives
FP	False positives
FXS	Fragile X syndrome
GB	Gigabytes

Gbp	Giga base pairs
GC content	Guanine + cytosine content
GEO	Gene Expression Omnibus repository
Gran	Granulocytes
gSEA	Genome-wide Shannon entropy acceleration
GWAS	Genome-wide association studies
H3K27me3	Histone H3 lysine 27 trimethylation
H3K36	Histone H3 lysine 36
H3K36me3	Histone H3 lysine 36 trimethylation
H3K4me3	Histone H3 lysine 4 trimethylation
hg19	Reference human genome assembly 19
hg38	Reference human genome assembly 38
IDOL	IDentifying Optimal DNA methylation Libraries, a strategy to build cell-type deconvolution references
IEAA	Intrinsic epigenetic age acceleration
IGF-1	Insulin-like growth factor 1
iPSCs	Induced pluripotent stem cells
kb	Kilo base pairs
KNN	k -nearest neighbours
m ⁶ A	N ⁶ -methyladenosine
MAE	Mean absolute error (in the context of cell-type deconvolution benchmarking) or median absolute error (in the context of Horvath's epigenetic clock)
MBD	Methyl-CpG-binding domain
MEFs	Mouse embryonic fibroblasts
Mono	CD14 ⁺ monocytes
mRNA	Messenger RNA
NAD ⁺	Nicotinamide adenine dinucleotide
NF	Theoretical number of fragments sequenced in cuRRBS

NFC	Normalised fold change
NK	CD56 ⁺ natural killer cells
NRC	Normalised read counts
NRE	Normalised RNA expression
NRF1	Nuclear respiratory factor 1
OOB	Out-of-band fluorescence intensities in the Infinium I probes of Illumina arrays
OR	Odds ratio
PBMC	Peripheral blood mononuclear cells
PC	Principal component
PCA	Principal component analysis
PCC	Pearson's correlation coefficient
pcgtAge	Mitotic age according to the epigenetic mitotic clock (epiToc)
PCR	Polymerase chain reaction
PRC2	Polycomb repressing complex 2
QC	Quality control
R	It can have two meanings: robustness variable in cuRRBS or the R programming language
R ²	Coefficient of determination
RAM	Random-access memory
Repli-seq	genome-wide analysis of replication timing by sequencing
RMSE	Root mean squared error
RNA	Ribonucleic acid
RNA-seq	RNA sequencing
ROS	Reactive oxygen species
RPC	Robust partial correlations
RRBS	Reduced Representation Bisulfite Sequencing
rRNA	Ribosomal RNA

SCC	Spearman's correlation coefficient
SD	Standard deviation
Sex_p	Sex predicted for a sample using DNA methylation data
SNP	Single-nucleotide polymorphism
SQN	Stratified quantile normalisation
sur	Signal of unique reads
TKO	Triple knockout
TN	True negatives
TOR	Target of rapamycin
TP	True positives
TSS	Transcription start site
UTR	Untranslated region
WGBS	Whole Genome Bisulfite Sequencing
WTS	Wavelet-transformed signals

Chapter 1

Introduction

1.1 The biology of ageing

1.1.1 A brief introduction to ageing theory

Potential quote: '... there are as many theories of ag[e]ing as there are biogerontologists.' Leonard Hayflick. Biological aging is no longer an unsolved problem

"At a fundamental level evolutionary survival is the preservation of a dynamic balance between information, or order, and entropy, or disorder." Thomas Kirkwood, Evolution of ageing, Nature 1977.

The ageing process is one of the most mysterious, complex and fascinating biological problems to be solved in the 21st century. Ageing and immortality have probably fascinated mankind since we have a conception of time and death [1].

Biological ageing (aka the ageing process) can be broadly defined as the time-dependent functional decline which increases vulnerability to death in most organisms [2]. The revolution taking place in genetics and molecular biology during the 20th century gave rise to more than 300 theories that attempt to explain the mechanisms behind biological ageing [3]. Any valid modern theory of ageing would need to explain at least two things [3]:

- The molecular causes behind the increase in **mortality rate** (aka death rate) over time in a given species population. Mortality rate can be broadly defined as the number of deaths in a population per unit of time and scaled by the size of the population. More formally, by quantifying the deaths of individuals in a population over time (and assuming that there are no increases in the population number due to reproduction, migration, ...), the survival fraction at a given time t , $S(t)$, is [4]:

$$S(t) = \frac{N(t)}{N_0} \quad (1.1)$$

where $N(t)$ is the number of individuals alive at a given time t and N_0 is the initial number of individuals in the population. It can be demonstrated that the mortality rate, $\lambda(t)$, can be expressed as [4]:

$$\lambda(t) = -\frac{1}{S(t)} \cdot \frac{dS(t)}{dt} \quad (1.2)$$

- The **evolutionary variations in lifespan between different species** [5]; where lifespan is defined as the time passed between birth and death of an organism. For example, the maximum lifespan in the case of the roundworm (*Caenorhabditis elegans*) is 0.16 years (58.4 days, in captivity); in the case of the fruit fly (*Drosophila melanogaster*) is 0.3 years (109.5 days, in captivity); in the case of the house mouse (*Mus musculus*) is 4 years (in captivity); in the case of humans (*Homo sapiens*) is 122.5 years and in the case of the bowhead whale (*Balaena mysticetus*) is 211 years (in the wild) according to the database AnAge [6]. Furthermore, some species (such as certain turtles, certain species of rockfish or the bristlecone pine) seem to have negligible senescence i.e. negligible changes in adult mortality rates over extended periods of time at advanced adult ages [7].

Nowadays, there are at least **two main paradigms**, complementary to each other, that try to conceptualise the problem and that are a topic of intense discussion among gerontologists:

- Ageing as a consequence of *molecular infidelity*. In this case, stochastic chemical modifications of biomolecules, such as DNA or proteins, exceed the capacity of the repair and turnover systems of the organism and accumulate over time, which increases the entropy of the system. This leads to changes in molecular structure and, finally, changes in function, which increase vulnerability to age-related diseases [8, 9]. From an evolutionary point of view, this fits into the *disposable soma theory*, originally proposed by Thomas Kirkwood in 1977. This theory suggests that organisms have evolved to optimise the amount of energy dedicated to repair errors in somatic cells in order to maximise reproductive success (at the expense of indefinite survival) [10, 11].
- Ageing as a consequence of *hyperfunction*. In this case, the primary cause of ageing is an excessive activity of certain growth or development-related genes and pathways

in later life [12–15]. In other words, ageing would be a program for development that has not been turned off [12]. This idea is rooted on the concept of *antagonistic pleiotropy*, an important pillar of the evolutionary theory of ageing originally proposed by George C. Williams in 1957 [16]. It implies that certain genes have opposite effects on fitness at different ages, which is a consequence of the decrease in selection forces after reproductive age. A strong candidate is the TOR (target of rapamycin) pathway, which promotes development in early life but also the advancement of several late-life pathologies [13].

It has become clear that no single molecular mechanism will be able to explain ageing across all kingdoms of life. Different species have different life histories that are subjected to evolutionary trade-offs (e.g. regarding reproduction strategies, developmental schedules, ...) and that can affect the rate of ageing [17, 5]. Nevertheless, it is possible to integrate all the ideas presented so far into a **theoretical framework** that can help to unify definitions across studies and set the foundations for mechanistic advancements on the biology of ageing (Fig. 1.1, inspired by ideas from [8, 15, 18, 19]). Under this theoretical framework:

- The ageing process is composed of different molecular mechanisms (subprocesses) that are operative at different stages of life and contribute, in variable proportions, to the appearance of different age-related diseases i.e. the risk of developing an age-related disease is the ‘integral of its ageing subprocesses operating over time’. Furthermore, the development of different diseases affects the mortality rate and, thus, the probability to die. The different ageing processes can also be understood as the sources of ageing-causing molecular damage [2].
- If the ageing subprocesses can be altered through different genetic, lifestyle or pharmaceutical interventions, it is possible to reduce the likelihood of several age-related diseases at the same time. This makes ageing research incredibly relevant for the biomedical sciences, since it changes the current paradigm of developing interventions for a specific already-existing disease towards the prevention of several diseases simultaneously.
- Differences in the average lifespan between different species should be explained by different combinations of ageing subprocesses and their rates.

Consequently, systems biology approaches become fundamental to understand the ageing process [19]. In the next sections, I will provide an overview of the ageing mechanisms that may be operative in different species, with a special focus on mammalian species.




a**b****c**

Fig. 1.1 Theoretical framework to conceptualise the ageing process. **a.** The ageing process is composed of different molecular mechanisms (subprocesses) that are operative at different stages of life and contribute, in variable proportions (specified by the weights), to the appearance of different age-related diseases. Furthermore, the development of different diseases affects the mortality rate and, thus, the probability to die. **b.** and **c.** Examples of the life histories of two organisms. In these examples, two ageing mechanisms are operative: A (which changes its rate after reproductive age e.g. activated growth-related pathways) and B (with a constant rate over time e.g. some type of (epi)mutational process). Differences in the mechanisms' profiles lead to differences in the age-related diseases that manifest over the lifespan of the organisms, even though the molecular mechanisms are the same. This, affects the mortality rate and, ultimately, the time-to-death. This figure is inspired by ideas from [8, 15, 18, 19].

1.1.2 The genetic basis of ageing

Given the differences in the lifespan between species and even within species [5, 20], it is nowadays clear that the ageing process must have a genetic basis. However, for a long time, the ageing process was thought to be a ‘haphazard process driven solely by entropy’ [21]. Furthermore, in 1935 Clive Maine McCay had shown that caloric restriction (a reduction in calories intake without malnutrition) could extend mean and maximal lifespan in rats [22, 23], which probably shifted the focus towards environmental or external causes as the main driver forces of the ageing process. Since then, dietary restriction (different types of dietary interventions that reduce food intake without malnutrition) has been established as the most successful non-genetic intervention to slow down the ageing process across species [24].

The establishment of the nematode *Caenorhabditis elegans* as a model organism in the 70s triggered its adoption in the ageing field [25], since it allowed well-controlled experiments in a much shorter period of time than rodents [26]. This lead to the discovery of the first mutants that dramatically extended lifespan, which mapped to genes in the insulin/IGF-1 signalling pathway [27, 28]. Since then, many genes have been found to significantly affect the lifespan of other model organisms as well, such as budding yeast (*Saccharomyces cerevisiae*), fruit fly (*Drosophila melanogaster*) or mouse (*Mus musculus*) [21, 29, 30].

Interestingly, the effects of many of these genetic mutations and their pathways are shared by distantly-related species. This suggests that at least part of the molecular mechanisms that drive the ageing process could be evolutionarily conserved. Among these ageing-related signalling pathways it is worth highlighting (Fig.) [21, 29–31]:

- **Insulin/IGF-1 pathway.** This underscores the central role of the endocrine system on the biology of ageing. Mutations that lower the level of *daf-2*, encoding an insulin/IGF-1 receptor, were originally found to double the lifespan of *C. elegans* [27, 32]. Activation of the insulin/IGF-1 pathway, a PI3K pathway, leads to the phosphorylation of a transcription factor of the FOXO family, encoded by *daf-16* in *C. elegans*, which prevents it to reach the nucleus [33]. FOXO transcription factors, of which there are several members in mammals, activate the expression of longevity-promoting genes involved in processes such as autophagy (which clears protein aggregates and damaged organelles in the cell) [30], resistance to oxidative stress or stem cell maintenance [34]. This partially explains why inhibiting the insulin/IGF-1 pathway can increase organismal lifespan. However, other downstream targets that regulate gene expression have been identified, such as *hsf-1* (a transcription factor that regulates heat-shock

response) [35] or *skn-1* (a transcription factor that coordinates a response to oxidative stress) [36] in *C. elegans*.

- **TOR pathway.** TOR (target of rapamycin) is a kinase that acts as a major amino-acid and nutrient sensor by stimulating growth (including protein translation) and blocking autophagy [29]. The effects of TOR are partly mediated by activating the ribosomal subunit S6 kinase (which promotes protein translation) and by inhibiting 4EBP (a translation inhibitor) [29, 37]. Reductions in TOR activity (through mutation, downregulation or pharmacologically) increase lifespan across many species [29]. Importantly, rapamycin, a drug that inhibits TOR, can increase the mean lifespan of mice when fed late in life, which showed for the first time that pharmacological interventions of mammalian ageing are possible [38]. Interestingly, the increase in lifespan differed in males (9%) and females (13%) [38], highlighting the sex-specific effects of some ageing mechanisms.
- **AMPK pathway.** The AMP-activated kinase (AMPK) controls the balance between catabolic and anabolic processes depending on the cellular levels of AMP/ATP (i.e. when ATP levels decrease, AMPK is activated to promote catabolic pathways) [29, 39]. Furthermore, AMPK activation promotes autophagy, partially by inhibiting TOR [39]. The anti-diabetic drug metformin, which activates AMPK among other targets, has been shown to extend lifespan in mice [40, 41] and has currently been included as the first drug to target the human ageing process in a clinical trial [42].
- **Sirtuins.** Sirtuins are a family of nicotinamide adenine dinucleotide (NAD^+)-dependent deacetylases i.e. they generally catalyse the removal of an acetyl group from lysine residues using NAD^+ as a cofactor [43]. Sirtuins have been shown to play complex roles in the biology of ageing and age-related diseases, in general by cross-talking with other nutrient-sensing pathways and promoting longevity [29, 43]. Several authors have shown that increasing NAD^+ levels enhances the activity of sirtuins, which could constitute an additional anti-ageing pharmacological avenue in mammals. Additionally, intensive research is being carried out to identify other molecules that activate sirtuins [43].
- **Other pathways.** Mitochondrial respiration (and its association with reactive oxygen species or ROS), genome surveillance pathways (such as those involved in DNA repair or telomere maintenance), signals from the reproductive system or Wnt signalling have also been implicated in different ways in the ageing process [29, 31, 44].

These pathways seem to have a dual role depending on the environmental context that the organism is facing, behaving as **nutrient and stress sensors** (Fig.). Under abundant nutrient availability and low stress (oxidative, temperature), they tend to promote growth and reproduction. On the contrary, under harsh conditions (such as those posed by dietary restriction), they favour cell protection and maintenance [21, 29]. It is worth mentioning that the responses of the different pathways to dietary restriction deeply depend on the characteristics of the diet and its timing [29]. This model also relates to the disposable soma theory, where more resources are allocated either to reproduction or somatic maintenance depending on the context [10, 11]. This is further mechanistically supported by experiments that show that decreased insulin/IGF-1 signalling (e.g. via *daf-2* mutation) produces the acquisition of germline characteristics (e.g. higher genomic stability) in *C. elegans* [45]. Even though this model is a clear oversimplification, it becomes useful when thinking about the way that the ageing process might have evolved and how the same biological pathways can be repurposed to activate complex genetic programs with completely different goals.

There are many more **complexities associated with these pathways** that would require an entire thesis in its own. For example, the insulin/IGF-1 signalling pathway can work in a cell non-autonomous manner (i.e. the activity of the pathway in one tissue can affect lifespan by influencing cells in a different tissue), which could help to coordinate ageing rates in the organism, and the effects are many times tissue-specific [21, 29]. Additionally, the pathways can have different effects depending on the life stage of the animal (e.g. development, adulthood, ...) [46]. Furthermore, cross-talk between the pathways has previously been reported [43, 47]. Therefore, the inner workings of these signalling pathways is still a topic of intense research.

The discovery of genetic pathways that can dramatically extend the lifespan of model organisms has demonstrated that **the ageing process has a genetic basis and it is possible to alter its rate**. More importantly, the appearance of age-related disease seems to be delayed in many of these long-lived organisms [29, 48], suggesting that these interventions indeed reduce the rate of some the operating ageing mechanisms (Fig. 1.1) and opening the door to the development of anti-ageing interventions.

1.1.3 A few notes on mammalian ageing

Most mammalian studies on the biology of ageing have been conducted in the mouse. Many genetic mutations in conserved pathways (mainly nutrient-sensing pathways) have been shown to significantly extend the lifespan of mice. Among them, those that affect growth

hormone signalling, which in mammals in turn controls the secretion of IGF-1 by the liver and therefore the insulin/IGF-1 signalling pathway, produce the longest lifespan improvements (in the order of 40-60%) [30]. Even though this is a remarkable result, it is far off the lifespan extensions achieved with ‘simpler’ model organisms such as *C. elegans* (where extensions of almost 1000% have been achieved with a mutation in a single gene of the insulin/IGF-1 pathway; the equivalent of a human living up to ≈ 1200 years!) [49]. This highlights a trend where translating lifespan interventions discovered in worms and flies yields generally less spectacular results in mice and potentially humans.

Evolution has been experimenting with lifespan extension for a long time. Consequently, some species of mammals, such as the naked mole rat (*Heterocephalus glaber*) or some species of bats, are exceptionally long-lived for their body size. Recent reports point towards the possibility that these species do not increase their mortality rate with age (i.e. they have negligible senescence) [50, 51], which makes them incredibly interesting systems to study the biology of ageing in mammals.

In 2013, López-Otín *et al.* reviewed the main common denominators of the ageing process across organisms [2]. They defined several **hallmarks of ageing**, which can be understood as the measurable consequences of the ageing mechanisms that I proposed in Fig 1.1. I will briefly discuss some of them, with a special focus on those that directly affect the genome during mammalian ageing [2, 30]:

- **Genomic instability.** Somatic DNA mutations (single nucleotide variants, copy number changes, structural rearrangements, ...) accumulate over time in the genomes of mammalian cells (both in the nuclear genome and the mitochondrial genome) [52, 53]. Different mutational processes (good candidates for ageing mechanisms) create specific patterns of mutations (aka mutational signatures) in the genome, which have been widely studied in the context of human cancer [54]. It is possible to assign specific endogenous (e.g. DNA replication errors) and exogenous factors (e.g. smoke exposure) that contribute to the different processes. In the context of ageing, deamination of 5-methylcytosine (5mC) in a CpG context leads to C>T (cytosine to thymine) mutations, which accumulate in a clock-like manner with a rate that seems to correlate with the proliferative activity of the tissue [55]. Furthermore, nuclear architecture and the 3-dimensional organisation of the genome both seem to change with age, which can distort nuclear homeostasis. Interestingly, several human diseases that are considered to display premature ageing, such as Werner syndrome or Hutchinson–Gilford progeria, have mutations in proteins that lead to genomic instability [56]. Finally, it is

possible that an increase in the mobilisation of transposable elements with age further contributes to destabilise the genome [57].

- **Telomere attrition.** The repetitive DNA linear ends of mammalian chromosomes are capped with a protein complex (shelterin) to form structures known as telomeres. Due to the nature of the standard DNA replication machinery, the chromosomal DNA ends of somatic cells are eroded after each cell division (net loss of 100-200 bp of telomeric sequence per cell division). After a certain number of doublings (and therefore telomeres shortening) cells stop dividing and they induce cellular senescence (see below) or cell death (apoptosis) [58]. For many years, this replicative limit, known as the Hayflick limit, was understood as the manifestation of the ageing process at the cellular level [59, 60]. Telomere shortening has indeed been shown to occur with age in most human tissues [61]. Importantly, stem cells and germ cells express telomerase, an enzymatic complex that synthesises new telomeric repeats, avoiding telomere shortening. This way organisms can regenerate their tissues if needed, which makes it unlikely that telomere attrition is the only mechanism behind ageing. Furthermore, in mammals other mechanisms could contribute to replicative senescence besides telomere length [58]. Nevertheless, telomere biology plays a critical role in many fundamental processes, such as DNA repair and genomic stability, and non-telomeric functions for telomerase have also been suggested (such as global chromatin regulation and transcription of developmentally-regulated genes) [58]. As such, telomere biology has been implicated in age-related diseases, such as cancer and cardiovascular disease [58, 61]. Interestingly, ectopic expression of the catalytic subunit of telomerase (TERT) extends the lifespan of mice that are cancer-resistant [62].
- **Epigenetic alterations.** This hallmark is reviewed in further detail in section , since it is the main focus of this thesis.
- **Cellular senescence.** Cellular senescence is a cellular state characterised by a stable cell cycle arrest. There are different types of senescence induced by different stress stimuli, including telomere shortening (replicative senescence, previously mentioned), sustained DNA damage (e.g. via irradiation) or derepression of the *INK4/ARF* locus (which encodes three tumour suppressor genes)[2, 63]. Under normal circumstances, cellular senescence carries out physiological functions such as stopping pre-malignant cells from dividing, wound healing and tissue remodelling. Furthermore, senescent cells also secrete a cocktail of factors (termed the senescence-associated secretory phenotype, or SASP) with pleiotropic effects (pro-inflammatory, matrix remodelling, inducing growth, ...) [63]. Senescent cells seem to accumulate in some mammalian

tissues during ageing. If this happens in excess, the SASP can perturb the homeostasis of the tissue. Consequently, the removal of senescent cells in mice increases lifespan and reduces the appearance of age-related phenotypes [64–66]. Drugs that selectively induce apoptosis in senescent cells (known as senolytics) [67] are currently undergoing clinical trials in humans.

- **Other hallmarks of ageing.** These include loss of proteostasis (appropriate quality control of the proteome, which is mechanistically connected with autophagy pathways; strongly implicated in neurodegenerative diseases); deregulated nutrient sensing (mediated by the pathways discussed in section 1.1.2; it is important to mention that in mammals the insulin/IGF-1 pathway is integrated in the somatotropic axis, which involves the growth hormone as an activator of IGF-1 production and); mitochondrial dysfunction (including a reduction in the efficacy of the respiratory chain with age); stem cell exhaustion (which is thought to contribute to the decline of regenerative potential of the tissues with ageing, such as in the case of the haematopoietic system) and altered intercellular communication (including an increase in inflammation, known as inflammageing, or alterations in the neuroendocrine system) [2].

Importantly, complex interactions and interdependencies emerge between the different hallmarks of ageing. For example, in senescent cells in the mouse, a type of transposable element (L1) becomes derepressed and activates type-I interferon response, which in turn causes inflammageing [68]. Furthermore, understanding the role of the environment in modulating the ageing process and the different hallmarks in mammals is becoming increasingly important.

Assuming that molecular damage is the main cause of biological ageing, the mechanisms that lead to genomic instability, telomere attrition, epigenetic alterations and loss of proteostasis are very likely the main drivers of the ageing process, with the rest of the hallmarks being a consequence of them [2]. Nevertheless, interventions targeting some of the more ‘integrative hallmarks’ (such as removing senescent cells, optimising dietary restriction or stem cell therapies) will probably arrive earlier in the clinic.

1.1.4 Studying the ageing process in humans

Average human lifespan has nearly doubled in most developed countries during the last 200 years. This has been the consequence of external factors, such as improvements in quality of water, food, hygiene, housing and lifestyle, immunization against infectious disease, antibiotics and medical care [69]. One of the most debated questions in the human ageing

field is whether there is a limit to maximal human lifespan [70]. Since Benjamin Gompertz's pioneering work in 1825, it is known that the mortality rate in humans increases exponentially with age [71]. However, a recent study on Italian centenarians suggests that mortality rate, which increases exponentially up to about age 80, decelerates thereafter and reaches or closely approaches a plateau after age 105 [72]. This implies that human lifespan will likely continue to increase in the next decades and that **we have probably not reached our lifespan evolutionary limit as a species yet** [72, 73].

Thus, in order to avoid a massive socioeconomic burden on our societies [74], biomedical research should focus on **extending human healthspan** (i.e. the amount of time that we live free of disease) and not only lifespan. This goal, known as the 'compression of morbidity' [69], is theoretically possible if we target the core mechanisms that drive the ageing process (Fig 1.1), which is assumed to be the biggest contributor to the development of most age-related diseases, such as cancer, diabetes, cardiovascular disorders and neurodegenerative diseases [2]. Indeed, genetic and pharmacological interventions that increase lifespan in model organisms also seem to extend healthspan [75] and the compression of morbidity is a characteristic of human centenarians [76].

Most of our understanding of human ageing comes from studies carried out in **population cohorts**. Furthermore, during the last years different datasets of high-throughput molecular data (broadly known as 'omics') have been generated for many of these cohorts, including genetic data, epigenetic data, metabolomic data, imaging data or even the microbiome. These data (sometimes referred as 'deep phenotypes') complement the more traditional phenotypic measurements and health records and allow, for the first time, characterising the human ageing process with unprecedented resolution and scale. An example of such a cohort is the UK Biobank, which has enrolled > 500,000 participants [77]. Importantly, there is a trend in many of these cohorts to collect more longitudinal data (i.e. data over time for the same individual), which will likely increase the power to discover causal ageing mechanisms when compared with cross-sectional data (i.e. when data from different individuals at different ages is used) [78]. As Nobel laureate Sydney Brenner (known for establishing *C. elegans* as a model organism) remarked 10 years: "We don't have to search for a model organism anymore. Because we are the model organisms" [79] (as a disclosure, I still believe we need model organisms to gain definitive mechanistic insights, and probably so does Dr. Brenner).

The ageing process is an extremely polygenic trait, probably one of the most complex phenotypes to be studied (as it would be expected if it is composed of many different molecular processes). Candidate gene studies (with biased hypotheses) and genome-wide association studies (GWAS, unbiased) have found genetic variants that may affect the rate of

ageing in humans. Many of them are associated with the function of genes that are part of nutrient-sensing pathways (such as *FOXO3* or *IGF1R*), that increase the risk of Alzheimer's (such as *APOE*), that are involved in cellular senescence (such as *CDKN2A*) or that are related to the immune system and inflammation (such as *HLA-DQA1*, *HLA-DRB1* or *IL6*) [30, 69]. Additionally, biological sex has a major impact on the ageing process and the incidence of age-related diseases. In the case of humans, females consistently live longer than males (females make around 90% of the supercentenarians i.e. individuals that live 110 years or more). However, they also seem to suffer greater morbidity in later life, which is known as the 'mortality-morbidity paradox' [80].

It is clear that human longevity has a genetic component. However, the latest estimates of heritability are quite low (ranging between 10-15%) [81, 82]. Furthermore, GWAS have yielded relatively few genetic variants compared with other complex phenotypes [30]. This could be due to the sample sizes required or methodological limitations (such as the way that the ageing phenotype is defined). Nevertheless, it is more likely that **the environment (and its interaction with the genetic background) accounts for most of the phenotypic variation in human ageing populations** [30, 69]. As such, there is increasing evidence that diet (not only the content but also the timing) and exercise can act through nutrient-sensing pathways to regulate human healthspan and potentially lifespan [30, 69, 83–86]. Interestingly, social relationships are hypothesised to have a causal role in mortality rate, with lower levels of social integration associated with higher levels of inflammation, blood pressure or waist circumference across all human lifespan [87]. An interesting example of the impact of environmental and lifestyle factors on human lifespan are the so called 'blue zones'. These are geographical areas (such as Ogliastra in Sardinia, Okinawa in Japan, the Nicoya peninsula in Costa Rica and the island of Ikaria in Greece) that have unusual proportions of longlived individuals. However, the genetics of these populations are similar to their neighbours and therefore differences in the rate of ageing must be attributed to environmental and lifestyle factors [69, 88]. As such, lifestyle interventions will likely complement pharmacological interventions (some of them mentioned in section 1.1.2) in order to slow down the human ageing process. Finally, epigenetic mechanisms constitute an interesting layer of biological information that could mediate the interactions between genetics and environment to affect the ageing process and it will be the topic of discussion in the next sections.

1.2 Epigenetics of ageing

1.2.1 A brief introduction to epigenetics

The **coining of the term epigenetics** is normally attributed to Conrad H. Waddington, when in 1942 he defined it as the studies that deal with the causal mechanisms behind embryonic development (i.e. the processes by which the genotype of a single cell brings about the phenotype of an organism) [89]. This led to the unification of two apparently distinct fields (genetics and embryology), today known as the field of developmental genetics [90]. Furthermore, Waddington is also known for introducing the concept of the *epigenetic landscape*, which depicted developmental trajectories and the theory behind them in an incredibly compelling way [91]. Later work by Nanney, Riggs, Holliday and others evolved the definition of epigenetics towards the concept of *cellular memory*, that was materialised at the molecular level through DNA methylation (since it could affect transcription and be inherited after each cell division) [92]. The next decades were characterised by the discovery of a great variety of ‘molecular routes’ to affect gene expression (such as chromatin modifications or non-coding RNAs), which in humans culminated with consortia such as ENCODE [93] or Roadmap Epigenomics [94] and created a broader concept of epigenetics [92, 95].

Nowadays there is a debate in the scientific community about the appropriate definition of epigenetics [95, 96]. For the purpose of this thesis I will define epigenetics as **the study of molecular variation that is beyond changes in the DNA sequence, that is inherited after cell division and that regulates gene expression** (in line with the definition by Wu and Morris) [97]. However, it is important to mention that, in the context of the epigenetic clock, we are still not sure whether these molecular changes have direct functional consequences (e.g. by affecting RNA expression) and/or whether they help to define a new metastable cellular state in the cells that they occur (see section).

There are different types of molecular mechanisms that are normally considered ‘epigenetic’. These include:

- **DNA methylation.** This will be discussed in detail in section 1.2.2.
- **Histone modifications.** The basic unit of chromatin is the nucleosome. It is composed of ~147 bp wrapped around an octomer of histones (generally two copies of each one of the four core histones: H2A, H2B, H3 and H4; although histone variants such as H3.3 or H2A.Z have also been characterised). In order to fit around 2 meters of

DNA into the nucleus of a human cell, chromatin needs to be further compacted with the help of scaffold proteins (with the furthest level of compaction achieved in the mitotic chromosome) [?]. Histones possess N-terminal regions (aka histone tails) that project towards the outside from the nucleosome and are positively charged, which helps to compact the chromatin by interacting with the negative charges of the DNA. However, many different types of post-translational modifications (acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ...) in the residues of the histone tails have been identified across the tree of life (although modifications have been also found in the globular domains) [?]. These histone modifications can affect the chemical properties of chromatin, its degree of compaction and ultimately contribute to the regulation of transcription. The sequence and combinations of these modifications that modulate chromatin activity was named the *histone code* [?] and its complexity is slowly being characterised thanks to technologies such as ChIP-seq [93, 94]. Finally, it is worth mentioning the nomenclature used to refer to histone modifications, where the information about histone (e.g. H3), the residue where the modification happens (e.g. lysine36 is K36)

-
-

The different epigenetic marks present complex patterns of correlation and cross-talk, which are mechanistically linked to the way that its addition and removal is regulated. This helps to define **chromatin states** (i.e. combination of different epigenetic marks) that affect gene regulation in different ways. Historically, chromatin has been broadly classified in two categories [98–100]:

- Euchromatin. It presents active gene activity and it is more accessible to the transcription machinery. It is generally characterised by histone modifications such as H4K16ac, H3K4me3 or H3K36me3.
- Heterochromatin. It is normally subdivided in constitutive (highly condensed and transcriptionally repressed; mostly found in pericentromeric regions, telomeres and other regions that contain repetitive elements; it is generally marked by H3K9me3 and high levels of 5mC) and facultative (normally transcriptionally silent but it has the potential to adopt open or compact conformations depending on the temporal and spatial context; it is generally marked by H3K27me3).

Consortia that have mapped many epigenetic marks (collectively known as the epigenome) in humans [93, 94] and advances in chromatin segmentation algorithms [?] have led to more a fine-grained definition of chromatin states. This has helped to identify functional elements in the genome in a high-throughput way, such as active transcription start sites (TSS, enriched in H3K4me3), enhancers (enriched in H3K4me1) or bivalent chromatin (enriched in H3K4me3 and H3K27me3) [93, 94].

Epigenetic marks contribute to define (or in Waddingtonian terms, ‘canalise’) different cell types and cellular states from the same genomic sequence. Cellular identity is normally established by master regulators (initiators), generally transcription factors that activate the expression of a genetic program (i.e. coordinated gene expression) [99]. However, in order for this cellular state to survive once the initiator is no longer present, the patterns of epigenetic marks need to be inherited after cell division. This is clearly the case for 5-methylcytosine (5mC, see section 1.2.2). In the case of histone modifications, there is evidence for the propagation of some of the repressing histone modifications (such as H3K9me3 and H3K27me3). This is possible because the machinery in charge of catalysing the addition of these chemical modifications (i.e. the *writers*, SUV39H1 and Polycomb Repressive Complex 2) also have the ability to recognise it (i.e. they are also *readers*), therefore creating a positive feedback. However, it is not clear whether many other histone modifications are copied after DNA replication in the newly synthesised DNA strand and therefore whether they are truly epigenetic [99]. Additionally, it is important to mention that enzymatic activities to reverse most (if not all) epigenetic marks (i.e. *erasers*) have been identified [98].

Besides regulation of transcription and defining cellular states, other important biological processes driven by epigenetic mechanisms: genomic imprinting, X chromosome inactivation, eusocial organisms (<https://www.nature.com/articles/nrg.2016.45>). From evolutionary point of view, Transgenerational epigenetic inheritance of longevity in C. elegans.<https://www.ncbi.nlm.nih.gov/pubmed/22012258>

Genetics vs environment. How much of the epigenome is genetically programmed. Efforts to predict epigenetic profiles from sequence. Response of chromatin to the environment [98]. Epigenetics and development, developmental disorders, imprinting disorders, overgrowth. Genomic imprinting, parental-of-origin. Embryological and molecular investigations of parental imprinting on mouse chromosome 7 Parental-origin-specific epigenetic modification of the mouse H19 gene

What happens to the IGF1 IGF2 locus during ageing. Loss-of-imprinting? <https://www.ncbi.nlm.nih.gov/p>

Potential energy landscapes identify the information-theoretic nature of the epigenome

1.2.2 Fundamentals of DNA methylation

2nd

DNA methylation. Chemical modifications of DNA bases were detected as early as 1948 (Ref. 10) and a role for DNA methylation, in particular for 5-methylcytosine (5mC), in gene regulation was proposed in the mid-1970s by Holliday and Pugh¹¹, among others see [98]

Step back, DNA modifications. Species. Not all inherited. Species / Enzymes / reactions. DNA methylation copy error rate.

Including briefly on technologies, mainly bisulfite sequencing. New protocols without bisulfite sequencing? As part of the DNA methylation section: Measuring DNA methylation (i.e. table with technologies). Adapt from Advances in the profiling of DNA modifications, Nature Review Genetics A bit on the mainstream technologies: WGBS, RRBS, arrays (differences between them: e.g. different chemistries), basic principles behind the measurement. Define colour channels, bead, probe, chemistries, ...

Mammalian embryonic development. Epigenetic reprogramming. <https://www.nature.com/articles/nrg.2017.17>

1.2.3 Epigenetic changes during mammalian ageing

3rd

Check hallmarks of ageing section to start with.

Unlike mutational processes, epigenetic processes are reversible, making them more difficult to study. Remodelling of the mouse epigenome. <https://www.biorxiv.org/content/10.1101/336172v1>

Define hypermethylated / hypermethylation and hypomethylated / hypomethylation.

Age-related epigenetic changes at different levels: histone modifications, m6-RNA <https://onlinelibrary.wiley.com/doi/full/10.1111/ace.12753>

Put in the context of theory (non-random):

As Cynthia Kenyon put it: "At the very least, it would be nice to find a form of damage whose increase or decrease in mutants correlates consistently with lifespan, at least within a single species." [29] It may well be that an important source of 'macromolecular damage' is actually 'epigenetic noise'. Instead of ROS, that has been shown to not be enough. Antioxidant defense and aging in C. elegans: is the oxidative damage theory of aging wrong?

Nuclear leakiness. <https://www.ncbi.nlm.nih.gov/pubmed/19167330>

Parabiosis

Stable epigenome in naked mole rats.

heterogeneity at the single-cell level.

Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging

Continuation of the epigenetic landscape during ageing, to converge in diseased cellular states (senescent, cancerous).

Twins

1.3 Epigenetic ageing clocks

1.3.1 Measuring the ageing process

4th

Biomarkers in human research are, on the one hand, used to detect individual variability in the progress of ageing, as risk indicators, and, on the other hand, for monitoring the response to interventions.

Small nucleoli are a cellular hallmark of longevity. Work across different model organisms has yielded biomarkers (Box 2) that predict remaining lifespan, such as nucleolar volume⁸² and telomere length^{83,84}, Form Partridge

At the population level: lifespan curves.

In all of this it was crucial → One of the most useful tools used in ageing research are survival curves (aka lifespan curves). Plotting the survival distribution. The mortality rate function can follow different functional forms. Among them, the following form is normally used in ageing experiments [4]:

$$\lambda(t) = h_0 \cdot e^{\gamma t} \quad (1.3)$$

where h_0 and γ are parameters of the model. This leads to the Gompertz survival distribution:

$$S(t) = \exp \left[\frac{h_0}{\gamma} \cdot (1 - e^{\gamma t}) \right] \quad (1.4)$$

In mammals generally Gompertz: <https://www.ncbi.nlm.nih.gov/pubmed/29444805>
<https://elifesciences.org/articles/31157>

Naked mole rat defy ageing. <https://elifesciences.org/articles/31157>

Big problem at the individual level. Definition of biomarker. Biological age vs chronological age. Other biomarkers, focus on telomere length. Conceptual root in the theories based on age changes [3].

Hype of telomere length. Longer telomeres in mice and still short life. It measures somatic redundancy. Telomere length behaves as biomarker of somatic redundancy rather than biological age.

1.3.2 The emergence of epigenetic clocks

5th

Conceptual root on molecular infidelity framework. At the genomic level, the frequency of this molecular damage (mutations, epimutations) seems to occur with a higher probability in specific regions. Holliday's work on DNA methylation, part of theories of biological clock [3]. Discuss the tissue-specificity of aDMPs: <https://www.ncbi.nlm.nih.gov/pubmed/29848354> <https://www.aging-us.com/article/101666/text>

Age-related aDMPs vs mortality DMPs: <https://clincalepigeneticsjournal.biomedcentral.com/articles/10.118019-0622-4>

Bocklandt S, et al.: Epigenetic predictor of age. PLoS One 2011, 6(6):e14821. 10.1371/journal.pone.0014821 PubMed Central

Make clarification: when we talk about the 'epigenetic clock' we are talking about the changes that the epigenome as a whole (and more specifically, the methylome) undergo upon ageing. If we refer to a specific epigenetic clock model, we will mention the name (e.g. Horvath epigenetic clock, mitotic epigenetic clock, ...)

Human (surprisingly came first)

In this case, biological age estimated by epigenetic clocks (trained on chronological age) is normally referred to epigenetic age.

Other species. Evolutionary perspective.

Why DNA methylation has been more successful than RNA-seq (more robust across tissues, with the downside that it is more difficult to gain functional insights): <https://www.ncbi.nlm.nih.gov/pubmed>

Idea that hypermethylation with age could be more conserved across tissues than hypomethylation with age. <https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1064-3>

All the time-to-death, mortality rate stuff

1.3.3 The landscape of epigenetic clocks

6th Statistically speaking, the construction of epigenetic clocks is highly degenerate <https://www.aging-us.com/article/101590/text>

Weird tissue cases: germ line?, breast, cerebellum, ... Rooted on ideas of different ageing rates across tissues: <https://www.ncbi.nlm.nih.gov/pubmed/12397350>

Define what I mean by epigenetic ageing clock. Multi-tissue?

1.3.4 What do we know about the epigenetic ageing clock so far?

7th Information from the background section in the screening paper.

Association of epigenetic age acceleration with breast cancer risk <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz020/5341521>

progeroid syndromes (e.g., Werner syndrome, Hutchinson Gilford Progeria Syndrome; Down syndrome) correlates with accelerated epigenetic aging

The epigenetic clock seems to work *in vitro*, in cells, explants [] and organoids[]. Also cells from transplant maintain age, so probably cell intrinsic property. Single-cell analysis will figure this out, efforts already made with scRNA-seq clock.

Epigenetic timer, similar to telomere length but at the epigenetic level.

Expressing telomerase makes cells immortal but not transformed

Indeed, the phenomenology of HIV+ patients, after several years of infection, shows striking similarities (regarding T cell subset derangement, T cell clonal expansion and telomere shortening of T cells) with that observed in aged people (Pawelec et al., 1999). It is possible to speculate that prolonged, chronic infections other than HIV, despite being less aggressive, can lead to similar results. Symptoms of accelerated immunosenescence are also present in Down's syndrome, considered a syndrome of precocious aging (Fabris et al., 1984). [<https://www.sciencedirect.com/science/article/pii/S0531556599000686?via>

Interestingly, epigenetic ageing according to Horvath's epigenetic clock (but not according to other epigenetic clocks, such as Hannum's clock, the skin-blood clock, *PhenoAge* or *GrimAge*) seems to start a few weeks post-conception in fetal tissues [101]. This could imply that the molecular processes responsible for mammalian ageing, at least at the epigenetic level, are already operative during pre-natal development. This **molecular continuum between development and ageing** is further reinforced by the fact that *in vitro* reprogramming of somatic cells into iPSCs reduces epigenetic age to values close to zero (or even negative) both in humans [102] and mice [103, 104], which opens the door to potential rejuvenation therapies [105, 106].

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509060/> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956763/> <https://www.ncbi.nlm.nih.gov/pubmed/21184773>

Reprogramming of epigenetic age <https://www.biorxiv.org/content/10.1101/573386v1>

Turning back time with emerging rejuvenation strategies In vivo amelioration of age-associated hallmarks by partial reprogramming

Caloric restriction and DNA methylation <https://genomebiology.biomedcentral.com/articles/10.1186/s13007-017-1187-1>

Forced expression of the telomere-extending enzyme telomerase can prevent human cells in culture from undergoing senescence (Bodnar et al., 1998). Overexpressing a protein that lengthens telomeres extends the life span of *C. elegans* (Joeng et al., 2004). This is intriguing because the somatic cells of *C. elegans* are postmitotic, so they are not susceptible to replicative telomere shortening.

It is, however, possible that the relatively sudden loss of a substantial proportion of cell replicative potential may account for the physical emaciation and loss of homeostasis associated with senile decay. Kirkwood evolution of ageing

NSD1 also catalyses H4K20 methylation. <https://www.pnas.org/content/106/51/21830> Although unclear. [https://www.cell.com/cell-chemical-biology/fulltext/S1074-5521\(13\)00424-9](https://www.cell.com/cell-chemical-biology/fulltext/S1074-5521(13)00424-9) H4K20 methylation seems to be enriched in telomeres <https://academic.oup.com/nar/article/46/5/2347/4816214> Consequences of losing H4K20 methylation in telomeres Review: <https://academic.oup.com/nar/article/41/5/279> NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming Epigenetic stress response to problems in telomeres (not only short length) Changes in chromatin structure have been shown to occur at dysfunctional telomeres⁷. These changes are often similar to those exhibited at sites of DNA damage, such as phosphorylation of H2AX, changes in H4K20me2 levels and recruitment of tumour suppressor p53-binding protein 1 (TP53BP1), implying that there is a general 'epigenetic' stress response (see the figure, part c).

Differences in sex

Chapter 2

Statistical aspects of the epigenetic clock

2.1 Analysing the blood methylome to study human ageing

2.1.1 Building a DNA methylation dataset from public data

During the last years large amounts of DNA methylation data have been generated to study complex diseases and ageing [107, 108]. Many of these datasets can be obtained from public repositories, such as the NCBI-hosted Gene Expression Omnibus (GEO) [109]. Given its clinical accessibility and ease of collection, blood is one of the most commonly profiled tissues in human DNA methylation studies [108], including published studies on developmental disorders [110] (see Chapter 3). Therefore, I decided to use blood as my surrogate tissue to broaden our understanding of the human epigenetic ageing clock.

Furthermore, most of these human datasets have been generated using different versions of the Illumina Infinium array technology, with the Illumina Infinium HumanMethylation450 array (450K) being the most frequently used platform [108]. Additionally, given that the different array versions have different chemistries, biases and number of probes [111–113], I decided to focus on 450K data for my analyses. Using the *GEOquery* R package [114], I programmatically downloaded from GEO all the DNA methylation data from human blood that I could find, including samples from both whole blood and peripheral blood mononuclear cells (PBMC). Furthermore, the data also had to satisfy the following criteria:

- Raw DNA methylation data was available (i.e. IDAT files). This was required so the pre-processing pipeline and the batch effect correction (which requires access to control probes intensities, see section 2.2.3) could be consistently applied across all the samples in the study.

- Metadata for the samples was available, with the chronological age as an absolute requirement.
- In order to study physiological ageing, the blood samples corresponded to humans without any major disease. However, it is important to mention that I could never be completely certain of this, since there could be a lack of diagnosis and/or lack of reporting of the disease in the metadata.

This allowed me to assemble a **human blood DNA methylation dataset for healthy individuals** (after QC, total $N = 2218$) with the characteristics shown in Table 2.1, which spans the entire human lifespan (0.5 to 101 years). Fig. 2.1 shows that the chronological age distribution is bimodal, with peaks around 10.69 and 58.81 years respectively. This reflects a sampling bias in human population studies, with more data being generated for the periods of postnatal development and during the appearance of age-related disease. However, in order to understand the development of complex diseases as a consequence of the ageing process, efforts should be made to sample people also in their middle ages, before the diseases are normally diagnosed.




Fig. 2.1 Histogram showing the chronological age distribution for all the healthy individuals included in the DNA methylation dataset. The blue line represents the 1D kernel density estimate, as calculate by the `stat_density` function in R with default parameters.

Batch name	$N_{\text{♀}}$	$N_{\text{♂}}$	N	Median age (years)	Other comments
Europe	0	121	121	10.96	-
Feb_2016	0	1	1	0.50	-
GSE104812	19	29	48	9.00	-
GSE111629	111	124	235	71.00	-
GSE40279	336	314	650	65.00	-
GSE41273	0	51	51	10.25	-
GSE42861	239	96	335	55.00	-
GSE51032	253	78	331	54.57	Only people that remained cancer-free in the follow-up after sample collection were included
GSE55491	1	5	6	29.50	-
GSE59065	49	46	95	34.00	-
GSE61496	72	78	150	57.00	Only one member of each twins pair was included
GSE74432	29	22	51	12.00	-
GSE81961	25	0	25	30.05	-
GSE97362	39	80	119	13.00	-
Total	1173	1045	2218	55.00	-

Table 2.1 Overview of the blood DNA methylation dataset from healthy individuals. All the batches were downloaded from GEO [109], with the exception of ‘Europe’ and ‘Feb_2016’, which were generated in-house by my collaborators in Canada (see Chapter 3). $N_{\text{♀}}$: number of samples from females. $N_{\text{♂}}$: number of samples from males. N: total number of samples. These numbers correspond to the samples left after applying quality control (QC, see section 2.1.2).

2.1.2 Main DNA methylation data pre-processing pipeline

The analysis of DNA methylation data generated in Illumina arrays has been a topic of huge discussion and statistical innovation in the epigenetic community. There are plenty of reviews in the literature that discuss the different steps that should be involved in the pre-processing of this data type [115–117]. More specifically, a recent study by Je Liu and Kimberly D. Siegmund systematically benchmarked the pre-processing methods available for the 450K array in order to reduce variation among technical replicates and improve the detection of biological differences [117]. Inspired by their results, I implemented, using the *minfi* R package [118], a pre-processing pipeline for the 450K data with the following steps (Fig. 2.2):

1. **Background correction.** I used the *noob* method [119], as implemented in the *pre-processNoob* function from the *minfi* R package [118]. *noob* allows accounting for technical variation in the background (i.e. non-specific) fluorescence signal, which can lead to a reduced dynamic range for the methylation values (β -values) obtained (Fig. 2.2b, Fig. S1.1) [119]. Briefly, when measuring fluorescence intensities in the Illumina array platforms, the observed intensity (also known as foreground, X_f) is composed of:

$$X_f = X_s + X_b \quad (2.1)$$

where X_s is the true signal and X_b is the background signal. Making use of a normal-exponential convolution (which assumes $X_s \sim Exp(\gamma)$ and $X_b \sim N(\mu, \sigma^2)$) and the ‘out-of-band’ (OOB) intensities (fluorescence signals in the opposite colour channel in Infinium I probes) to model X_b , *noob* is capable of estimating X_s given X_f . Furthermore, I also applied the default dye-bias correction strategy, which controls for the different average intensities in the two colour channels [119].

2. **Quality control (QC).** Following guidelines from the *minfi* R package [118], I kept only those samples that satisfied the following criteria:
 - (a) The sex predicted from the DNA methylation data (Sex_p) was the same as the reported sex in the metadata. The sex was predicted using the *getSex* function from the *minfi* R package [118], which employs intensity information from the sex chromosomes, such that:

$$\text{Sex}_p = \begin{cases} \text{female}, & \text{if: } (\text{median}\{\log_2(M_y + U_y)\} - \text{median}\{\log_2(M_x + U_x)\}) < c \\ \text{male}, & \text{if: } (\text{median}\{\log_2(M_y + U_y)\} - \text{median}\{\log_2(M_x + U_x)\}) \geq c \end{cases} \quad (2.2)$$

where M_y and U_y represent the methylated and unmethylated intensity measurements for the array probes in the Y chromosome, M_x and U_x represent the methylated and unmethylated intensity measurements for the array probes in the X chromosome and c is a predefined cutoff (default in *minfi*: $c = -2$).

- (b) They were not outliers according to their global intensity values after background correction, such that:

$$\frac{\text{median}\{\log_2(M_i)\} + \text{median}\{\log_2(U_i)\}}{2} \geq 10.5 \quad (2.3)$$

where M_i and U_i represent the background-corrected methylated and unmethylated intensity measurements for all the 450K array probes (Fig. S1.2).

3. Probe filtering.

I filtered out the following types of probes:

- Probes that contain SNPs at the single base extension site (position 0) or at the proximal CpG on the probe (positions 1-2), using the *dropLociWithSnps* function in the *minfi* package [118].
- Cross-reactive probes, as defined by Chen *et al.* [120]. These are probes that can co-hybridise to alternative genomic sequences that are highly homologous to the target sequences [120].
- Probes that map to the sex chromosomes (X and Y).

It is important to mention that other authors have also filtered out probes with high detection p-value or low bead counts across samples [115, 116]. However, I did not include these filters since it was not pointed out in the *minfi* guidelines [118, 121] and it could complicate further downstream analyses (e.g. different sets of probes missing across different batches).

4. β -value calculation.

The methylation status of a given CpG site in one of the array probes is normally quantified using the β -value statistic, which can be calculated as [115, 122]:




Fig. 2.2 Main DNA methylation data pre-processing pipeline. **a.** Flowchart showing the main steps implemented to pre-process the DNA methylation data from the 450K methylation arrays. The number of samples (N_{samples}) and the number of array probes (N_{probes}) left after each step are also specified for the samples from the healthy individuals. **b.** β -value distributions, calculated using the raw fluorescence intensities (i.e. before any pre-processing), for the samples in the GSE41273 batch. Each curve represents a different sample. In grey: 51 samples that passed quality control (QC). In red: 2 samples that failed QC. **c.** As in b., but calculating the β -values after background correction. **d.** As in b., but calculating the β -values after background correction, QC, probe filtering and BMIQ normalisation (i.e. the final β -values that I used for downstream analyses). Note that the samples that failed QC have been removed.

$$\beta_i = \frac{\max(M_i, 0)}{\max(M_i, 0) + \max(U_i, 0) + \alpha} \quad (2.4)$$

where M_i and U_i represent the methylated and unmethylated intensity measurements for the i th-probe and α is a constant offset (in this work $\alpha = 100$, as recommended by Illumina) [122].

In a DNA molecule of a single cell, a specific cytosine is either unmethylated or methylated (categorical / binary variable). However, given that a bulk DNA sample from a tissue is composed of thousands of cells (which can include different cell types with different methylation patterns), β -values result in a continuous variable between 0 and 1. A value of 0 means that all the measured DNA molecules are unmethylated (0%) and a value of 1 means that all the measured DNA molecules are methylated (100%) in that cytosine, which is roughly equivalent to say that 100% of the cells are either unmethylated or methylated respectively in that cytosine for the sampled tissue. The β -values for a given sample (i.e. considering all the cytosines measured, normally in a CpG context) usually follow a bimodal distribution, where the two peaks are centred around 0 and 1 (Fig. 2.2d).

Other authors have used M-values to quantify methylation levels in arrays (Fig. S1.3), which can be calculated as:

$$\text{M-value}_i = \log_2 \left(\frac{\max(M_i, 0) + \alpha}{\max(U_i, 0) + \alpha} \right) \quad (2.5)$$

with a default offset value of $\alpha = 1$. Du *et al.* reported that β -values suffer from severe heteroscedasticity for highly methylated or unmethylated CpG sites and therefore the M-values have more desirable statistical properties [122]. However, Zhuang *et al.* later showed that this only becomes a problem in studies with small sample sizes [123] (which is not the case for my analyses). Furthermore, β -values are easier to interpret biologically and can be readily used in the context of BMIQ normalisation (see below). For these reasons, I choose β -values as the main methylation variable for this work.

5. **Beta-mixture quantile normalisation (BMIQ).** As mentioned in Chapter 1, in the case of the 450K arrays two types of probes / chemistry coexist in the same platform. Infinium I probes and Infinium II probes have different β -values distributions (a.k.a. Infinium II probe bias). BMIQ is an intra-array normalisation strategy that allows to

correct for this bias and has been shown to outperform other methods used in this context [124–127]. BMIQ fits a three-state beta-mixture model to Infinium I and Infinium II probes separately and then maps the Infinium II probes distribution into the Infinium I probe distribution (Fig. 2.3). In the case of unmethylated (β -values close to 0) and methylated (β -values close to 1) probes, this is done by transforming probabilities into quantiles. In the case of ‘hemimethylated’ probes (intermediate β -values), a dilation transformation is applied to preserve the monotonicity and continuity of the data [124]. I applied BMIQ to my samples and discarded those that failed the normalisation step.




Fig. 2.3 Effect of BMIQ normalisation on the β -value distribution of different subsets of array probes with different chemistries (Infinium I, Infinium II). These results correspond to a DNA methylation sample from the GSE41273 batch. It can be appreciated how BMIQ transforms the distribution of the Infinium II probes into a distribution more similar to the Infinium I probes.

2.1.3 Accounting for blood cell composition changes during ageing

Whole blood is composed of several cell types that contain a nucleus, including neutrophils, eosinophils, basophils, CD14⁺ monocytes, CD4⁺ T cells, CD8⁺ T cells, CD19⁺ B cells and CD56⁺ natural killer (NK) cells [128]. These cell types have different epigenetic profiles and, as a consequence, changes in their proportions (i.e. changes in blood cell composition) can affect bulk DNA methylation measurements [129].

Accounting for this cellular heterogeneity is really important in epigenome-wide association studies (EWAS) [130–132]. Furthermore, previous research has highlighted changes in blood cell composition with age, which could be one of the causes behind immunosenescence [133–137]. Therefore, considering blood cell composition in the context of ageing-related studies and the epigenetic clock is fundamental in order to make sure that the observed age-related changes in the methylome are not a direct consequence of the changes in blood cell composition during ageing [131, 138, 139].

Several methods have been developed to estimate the cell composition of a blood sample given a bulk DNA methylation measurement (a.k.a. cell-type deconvolution) [128, 140–142]. These methods can be broadly split in two categories:

- **Reference-based approaches.** They use a pre-defined set of DNA methylation reference profiles for the cell types that are supposed to be present in the tissue. In the case of methylation arrays, these reference profiles can be constituted by the β -values for a subset of array probes that are highly discriminative of the underlying cell types. Assuming that the blood sample is a weighted linear sum of the reference profiles, the objective of the method is to find these weights (w_c), which should be equivalent to the actual cell type proportions (given the assumption $\sum_{c=1}^C w_c \leq 1$) [128]. In mathematical terms:

$$\mathbf{y} = \sum_{c=1}^C w_c \mathbf{b}_c + \boldsymbol{\varepsilon} \quad (2.6)$$

where \mathbf{y} is the DNA methylation profile of the sample being considered, C is the number of underlying cell types, \mathbf{b}_c is the DNA methylation profile for the c th cell type and $\boldsymbol{\varepsilon}$ is the error [141]. Different algorithms have been applied to estimate the values of w_c , with the approach by Houseman *et al.* (which uses a linear constrained projection) [143] being the most widely used.

- **Reference-free approaches.** Instead of making use of reference profiles for the cell types of interest, these methods generally calculate latent variables that capture variation driven by cell type composition, although the strategy and assumptions to derive these latent variables from the DNA methylation data is highly method-specific [128]. These methods become particularly useful when no references are available for the cell types that constitute the tissue [128].

However, reference-free approaches rarely provide with estimates for the specific cell types in a given sample [128] (which are needed in the current modelling framework of the epigenetic clock) and they often rely on the assumption that the top components of variation correlate with cell composition [141], something that is not always true (especially in the case of developmental disorders, see Chapter 3). Thus, I decided to benchmark different reference-based cell-type deconvolution strategies in blood. In this context I tested (Fig. S1.4):

- **Different blood references.** As pointed out before, the quality of the reference, containing the DNA methylation profiles of the cell types to be inferred, is crucial [141, 144]. The reference must be composed of those CpG sites (in this case, array probes) that are able to better discriminate between the different cell types. In my case I considered 6 major blood ‘cell types’ for the inference: granulocytes (‘Gran’), CD4⁺ T cells (‘CD4T’), CD8⁺ T cells (‘CD8T’), CD19⁺ B cells (‘B’), CD14⁺ monocytes (‘Mono’) and CD56⁺ natural killer cells (‘NK’). It is important to point out that granulocytes are not themselves a ‘biological cell type’ (since they are composed of neutrophils, eosinophils and basophils), but will be considered as a ‘computational cell type’ as previously done [138, 139]. I tested three different blood references whose constitutive probes were selected using different strategies:

1. The reference implemented in the *estimateCellCounts* function from the *minfi* R package [118], which is widely used in the epigenetic literature. The reference probes were selected using *t*-statistics, by finding those probes that were differentially methylated in each cell type when compared with the rest of the cell types. Among those probes that showed differences at p-value < 10⁻⁸, the 100 most differentially methylated probes by effect size (50 hypermethylated and 50 hypomethylated) were chosen for each cell type (making a total of 600 probes for the reference) [131].
2. The reference implemented in the *EpiDISH* R package (*centDHSbloodDMC.m*) [145]. The reference probes (DHS-DMCs, 333 in total) were selected by leveraging information of both differentially methylated cytosines (DMCs, using

moderated *t*-statistics) and chromatin accessibility (DNase Hypersensitive Sites or DHS) for each cell type [141].

3. The reference implemented as part of the IDOL strategy (IDentifying Optimal DNA methylation Libraries) [144]. In this case, the reference probes (300 in total) were originally selected based on differential methylation criteria and are updated in an iterative manner, with the probability of being selected based on their contribution to prediction accuracy [144].

The three references were built using the dataset from Reinius *et al.* (GSE35069) [129], which I obtained directly from the *FlowSorted.Blood.450k* R package [146]. This dataset contains DNA methylation data generated in the 450K array for the 6 cell types considered, that were isolated using flow cytometry [129]. The β -values for the selected probes were averaged across the biological replicates for each cell type.

- **Different DNA methylation pre-processing pipelines.** I tested different configurations for the pre-processing of both the gold-standard (see below) and the reference data. For example, I tested whether probe filtering according to the criteria outlined in the previous section (section 2.1.2) is desirable, since this leads to the removal of some of the probes originally selected for the reference in the original publications [141, 144] (Fig. S1.4). Furthermore, I also tested whether the prediction benefits from a similar pre-processing of both the gold-standard (or the dataset where the prediction will be made) and the reference.
- **Different deconvolution algorithms.** I tested the performance of the following algorithms: CP/QP (constrained projection/quadratic programming, originally implemented by Houseman *et al.* [143]), RPC (robust partial correlations) [141] and CIBERSORT (which was originally developed for cell-type deconvolution using RNA expression data) [141, 147]. One of the key differences between the algorithms is how the normalisation constrain ($\sum_{c=1}^C w_c \leq 1$) is implemented [141]. All the algorithms were run using the implementations in the *epidish* function from the *EpiDISH* R package [145], with the exception of the run in the *minfi* reference, for which I used the *estimateCellCounts* function with default parameters for the 450K array [118].

In order to compare the results from the predictions against real cell composition values, I used a **gold-standard** dataset (GSE77797) containing 12 samples where known proportions of DNA isolated from the different blood cell types were mixed [144]. I assessed the accuracy of the predictions using 3 different metrics:

- Root mean squared error (*RMSE*), which can be calculated as (for a given cell type c):

$$RMSE_c = \sqrt{\frac{\sum_{n=1}^N (\hat{y}_{cn} - y_{cn})^2}{N}} \quad (2.7)$$

where \hat{y}_{cn} is the predicted proportion of the c th cell type in the n th sample, y_{cn} is the real proportion of the c th cell type in the n th sample and N is the total number of samples in the gold-standard dataset ($N = 12$). A perfect prediction for a cell type would minimise the value of $RMSE_c$ (i.e. $RMSE_c = 0$).

- Mean absolute error (*MAE*), which can be calculated as (for a given cell type c):

$$MAE_c = \frac{\sum_{n=1}^N |\hat{y}_{cn} - y_{cn}|}{N} \quad (2.8)$$

A perfect prediction for a cell type would minimise the value of MAE_c (i.e. $MAE_c = 0$).

- Coefficient of determination (R^2), which can be calculated as (for a given cell type c):

$$R_c^2 = \frac{\sum_{n=1}^N (\hat{y}_{cn} - \bar{y}_c)^2}{\sum_{n=1}^N (y_{cn} - \bar{y}_c)^2} \quad (2.9)$$

where $\bar{y}_c = \frac{\sum_{n=1}^N y_{cn}}{N}$. A perfect prediction would maximise the value of R_c^2 (i.e. $R_c^2 = 1$).

The most accurate strategy, according to the *RMSE* (mean across cell types: 1.9270) and *MAE* (mean across cell types: 1.5498), is ‘idol_NFB_houseman’ (Fig. 2.4, Fig. S1.5) i.e. the strategy that uses the IDOL reference, with all the pre-processing steps from my main pipeline for both reference and gold-standard (*noob* background correction, probe filtering and BMIQ normalisation) and employs Houseman’s CP/CQ algorithm (Fig. S1.4). This strategy performed well in all the cell types (Fig. 2.5) and I selected it for my cell-type deconvolution analyses.

It is important to mention that the gold-standard dataset was generated as part of the same study where the IDOL reference was also derived [144]. However, the gold-standard samples were used as an independent validation of the IDOL reference and should not have an influence on the conclusions of the benchmarking that I performed. In the future, it will

be interesting to validate these conclusions using new gold-standard datasets generated from whole blood.

Next, I ran the optimal blood cell-type deconvolution strategy in the DNA methylation dataset that I built from healthy individuals (Table 2.1). The main goal of this analysis was to provide blood cell type proportions that can be used as covariates as part of the epigenetic clock modelling (see section 2.2.2). However, this also allowed me to broadly quantify the **changes in blood composition that occur during human ageing** (Fig. 2.6). The mammalian immune system undergoes dramatic changes during ageing. These changes are normally referred as *immunosenescence* and can be broadly defined as a decline in immune system functionality and its ability to fight infections, which results in an increase in morbidity and mortality with age [148]. Furthermore, human ageing is also characterised by an increase in chronic, low-grade inflammation referred as *inflammageing*, which is thought to contribute to the development of age-related diseases (such as atherosclerosis, type 2 diabetes, Alzheimer's disease and osteoporosis) [149].

In my dataset, I observe the following (Fig. 2.6):

- A relative decrease in cell types from the adaptive immune system ($CD4^+$ T cells, $CD8^+$ T cells and $CD19^+$ B cells). Interestingly, the decline in $CD8^+$ T cells was more pronounced (i.e. higher absolute value of the slope) than in the case of $CD4^+$ T cells, which has been previously pointed out [133].
- A relative increase in cell types from the innate immune system (granulocytes, $CD14^+$ monocytes and $CD56^+$ natural killer cells).

These results are highly consistent with the literature [131, 133–137], which validates the methodology for cell-type deconvolution that I have used. These variations in blood cell composition may be caused by the age-related changes that happen in the two primary lymphoid organs: the bone marrow (whose hematopoietic stem cells exhibit reduced self-renewal potential and increased skewing towards myelopoiesis) and the thymus (which undergoes tissue involution) [150].

This analysis provides a preliminary overview of the blood composition landscape during human ageing. However, only relative changes in blood composition were quantified and the analysis is limited by the ‘cell types’ that I have deconvoluted (e.g. granulocytes include different cell types, different subsets of monocytes exist, ...), which means that these conclusions must be taken with care [148]. Furthermore, the sex of the individual can influence the proportions of blood leukocytes [135] and it should be taken into account in future analyses.



a**b**

Fig. 2.4 Benchmarking of the cell-type deconvolution strategies in blood. The x-axis shows the different strategies that were tested (for a detailed description see Fig. S1.4). The y-axis shows the results for **a.** the root mean squared error (RMSE) and **b.** the mean absolute error (MAE) when comparing the predictions with the real proportions of cells in a gold-standard dataset (GSE77797) [144]. The grey horizontal solid lines represent the mean for the RMSE or the MAE across cell types and the grey dashed line the minimum of these values.




Fig. 2.5 Comparison of the predictions for the different cell types using the optimal deconvolution strategy ('idol_NFB_houseman') with the real cell type fractions in the gold-standard dataset (GSE77797) [144]. Each point corresponds to a different sample in the gold-standard. The black dashed line represents the diagonal to aid visual interpretation.




Fig. 2.6 Changes in blood cell composition during human ageing. Scatterplots showing the changes in the proportions of the 6 cell types considered (inferred using the cell-type deconvolution strategy) as a function of chronological age. Each point represents a different DNA methylation human sample from Table 2.1. The black line displays the linear model $\% \text{cell_type} \sim \text{Age}$ (see section 2.4 for more details on linear modelling), with the slope and intercept shown in the titles. The Spearman's correlation coefficient (SCC) and the p-value associated with it are also displayed.

2.1.4 Identifying differentially methylated positions during ageing

Differential methylation analysis is one of the most common types of downstream analyses in the context of DNA methylation data [115, 116, 142]. It involves finding associations between the DNA methylation levels at specific CpG sites in the genome (a.k.a. differentially methylated positions or DMPs) and a given phenotypic variable of interest (e.g. a specific disease, when compared with a healthy sample). It is worth mentioning that DMPs are also called differentially methylated cytosines (DMCs) in the literature [142].

In order to study the changes that the methylome undergoes during physiological ageing, it is useful to identify differentially methylated positions during ageing (aDMPs) i.e. individual cytosines (normally found in a CpG context) that change their methylation status as a function of chronological age. Linear models, widely used in the context of differential RNA expression analysis [151], can also been adapted to find aDMPs [123, 142]. In the case of a continuous variable (such as chronological age) the association is performed using a linear regression modelling framework [123] (see section 2.4 for a short description of linear regression and the nomenclature used through this thesis). Briefly, for each probe in the methylation array, I fitted the following **linear regression models** to the data from the healthy individuals:

- A model with cell composition correction (CCC). As I have shown previously, the different blood cell types change their abundance with age. Therefore, in order to maximise the chances of finding aDMPs that are conserved across different cell types, it is important to include the estimated cell proportions as covariates in the model:

$$\text{Beta} \sim \text{Age} + \text{Sex} + \text{Gran} + \text{CD4T} + \text{CD8T} + \text{B} + \text{Mono} + \text{NK} + \text{PC1} + \dots + \text{PC17} \quad (2.10)$$

where *Beta* is the β -value for the array probe being evaluated; *Age* is the chronological age (in years) of the samples; *Sex* encodes for the sex of the samples (0/1); *Gran*, *CD4T*, *CD8T*, *B*, *Mono* and *NK* are the cell type proportions from the samples as calculated with my cell-type deconvolution strategy and *PCN* is the *N*th principal component that captures technical variance and accounts for potential batch effects (see section 2.2.3 for more details).

- A model without CCC, which can be expressed as:

$$\text{Beta} \sim \text{Age} + \text{Sex} + \text{PC1} + \dots + \text{PC17} \quad (2.11)$$

This leads to the identification of aDMPs which will be more confounded with the proportions of the different cell types (i.e. the change in β -value with age could be entirely driven by a change in a specific cell type that is differentially methylated at that particular probe).

Furthermore, for each probe, I calculated a p-value, based on t -statistics [142], to assess whether the putative linear association between the methylation status and chronological age was significant or not (at a significance level of $\alpha = 0.01$ after applying Bonferroni correction to account for multiple testing, see section 2.4 for more details). I used a customised version of the *dmpFinder* function in the *minfi* R package [118] to identify the aDMPs, which internally uses the *limma* framework [151]. Given the big sample size ($N = 2218 \gg 10$), I did not use variance shrinkage (i.e. empirical Bayes moderated t -statistics) as part of the statistic calculations [151].

An overview of the different aDMPs (with and without CCC) identified in the healthy individuals can be found in Figure 2.7. Around 30% of the blood methylome (at least according to the 450K array) is affected by the ageing process during human lifespan. However, it is worth mentioning that Bonferroni correction provides a very conservative picture of the methylomic changes (when compared with other methods to control for type-I error, like FDR) and it is likely that an even greater proportion of the methylome is indeed altered with age [152]. CpG sites can become both hypomethylated (i.e. lose methylation with age) or hypermethylated (i.e. gain methylation with age). Importantly, the effect sizes of the age coefficient (i.e. the observed changes in the β -values per year) are generally small. More specifically, in the model with CCC, the median age coefficient for the hypomethylated aDMPs is -0.000426 (equivalent to a -4.26% methylation change over 100 years of human life) and for hypermethylated aDMPs is 0.000437 (equivalent to a +4.37% methylation change over 100 years of human life). This is consistent with the progressive functional decline observed during ageing [2]. It is worth mentioning that around 50% of the CpG sites that constitute the Horvath epigenetic clock are blood aDMPs according to my analysis (Fig. 2.7c,d). Overall, these results are consistent with previous studies [153, 154, 152, 155].

Next, I looked at the top 100 aDMPs that were identified (according to their p-value and t -statistic, Fig. S1.6 and Fig. 2.8). The first aDMP in the list was cg16867657, a probe that consistently gains methylation with age (Fig. 2.8a) and has been previously identified as




Fig. 2.7 The blood methylome changes during physiological human ageing. **a.** Barplot showing the total number of differentially methylated positions during ageing (aDMPs) that were identified (in grey: probes that did not reach statistical significance). In this case, the model with cell composition correction (CCC) was applied. **b.** As in a., but using the model without CCC. **c.** Volcano plot showing the relationship between the p-value (y-axis) and the effect size (x-axis) of the age coefficient for each one of the array probes (each point represents a probe). Those probes above the dashed green line ($\alpha = 0.01$ after Bonferroni correction) are the identified aDMPs. Above the volcano plot, a density plot captures the distributions of the age coefficient for the hypermethylated aDMPs (in red) and the hypomethylated aDMPs (in blue). In this case, the model with CCC was applied. The black points are the 353 CpG probes that constitute the Horvath epigenetic clock model [102]. **d.** As in c., but using the model without CCC.

the strongest aDMP across tissues and human populations in several studies [154, 156–160]. cg16867657 is associated with the CpG island in the promoter of the ELOVL2 gene, which encodes an enzyme that catalyses one of the reactions in the elongation of polyunsaturated fatty acids [159]. Furthermore, other aDMPs that were located among my top hits have previously been reported as well (such as cg06639320 in the FHL2 gene, which is the second aDMP, Fig. 2.8b) [156]. These results validate the statistical methods used so far to process the DNA methylation data and to identify aDMPs.




Fig. 2.8 Changes in the β -values of four different differentially methylated positions during ageing (aDMPs) in the blood of the healthy individuals. cg16867657 and cg06639320 are the top aDMPs that gain methylation with age (i.e. become hypermethylated) according to the model that accounts for cell composition correction (CCC). cg19283806 and cg10501210 are the top aDMPs that lose methylation with age (i.e. become hypomethylated) according to the model that accounts for CCC. In order to aid visualisation, the black line displays the linear model β -value \sim Age.

It is important to mention that not all the CpG sites change their DNA methylation levels with age in a perfectly linear manner. For instance, the two top hypomethylated aDMPs (Fig. 2.8c,d) modify their rate at ages 20-25 years. This was already recognised by Horvath [102] and that is why the age is transformed into a logarithmic scale before the age of 20 years in order to improve the model fit (see section 2.2.1). Furthermore, genetic background can have a significant effect on the DNA methylation patterns and interact with the ageing process to shape the epigenome [155, 160]. Unfortunately, I did not have genetic data for the healthy individuals but this could help to refine the identification of aDMPs in the future. Additionally, it would be interesting to apply methods to control for bias and inflation in the test statistics, by estimating the empirical null distribution [161]. Finally, other types of epigenetic features can be derived to understand the effects of ageing in the epigenome, such as variably methylated positions during ageing (aVMPs) [153], differentially methylated regions (DMRs, which consider several correlated CpGs at the same time) [142] or differentially methylated cytosines in individual cell types (DMCTs, which consider interactions between the phenotypic variable and the proportions of cell types) [162].

2.1.5 Shannon methylation entropy

Shannon entropy (H) can be used in the context of DNA methylation analysis to estimate the information content stored in a given set of CpG sites [153, 160, 163–165]. I calculated it using the same approach as in Hannum *et al.* [160]:

$$H = -\frac{1}{N} \cdot \sum_{i=1}^N [\beta_i \cdot \log_2(\beta_i) + (1 - \beta_i) \cdot \log_2(1 - \beta_i)] \quad (2.12)$$

where β_i represents the methylation β -value for the i th array probe (or CpG site) and $N = 428266$ if all the array probes that survived the pre-processing pipeline are considered (i.e. genome-wide, or at least array-wide). Shannon entropy is minimised when the methylation levels of all the CpGs are either 0% or 100%. and maximised when all of them are 50% (Fig. 2.9).

Next, I calculated the genome-wide Shannon entropy for the blood samples in the healthy individuals. Consistent with previous reports [153, 160, 163, 165], the genome-wide Shannon entropy associated with the methylome increases during ageing (Fig. 2.10a; Spearman correlation coefficient = 0.1985; p-value = $3.8281 \cdot 10^{-21}$), which implies that the epigenome loses information content. Finally, it is worth mentioning that I observed

a remarkable effect of the batch on the Shannon entropy calculations, which can generate high entropy variability for a given age (Fig. 2.10b). However, after removing potential outlier batches (such as GSE41273, GSE59065 or GSE97362) the increase of Shannon methylation entropy during ageing was still consistent. Thus, accounting for technical variation (see section 2.2.3) becomes crucial when assessing this type of data, even after careful pre-processing.




Fig. 2.9 Plot showing the relationship between the β -value and the methylation Shannon entropy at a given CpG site (in my case, at a given array probe).

2.2 Behaviour of Horvath's epigenetic clock during ageing

2.2.1 Calculating epigenetic age using Horvath's epigenetic clock

Steve Horvath's model, originally published in 2013 [102], is without any doubt the most widely used epigenetic clock in the literature. Given that it works across tissues with high accuracy and that it has been validated in many human cohorts, I have used it as the main tool to quantify epigenetic ageing in this work.

Horvath's model measures epigenetic age (a.k.a. *DNAmAge*) by making use of the DNA methylation levels at 353 CpG sites, as quantified with the Illumina methylation arrays (27K or 450K). Previous studies have generally employed a ready-to-use online calculator for *DNAmAge* provided by Steve Horvath [166]. This has clearly simplified the computational




Fig. 2.10 **a.** Scatterplot showing the changes in genome-wide methylation Shannon entropy during ageing in the healthy individuals. Each sample is represented by one point. The black line displays the linear model Entropy \sim Age. **b.** Same as in a., but colouring the samples according to the batch where they came from.

process and helped a lot of research groups to test the behaviour of the epigenetic clock in their system of interest. However, this has also led to the treatment of the epigenetic clock as a ‘black-box’, without critical assessment of the statistical methodology behind it. Therefore, I decided to replicate the original code and to make it available in a GitHub repository for the scientific community to be used [167]. Furthermore, I tested the impact of different steps involved in the estimation of epigenetic age acceleration (EAA), including the presence/absence of background correction, removal of technical variation from batch effects and the importance of the age distribution when fitting the control models, which I discuss in the following sections.

The main pipeline to calculate the epigenetic age (*DNAAge*) from a sample has the following steps (some of them are shared with the previously described pipeline for DNA methylation pre-processing in section 2.1.2):

- 1. Background correction.** I implemented a pipeline that starts with the raw DNA methylation data (IDAT files) for a sample. First, I tested what was the effect of applying *noob* background correction, before calculating the β -values, on the median absolute error (MAE) of the predictions (see section 2.2.2). Background correction did not have a major impact in the final predictions as long as I also corrected for batch effects (Fig. S1.7, Fig. 2.13c, see section 2.2.3). Therefore, I decided to keep the *noob* background correction for consistency with the other pre-processing pipeline.

2. **Quality control.** I applied the same criteria as previously described in section 2.1.2.
3. **Probe filtering.** Horvath's model was originally trained starting with 21368 array probes that had the following characteristics [102]:
 - They were shared between the 27K and 450K methylation arrays.
 - They had ≤ 10 missing values across all the training data.

Therefore, these were the probes selected for downstream analysis.

4. **β -value calculation.** β -values were calculated as previously described in section 2.1.2. It is worth mentioning that Horvath's original code includes two alternatives for the imputation of missing β -values:
 - Slow imputation (applied when the number of missing β -values is < 3000). In this case, k -nearest neighbours (KNN) is used. KNN imputation borrows information from the DNA methylation profiles of the most similar probes (the neighbours) according to a metric (normally the Euclidean distance). The *impute.knn* function from the *impute* R package can be used for these purposes [168].
 - Fast imputation (applied when the number of missing β -values is ≥ 3000). In this case, the values from the blood gold-standard (see below) can be used as the imputed values.

In the case of my dataset, no missing values were present for the 21368 probes so there was no need to perform imputation.

5. **Gold-standard normalisation.** A modified version of BMIQ normalisation is used [124]. In this case, instead of mapping the distribution of the Infinium II probes to the distribution of Infinium I probes, the mapping is done from the distribution of the 21368 probes in the sample to the distribution of a previously derived gold-standard for the same set of probes. This gold-standard was created by taking the average β -values for the 21368 probes across all the whole blood samples from [169].
6. **Calculating epigenetic age (*DNAmAge*).** As previously observed for some of the aDMPs, the rate of β -value change can be different before and after adult age (Fig. 2.8). For this reason, Horvath performed a transformation of the chronological age before training the model:

$$f(c) = c_t = \begin{cases} \ln\left(\frac{c+1}{a+1}\right) & \text{if: } c \leq a \\ \left(\frac{c-a}{a+1}\right) & \text{if: } c > a \end{cases} \quad (2.13)$$

where c_t is the transformed chronological age that was used as the dependent variable during training, c is the chronological age (in years) and a is the adult age (for humans, 20 years). This transformation allows to account for a relationship between chronological age and methylation changes that is logarithmic until adult age and linear afterwards (Fig. 2.11).



Fig. 2.11 Plot showing the relationship between the chronological age in years (c) and the transformed chronological age (c_t) in Horvath's model. This transformation allows accounting for different rates of β -value change before and after adult age (20 years in humans, as pointed out by the dashed black line).

Given a sample to predict, the epigenetic age can then be calculated as:

$$DNAAge = g(\hat{c}_t) = g(\hat{\beta}_0 + \sum_{i=1}^{353} \hat{\beta}_i \cdot x_i) \quad (2.14)$$

where \hat{c}_t is the predicted transformed age according to Horvath's model, $\hat{\beta}_0$ is the intercept in the Horvath's model, $\hat{\beta}_i$ is the coefficient (weight) for the i th probe (only 353 probes are finally used), x_i is the β -value for the i th probe after gold-standard normalisation and $g(\cdot)$ is the inverse of $f(\cdot)$, such that:

$$g(\hat{c}_t) = f^{-1}(\hat{c}_t) = \hat{c} = \begin{cases} e^{\hat{c}_t} \cdot (a + 1) - 1 & \text{if: } \hat{c}_t \leq 0 \\ \hat{c}_t \cdot (a + 1) + a & \text{if: } \hat{c}_t > 0 \end{cases} \quad (2.15)$$

where \hat{c} is the predicted age according to Horvath's model (i.e. *DNAAge*).

2.2.2 Horvath's epigenetic clock measures physiological ageing

Using the methodology from the previous section, I calculated the epigenetic age (*DNAAge*) in the blood of the healthy individuals. Given that these individuals are supposed to be disease-free, Horvath's epigenetic clock should predict epigenetic ages that are similar to the chronological age of the samples, and this was indeed the case (Fig. 2.12a, Pearson's correlation coefficient (PCC) = 0.9671, p-value ≈ 0). This validates that Horvath's epigenetic clock does indeed measure the ageing process (at least in a cross-sectional population) and sets a foundation for the rest of the analyses presented in this thesis.

As mentioned in Chapter 1, the difference between epigenetic age and chronological age is known as **epigenetic age acceleration** (EAA), with a positive EAA (i.e. $DNAAge > Age$) associated with several age-related health problems. In order to calculate the EAA for the healthy individuals, I fitted the following linear regression models (hereinafter referred as the *control models*):

- With cell composition correction (CCC):

$$DNAAge \sim Age + Sex + Gran + CD4T + CD8T + B + Mono + NK + PC1 + \dots + PC17 \quad (2.16)$$

where *DNAAge* is the epigenetic age calculated with Horvath's epigenetic clock; *Age* is the chronological age (in years) of the samples; *Sex* encodes for the sex of the samples (0/1); *Gran*, *CD4T*, *CD8T*, *B*, *Mono* and *NK* are the cell type proportions from the samples as calculated with my cell-type deconvolution strategy and *PCN* is the *N*th principal component that captures technical variance and accounts for potential batch effects (see section 2.2.3 for more details).

Horvath's epigenetic clock was trained using multiple tissues and its predictions should be robust to changes in blood cell composition. However, previous studies

have highlighted that adding this correction can improve the ability to detect ‘pure’ ageing effects [138, 139] (i.e. epigenetic age acceleration mainly caused by DNA methylation changes that happen in the nucleus of all cell types). For a given sample, the $EAA_{\text{with CCC}}$ is the residual from the model i.e. the difference between the actual $DNAmAge$ and the prediction from the control model (which is conceptually similar to the difference between $DNAmAge$ and chronological age, but accounting for the rest of covariates as well). The $EAA_{\text{with CCC}}$ that I have defined is very similar to the previously reported measure of ‘intrinsic EAA’ (IEAA) [138, 139].

- Without CCC:

$$DNAmAge \sim Age + Sex + PC1 + \dots + PC17 \quad (2.17)$$

In this case the residuals of the model are referred as the $EAA_{\text{without CCC}}$ for the different samples.

It is possible to calculate the overall accuracy of the predictions using the median absolute error (MAE), that can be calculated as:

$$MAE = \text{median} \{ |EAA_i| \} \quad (2.18)$$

where EAA_i is the epigenetic age acceleration for the i th sample calculated with one of the models (with CCC or without CCC). The MAE for all the healthy individuals (full lifespan) in the control models should be close to zero, and this was indeed what I observed ($MAE_{\text{with CCC}} = 2.7117$ years, $MAE_{\text{without CCC}} = 2.8211$ years). These results are below the original MAE reported by Horvath in his test set (3.6 years) [102]. However, it is worth mentioning that some of the samples from my healthy individuals (such as samples from batches GSE40279 and GSE42861) could have been used by Horvath as part of his training set [102], and therefore these results must be interpreted carefully.

Even though Horvath’s model seems to predict epigenetic age accurately, it is also clear that some samples deviate substantially from the expected prediction. This is specially obvious for the older samples (> 55 years), that have a systematically younger epigenetic age than expected (see deviations from the diagonal in Fig. 2.12a). If a control model is fit to the full lifespan dataset (which contains around 50% samples which are > 55 years), this leads to a model with a smaller than expected age coefficient (slope), which introduces a bias when




Fig. 2.12 Horvath's epigenetic clock measures physiological ageing. **a.** Scatterplot showing the relationship between epigenetic age ($\text{DNA}_{\text{m}}\text{Age}$) according to Horvath's model [102] and chronological age of the samples for the healthy individuals. Each sample is represented by one point. The black dashed line represents the diagonal to aid visualisation. The solid brown line represents the linear model $\text{DNA}_{\text{m}}\text{Age} \sim \text{Age}$, which deviates from the diagonal if the full lifespan samples are used. **b.** Boxplots displaying the epigenetic age acceleration (EAA) distributions for different age ranges (young age: ≤ 20 years; middle age: $20 < \text{Age} \leq 55$ years; old age: > 55 years) after fitting the control models to the full lifespan samples. The dashed black line represents $\text{EAA} = 0$, where the distributions should be centred around. This is not the case for the samples in the young age and middle age groups. In red: EAA model with cell composition correction (CCC). In blue: EAA model without CCC. **c.** As in a., but removing the samples in the old age group (> 55 years). The solid green line represents the linear model $\text{DNA}_{\text{m}}\text{Age} \sim \text{Age}$, which is much more similar to the diagonal if only young and middle age samples are considered. **d.** As in b., but fitting the control models to the samples in the young and middle age groups (0–55 years). The bias in the EAA is corrected in this case (the distributions are centred around zero for the different age groups).

estimating epigenetic age acceleration for different age groups (Fig. 2.12b). Although many studies do not take this problem into account, this phenomenon has been previously reported in the context of humans [170, 171] and mice [172]. However, to this date, it is unclear whether it represents a technical artefact or it has a biological explanation (e.g. survivor bias of the older individuals, the molecular processes that drive ageing slow down with age, ...).

This highlights the importance of having a properly age-matched control when performing analyses with the Horvath's epigenetic clock. As expected, removing the older samples (> 55 years) from the control models corrected for this bias (Fig. 2.12c,d) and reduced the *MAE* ($MAE_{\text{with CCC}} = 2.2742$ years, $MAE_{\text{without CCC}} = 2.3237$ years). This is the strategy that I used when screening for epigenetic age acceleration in the context of developmental disorders (see Chapter 3).

2.2.3 Correcting for batch effects in the context of the epigenetic clock

As mentioned in the previous section, it is expected that, after fitting the control models, the EAA distributions of the samples from the healthy individuals should be centred around zero. However, if the principal components (PCs) that capture technical variation were not included in the control models (see equations 2.16 and 2.17), this was not the case for several batches (Fig. 2.13a, Fig. S1.8a). Therefore, I hypothesised that technical variation can affect the predictions from Horvath's epigenetic clock and that batch effects need to be explicitly accounted for in this context, even after applying the internal normalisation step against the blood gold-standard [102]. This section explains how I implemented this batch effect correction (i.e. how I derived the principal components that capture technical variance across batches).

A batch effect is a systematic technical source of variation that is unrelated to the biological or scientific variables in a study [173]. They affect low- and high-throughput measurements and can be caused by a wide variety of situations: different technicians performing the experiments, different laboratories generating the data, different lots of reagents or arrays used, ... [173]. Correcting for bath effects is crucial, especially when integrating data from different studies and sources [174], as it is the case in the analyses presented in this thesis. Data generated by DNA methylation arrays is also affected by batch effects and several methods have been described in the literature to correct for them, normally at the level of probe intensities [175] or M-values [174, 176]. In the context of the epigenetic clock, previous attempts to account for technical variation have used the first 5 principal components (PCs) estimated directly from the DNA methylation data (presumably

the β -values) [177]. However, this approach potentially removes meaningful biological variation, especially in studies where there are global changes in DNA methylation, such as cancer [175] or developmental disorders (see Chapter 3). Furthermore, given that Horvath's epigenetic clock was trained with data pre-processed using different strategies, it is unclear how applying an additional batch effect correction step to the intensities or β -values would impact the predictions [178].

Thus, I decided to correct for the potential batch effects when fitting the control models (see equations 2.16 and 2.17). I make use of the control probes present on the 450K array, which have been shown to carry information about unwanted variation from a technical source (i.e. technical variance) [174, 175, 179]. These probes are designed to capture technical variance in negative controls, measure between-array differences and quantify the performance of different steps of the array protocol, such as bisulfite conversion, staining or hybridisation [175, 180]. I performed principal component analysis (PCA, with centering but not scaling using the *prcomp* function in R) on the raw intensities of the control probes ($847 \text{ probes} \cdot 2 \text{ channels} = 1694$ intensity values) for all the healthy individuals ($N = 2218$) and the samples with developmental disorders (cases, $N = 666$, see Chapter 3). This showed that the first two PCs capture the batch structure in both healthy individuals (Fig. 2.13b) and cases (Fig. S1.9). Including the first 17 PCs as part of the epigenetic age acceleration (EAA) modelling (see equations 2.16 and 2.17), which together accounted for 98.06% of the technical variance in all the samples (Fig. S1.10), significantly reduced the median absolute error (MAE) of the predictions in the healthy individuals ($MAE_{\text{with CCC}} = 2.7117$ years, $MAE_{\text{without CCC}} = 2.8211$ years, mean $MAE = 2.7664$, Fig. 2.13c). Notably, the reduction in the MAE provided by the batch effect correction was higher than the improvement provided by cell composition correction, a common practice in the epigenetic clock field [138, 139]. The optimal number of PCs was found by making use of the *findElbow* function from [181].

Finally, deviations from a median EAA close to zero in some of the batches after batch effect correction (Fig. 2.13d, Fig. S1.8b) could be explained by other variables, such as a small batch size or an overrepresentation of young samples (Fig. 2.14). The latter is a consequence of the fact that Horvath's model underestimates the epigenetic ages of older samples, which I have discussed in the previous section. Thus, I have shown that correcting for batch effects in the context of the epigenetic clock is important, especially when combining datasets from different sources for meta-analysis purposes. Batch effect correction is essential to remove technical variance that could affect the epigenetic age of the samples and confound biological interpretation. Furthermore, given the flexibility of this modelling approach, I have




Fig. 2.13 Correcting for batch effects in the context of the epigenetic clock. **a.** Distribution of the epigenetic age acceleration (EAA) for the different batches of healthy individual samples, using the control model with cell composition correction (CCC) and before applying batch effect correction. The dashed black line represents $EAA = 0$, where the distributions should be centred around. **b.** Scatterplot showing the values of the first two principal components (PCs) for the healthy individual samples after performing PCA on the control probes of the 450K arrays. Each point corresponds to a different sample and the colours represent the different batches. The different batches cluster together in the PCA space, showing that the control probes indeed capture technical variation. Please note that all the PCA calculations were done using samples from both healthy individuals (full lifespan, $N = 2218$) and cases from developmental disorders ($N = 666$, see Chapter 3). **c.** Plot showing how the median absolute error (MAE) of the prediction in the healthy individual samples, that should tend to zero, is reduced when the PCs capturing the technical variation are included as part of the modelling strategy (see equations 2.16 and 2.17). The dashed line represents the optimal number of PCs (17) that was finally used. The optimal mean MAE is calculated as the average MAE between the green and purple lines. **d.** As in a., but after applying batch effect correction (i.e. equivalent to equation 2.16).

applied batch effect correction across other types of analyses in the thesis, such as DMPs identification (see equation 2.10).




Fig. 2.14 After applying batch effect correction in the samples from the healthy individuals, deviations from a median epigenetic age acceleration (EAA) of zero (dotted black line) in some of the batches can be explained by other causes. The grey line separates in the lower left corner those weird batches (Feb_2016, GSE104812, GSE41273, GSE55491), which have a small sample size and/or a low median age.

2.3 Behaviour of other epigenetic clocks during ageing

2.3.1 Hannum's epigenetic clock

Besides Horvath's epigenetic clock, other models have been proposed in the literature to measure the ageing process using DNA methylation. Among them, Hannum's epigenetic clock has also been shown to accurately predict epigenetic age in several cohorts [138, 139, 171, 182–184]. Hannum's model was originally trained in whole blood and it makes use of a linear combination of β -values from 71 probes in the 450K array.

I calculated the epigenetic ages according to Hannum's model (*HannumAge*), although I only used 68 out of the 71 probes (the other 3 were filtered out during my pre-processing). Hannum's epigenetic clock predicted quite accurately in the dataset of healthy individuals, although with a slight overestimation of the epigenetic ages (Fig 2.15a), which has also been previously observed [182]. Furthermore, it is possible to observe the non-linear behaviour of Hannum's clock for young ages (≤ 20 years), for which the authors did not correct in their original publication [160]. Horvath's and Hannum's epigenetic clocks correlate between them (Fig. 2.15b). The magnitude of this correlation (*HannumAge* vs *DNAmAge*: PCC = 0.9778) was slightly stronger than the correlation between *HannumAge* and chronological age (PCC = 0.9756), which could highlight the fact that both models indeed measure epigenetic age.

Next, I estimated the epigenetic age acceleration (EAA) according to Hannum's epigenetic clock, using similar models to the ones previously described (although in this case the dependent variable was *HannumAge*, see equations 2.16 and 2.17). The median absolute errors for Hannum's model ($MAE_{\text{with CCC}} = 2.8422$ years, $MAE_{\text{without CCC}} = 2.9484$ years) were slightly higher than the ones obtained for Horvath's clock ($MAE_{\text{with CCC}} = 2.7117$ years, $MAE_{\text{without CCC}} = 2.8211$ years), which could also be influenced by the fact that 3 of the model probes were not available. The EAAs estimated by Hannum's and Horvath's clocks showed a moderate correlation (Fig. 2.15c,d), consistent with previous estimates [184]. Including cell composition correction improved the correlation between the EAAs from both clocks, highlighting the fact that Hannum's clock seems to be confounded with the changes in blood cell composition with age [182, 184].

Overall, Hannum's epigenetic clock performed well in my dataset. However, given that it produces slightly worse predictions than Horvath's and could be partially tracking blood immunosenescence instead of multi-tissue ageing effects, I used the latter as my main proxy to measure the ageing process in this thesis. Finally, it is also worth mentioning that the data that was used to train Hannum's model (GSE40279) is also part of the dataset of healthy individuals that I assembled and, therefore, this analysis does not constitute a completely independent assessment of the behaviour of Hannum's epigenetic clock.

2.3.2 Epigenetic mitotic clock: *epiToc*

In 2016, Yang and colleagues conceived a novel type of epigenetic clock called *epiToc* (epigenetic Timer Of Cancer), which measures the rate of (stem) cell division in both normal and cancerous tissues [185]. This epigenetic mitotic clock tracks the gain in methylation




Fig. 2.15 Behaviour of Hannum's epigenetic clock in the healthy individuals. **a.** Scatterplot showing the relationship between the epigenetic age predicted with Hannum's model (*HannumAge*) [160] and chronological age of the samples for the healthy individuals. Each sample is represented by one point. The black dashed line represents the diagonal to aid visualisation. The solid brown line represents the linear model $\text{HannumAge} \sim \text{Age}$. **b.** Relationship between the Hannum and Horvath epigenetic ages estimated for the same sample. The solid brown line represents the linear model $\text{HannumAge} \sim \text{DNAmAge}$. **c.** Relationship between the epigenetic age acceleration (EAA) calculated with the Hannum and the Horvath's epigenetic clocks. In this case the models include cell composition correction (CCC). The solid brown line represents the linear model $\text{Hannum_EAA}_{\text{with CCC}} \sim \text{Horvath_EAA}_{\text{with CCC}}$. **d.** As in c., but in this case the models do not include CCC.

levels that happens in 385 CpG sites, which localise in the promoter of genes that are targeted by Polycomb Repressing Complex 2 (PRC2). Importantly, these CpG sites are unmethylated across fetal tissues and therefore this provides a ground state to measure these changes during human lifespan.

I calculated the mitotic age (*pcgtAge*) of the healthy individuals in my dataset, although I only used 378 out of the 385 probes (the other 7 were filtered out during my pre-processing). The mitotic age of the individuals correlated with both chronological age (PCC = 0.5131, Fig. 2.16a) and *DNAAge* (PCC = 0.5602, Fig. 2.16b), which is expected given the cumulative number of divisions of the hematopoietic stem cells [186]. Furthermore, I estimated the epigenetic age acceleration (EAA) according to the epigenetic mitotic clock, using similar models to the ones previously described (although in this case the dependent variable was *pcgtAge*, see equations 2.16 and 2.17). Interestingly, the EAAs for *pcgtAge* and *DNAAge* showed a small but highly statistically significant correlation (Fig. 2.16c,d), which was stronger in the case of the model with cell composition correction. This, together with the fact that *DNAAge* has a stronger correlation with *pcgtAge* than chronological age, could suggest that the Horvath epigenetic clock captures methylation changes linked to cell division.

This was quite surprising given that Horvath's epigenetic clock predicts across tissues with different turnover rates [185]. Nevertheless, it has been recently demonstrated that *DNAAge* increases linearly with cell passage *in vitro* if TERT (the catalytic subunit of telomerase) is expressed, suggesting that *DNAAge* does seem to track cell division to a certain extent [187]. Furthermore, I also did some preliminary work where I calculated the *DNAAge* of different healthy tissues (that came from cancer patients). I observed that tissues with a high turnover (such as breast) [102, 188] had a higher *DNAAge* when compared with tissues with a low turnover (data not shown). Therefore, it would be interesting to further our understanding of the contribution of cell division to Horvath's epigenetic clock and its relation to the hypermethylation in PRC2-bound regions as measured by the epigenetic mitotic clock.

2.4 Additional methods

A short introduction to the linear regression framework

Linear models are a broad class of statistical analyses that are at the core of many bioinformatic methods, including differential RNA expression analyses [151] or genome-wide




Fig. 2.16 Behaviour of the epigenetic mitotic clock (*epiT*OC) in the healthy individuals. **a.** Scatterplot showing the relationship between mitotic age (pcgtAge) [185] and chronological age of the samples for the healthy individuals. Each sample is represented by one point. The solid brown line represents the linear model $\text{pcgtAge} \sim \text{Age}$. **b.** Relationship between pcgtAge and DNAmAge estimated for the same sample. The solid brown line represents the linear model $\text{pcgtAge} \sim \text{DNAmAge}$. **c.** Relationship between the epigenetic age acceleration (EAA) calculated with the mitotic and the Horvath's epigenetic clocks. In this case the models include cell composition correction (CCC). The solid brown line represents the linear model $\text{pcgtAge_EAA}_{\text{with CCC}} \sim \text{Horvath_EAA}_{\text{with CCC}}$. **d.** As in c., but in this case the models do not include CCC.

association studies (GWAS) [189]. An instance of such models is linear regression [190], a statistical approach that allows modelling of the relationship between:

- A dependent variable \mathbb{Y} , with observations $y_i \in R$ and $i \in \{1, \dots, n\}$, where n is the total number of observations (i.e. samples).
- One or more independent variables \mathbb{X}_j , with observations $x_{ij} \in R$ and $j \in \{1, \dots, k\}$, where k is the total number of independent variables (a.k.a covariates). These variables can indicate, for example, whether a specific condition or phenotype is present in a given sample, quantify the effects of a continuous variable (such as chronological age) or adjust for the effects of batch effects; which gives this statistical framework a great analysis flexibility [151].

We assume that:

$$y_i = \sum_{j=1}^k x_{ij}\beta_j + \varepsilon_i \quad (2.19)$$

where β_k are unknown parameters that need to be estimated from the data and ε_i is the random error. In matrix form:

$$Y = X\beta + \varepsilon \quad (2.20)$$

where $Y \in R^n$ is the vector $\{y_1, \dots, y_n\}$, $X \in R^{n \times k}$ is the $n \times k$ matrix of x_{ij} 's, $\beta \in R^k$ is the vector $\{\beta_1, \dots, \beta_k\}$ and $\varepsilon \in R^n$ is the vector $\{\varepsilon_1, \dots, \varepsilon_n\}$.

Assuming that $\mathbb{E}(\varepsilon) = 0$, $\text{Var}(\varepsilon) = \sigma^2 > 0$ and $\text{Cov}(\varepsilon) = \sigma^2 I_n$ (where I_n is the $n \times n$ identity matrix) and applying the Gauss-Markov theorem [190], it can be demonstrated that:

$$\hat{\beta} = (X'X)^{-1}X'Y \quad (2.21)$$

where X' is the transpose of X and $\hat{\beta}$ is the least-squares estimator of β , since it minimises:

$$\sum_{i=1}^n (y_i - \sum_{j=1}^k x_{ij}\hat{\beta}_j)^2 \quad (2.22)$$

It is possible to test whether there is a statistically-significant linear association between the dependent variable (\mathbb{Y}) and one of the independent variables (\mathbb{X}_j) i.e. to test:

$$H_0 : \beta_j = 0 \quad \text{against} \quad H_A : \beta_j \neq 0 \quad (2.23)$$

where H_0 is the null hypothesis and H_A is the alternative hypothesis. A t -statistic (T) can be derived after performing the fitting of the linear regression model [191]:

$$T = \frac{\hat{\beta}_j}{se(\hat{\beta}_j)} \quad (2.24)$$

where $se(\hat{\beta}_j)$ is the standard error of $\hat{\beta}_j$. When H_0 is true, then the statistic T follows a Student's t distribution with $n - k$ degrees of freedom i.e. $T \sim t_{n-k}$. This allows to estimate the p-value for the linear association of \mathbb{Y} with a given \mathbb{X}_j .

Finally, it is worth mentioning the nomenclature that I used for the linear regression models along this thesis. For example, the following model fits a linear association between the dependent variable (e.g. β -value at a specific CpG probe in the array) with intercept and 3 covariates (e.g. age, sex and disease status):

$$\begin{bmatrix} y_1 \\ y_2 \\ \dots \\ y_n \end{bmatrix} = \begin{bmatrix} 1 & x_{11} & x_{12} & x_{13} \\ 1 & x_{21} & x_{22} & x_{23} \\ \dots & \dots & \dots & \dots \\ 1 & x_{n1} & x_{n2} & x_{n3} \end{bmatrix} \begin{bmatrix} \beta_0 \\ \beta_1 \\ \beta_2 \\ \beta_3 \end{bmatrix} + \begin{bmatrix} \varepsilon_1 \\ \varepsilon_2 \\ \dots \\ \varepsilon_n \end{bmatrix} \quad (2.25)$$

where y_i is the β -value at a certain CpG probe for the i th sample, x_{i1} is the age for the i th sample, x_{i2} is the sex (e.g. 0 for male and 1 for female) for the i th sample, x_{i3} is the disease status (e.g. 0 for a healthy individual and 1 for an individual with a disease) for the i th sample, β_0 is the intercept coefficient, β_j are the covariate coefficients ($j = 1$ for age, $j = 2$ for sex, $j = 3$ for disease status) and ε_i is the error for the i th sample.

I would use the following nomenclature for the previous model (following 'R-style' nomenclature):

$$\text{Beta} \sim \text{Age} + \text{Sex} + \text{Disease_status} \quad (2.26)$$

Chapter 3

Biological aspects of the epigenetic clock

3.1 Background

Epigenetic clocks can be understood as a proxy to quantify the changes of the epigenome with age. However, little is known about the molecular mechanisms that determine the rate of these clocks. Steve Horvath proposed that the multi-tissue epigenetic clock captures the workings of an **epigenetic maintenance system** [102]. Recent GWAS studies have found several genetic variants associated with epigenetic age acceleration in genes such as *TERT* (the catalytic subunit of telomerase) [187], *DHX57* (an ATP-dependent RNA helicase) [192] or *MLST8* (a subunit of both mTORC1 and mTORC2 complexes) [192]. Nevertheless, to my knowledge no genetic variants in epigenetic modifiers have been found and the molecular nature of this hypothetical system is unknown to this date.

I decided to take a reverse genetics approach and look at the **behaviour of the epigenetic clock in patients with developmental disorders**, many of which harbour mutations in proteins of the epigenetic machinery [110, 193]. I performed an unbiased screen for epigenetic age acceleration and found that Sotos syndrome accelerates epigenetic ageing, potentially revealing a role of H3K36 methylation maintenance in the regulation of the rate of the epigenetic clock.

3.2 Screening for genes that accelerate the epigenetic clock

The main goal of this analysis is to identify genes, mainly components of the epigenetic machinery, that can **affect the rate of epigenetic ageing in humans** (as measured by Horvath's epigenetic clock) [102]. For this purpose, I assembled a dataset with all the DNA

methylation data from patients with different developmental disorders that I could find, in order to perform an unbiased screen. This dataset combines samples publicly available in GEO [109] with in-house data generated by my collaborators in the London Health Sciences Centre, Canada (Table S2.1, Fig. S2.1). All the data were generated from blood using the 450K methylation array, as in the case of the healthy individuals described in Chapter 2.

Many of these developmental syndromes present overlap of some of their clinical features [110, 193]. Furthermore, in some cases with a clinical diagnosis, the genetic cause remains unknown, probably due to locus heterogeneity or difficulty to assess the clinical significance of some genetic variants [194]. Therefore, several studies have explored the ability of DNA methylation signatures to aid differential diagnoses of these syndromes [110, 194–204]. Given that most of the diagnoses for developmental disorders are carried out early in life, this led to a dataset with a bias towards younger ages (Fig. 3.1). In order to maximise the ability to detect ageing-associated effects, I kept only those developmental disorders that had at least 5 samples, with 2 of them with an age ≥ 20 years (which, according to Horvath's model, is the adult age for humans) [102]. This filtering resulted in a dataset for the main screen with $N = 367$ samples from cases, which had ages between 0 and 55 years (Fig. 3.2, Table 3.1).




Fig. 3.1 Histogram showing the chronological age distribution for all the individuals with developmental disorders (cases) included in the final dataset (i.e. after QC and filtering). The blue line represents the 1D kernel density estimate, as calculate by the *stat_density* function in R with default parameters.




Fig. 3.2 Flow diagram that portrays an overview of the different analyses that are carried out in the raw DNA methylation data (IDAT files) from human blood for cases (developmental disorders samples) and controls (healthy samples). The control samples are filtered to match the age range of the cases (0-55 years). The cases are filtered based on the number of ‘adult’ samples available (for each disorder, at least 5 samples, with 2 of them with an age ≥ 20 years). QC: quality control. DMPs: differentially methylated positions.

The purpose of the screen is to **test whether the epigenetic ages of the samples from a given developmental disorder (cases) deviate from their chronological age** i.e. identify those developmental disorders that present epigenetic age acceleration (EAA). For a given sample, a positive EAA indicates that the epigenetic (biological) age of the sample is higher than the one expected for someone with that chronological age. In other words, it means that the epigenome of that person resembles the epigenome of an older individual. The opposite is true when a negative EAA is found (i.e. the epigenome looks younger than expected). I calculated the epigenetic ages (*DNAmAge*) of all the samples according to Horvath’s epigenetic clock (see section 2.2.1) and I fitted the control models to the samples from the healthy individuals, including models with and without cell composition correction (CCC) and always accounting for potential batch effects (see equations 2.16 and 2.17). As previously discussed (see section 2.2.2), due to the fact that Horvath’s model underestimates the epigenetic age of old samples, the age distribution of the control samples can have an impact on the results of the screen. Therefore, I filtered the ages of the healthy individual samples to make them match the age range of the developmental disorders (0-55 years, $N = 1128$, see Fig. 3.2).

Developmental disorder	Gene(s) involved	Gene(s) function	Molecular cause	N	Age range (years)
Angelman	<i>UBE3A</i>	Ubiquitin protein ligase E3A	Imprinting, mutation	14	1 to 55
Autism spectrum disorder (ASD)	-	-	-	119	1.83 to 35.16
Alpha thalassemia/mental retardation X-linked syndrome (ATR-X)	<i>ATRX</i>	Chromatin remodelling	Mutation	15	0.7 to 27
Claes-Jensen	<i>KDM5C</i>	H3K4 demethylase	Mutation	10	2 to 42
Coffin-Lowry	<i>RPS6KA3</i>	Serine / threonine kinase	Mutation	10	1.3 to 22.8
Floating-Harbour	<i>SRCAP</i>	Chromatin remodelling	Mutation	17	4 to 42
Fragile X syndrome (FXS)	<i>FMR1</i>	Translational control	Mutation (CGG expansion)	32	0.08 to 48
Kabuki	<i>KMT2D</i>	H3K4 methyltransferase	Mutation	46	0 to 24.1
Noonan	<i>PTPN11, RAF1, SOS1</i>	RAS/ MAPK signalling	Mutation	15, 11, 14	0.2 to 49
Rett	<i>MECP2</i>	Transcriptional repression	Mutation	15	1 to 34
Saethre-Chotzen	<i>TWIST1</i>	Transcription factor	Mutation	22	0 to 38
Sotos	<i>NSD1</i>	H3K36 methyltransferase	Mutation	20	1.6 to 41
Weaver	<i>EZH2</i>	H3K27 methyltransferase	Mutation	7	2.58 to 43
Total	-	-	-	367	0 to 55

Table 3.1 Overview of the developmental disorders that were included in the screening after quality control and filtering (total $N = 367$).

The EAA for the control samples corresponds to the residuals from the control models (see section 2.2.2). On the other hand, the EAA for a case sample is calculated by taking the difference between the epigenetic age (*DNAmAge*) and the predicted value from the corresponding control model (with or without cell composition). Finally, I compared the distributions of the EAA for the different developmental disorders against the EAA distributions for the healthy controls using the non-parametric two-sided Wilcoxon's test. P-values were adjusted for multiple testing using Bonferroni correction and a significance level of $\alpha = 0.01$ was applied. It is worth mentioning that some of the developmental disorders included in the screen (such as autism spectrum disorder or Coffin-Lowry syndrome) are not necessarily caused by alterations in the epigenetic machinery, but were still included to maintain the unbiased nature of the screen.

3.3 Sotos syndrome accelerates epigenetic ageing

The results from the screen are portrayed in Fig. 3.3. Most syndromes do not show evidence of accelerated epigenetic ageing, but **Sotos syndrome presents a clear positive EAA** (median EAA_{with CCC} = + 7.64 years, median EAA_{without CCC} = + 7.16 years), with p-values considerably below the significance level of 0.01 after Bonferroni correction (p-value_{corrected, with CCC} = $3.40 \cdot 10^{-9}$, p-value_{corrected, without CCC} = $2.61 \cdot 10^{-7}$). Additionally, Rett syndrome (median EAA_{with CCC} = + 2.68 years, median EAA_{without CCC} = + 2.46 years, p-value_{corrected, with CCC} = 0.0069, p-value_{corrected, without CCC} = 0.0251) and Kabuki syndrome (median EAA_{with CCC} = - 1.78 years, median EAA_{without CCC} = - 2.25 years, p-value_{corrected, with CCC} = 0.0011, p-value_{corrected, without CCC} = 0.0035) reach significance, with a positive and negative EAA respectively. Finally, fragile X syndrome (FXS) shows a positive EAA trend (median EAA_{with CCC} = + 2.44 years, median EAA_{without CCC} = + 2.88 years) that does not reach significance in the screen (p-value_{corrected, with CCC} = 0.0680, p-value_{corrected, without CCC} = 0.0693).

Next, I tested the effect of changing the median age used to build the healthy control model (i.e. the median age of the controls) on the screening results (Fig. S2.2). Sotos syndrome is robust to these changes, whilst Rett, Kabuki and FXS are much more sensitive to the control model used. This again highlights the importance of choosing an appropriate age-matched control when testing for epigenetic age acceleration, given that Horvath's epigenetic clock underestimates epigenetic age for advanced chronological ages [170, 171].

Moreover, all but one of the Sotos syndrome patients (19/20 = 95%) show a consistent deviation in EAA (with CCC) in the same direction (Fig. 3.4a,b), which is not the case for the




Fig. 3.3 Screening for epigenetic age acceleration (EAA) in developmental disorders. The upper panel shows the p-values derived from comparing the EAA distributions for the samples in a given developmental disorder and the control (two-sided Wilcoxon's test). The dashed green line displays the significance level of $\alpha = 0.01$ after Bonferroni correction. The bars above the green line reach statistical significance. The lower panel displays the actual EAA distributions, which allows assessing the direction of the EAA (positive or negative). In red: EAA model with cell composition correction (CCC). In blue: EAA model without CCC. ASD: autism spectrum disorder. ATR-X: alpha thalassemia/mental retardation X-linked syndrome. FXS: fragile X syndrome.

rest of the disorders, with the exception of Rett syndrome (Fig. S2.3). Even though the data suggest that there are already some methylomic changes at birth, the EAA seems to increase with age in the case of Sotos patients (Fig. 3.4b). This implies that at least some of the changes that normally affect the epigenome with age are happening at a faster rate in Sotos syndrome patients during their lifespan (as opposed to the idea that the Sotos epigenetic changes are only acquired during prenatal development and remain constant afterwards).

Finally, I investigated whether Sotos syndrome leads to a higher rate of (stem) cell division in blood when compared with the healthy population. I employed the epigenetic mitotic clock, that makes use of the fact that some CpGs in promoters that are bound by Polycomb group proteins become hypermethylated with age (captured by a metric called *pcgtAge*; see section 2.3.2). This hypermethylation correlates with the number of cell divisions in the tissue and is also associated with an increase in cancer risk [185]. I calculated *pcgtAge* for the Sotos samples and compared them against the healthy controls (using a model similar to the one in equation 2.16, although in this case the dependent variable was *pcgtAge*; see section 2.3.2). I found a trend suggesting that **the epigenetic mitotic clock might be accelerated in Sotos patients** (*p*-value = 0.0112, Fig. 3.4c,d), which could explain the higher cancer predisposition reported in these patients and might relate to their overgrowth [205].

Consequently, I report that individuals with Sotos syndrome present an accelerated epigenetic age, which makes their epigenome look, on average, more than 7 years older than expected. These changes seem to be the consequence of a higher ticking rate of the epigenetic clock (or at least part of its machinery), with epigenetic age acceleration increasing during lifespan: the youngest Sotos patient (1.6 years) has an $EAA_{\text{with CCC}} = 5.43$ years and the oldest (41 years) has an $EAA_{\text{with CCC}} = 24.53$ years. Additionally, Rett syndrome, Kabuki syndrome and fragile X syndrome could also have their epigenetic ages affected, but more evidence is required to be certain about this conclusion.

3.4 Comparing Sotos syndrome and physiological ageing

Sotos syndrome is caused by loss-of-function heterozygous mutations in the NSD1 gene, a histone H3K36 methyltransferase [197, 206]. These mutations lead to a specific DNA methylation signature in Sotos patients, potentially due to the crosstalk between the histone and DNA methylation machinery [197]. In order to gain a more detailed picture of the reported epigenetic age acceleration, I decided to compare the genome-wide (or at least array-wide) changes observed in the methylome during ageing with those observed in Sotos syndrome. For this purpose, I **identified differentially methylated positions (DMPs)**




Fig. 3.4 Sotos syndrome accelerates epigenetic ageing. **a.** Scatterplot showing the relationship between epigenetic age (*DNAAge*) according to Horvath's model [102] and chronological age of the samples for Sotos (orange) and control (grey). Each sample is represented by one point. The black dashed line represents the diagonal to aid visualisation. **b.** Scatterplot showing the relationship between the epigenetic age acceleration (EAA) and chronological age of the samples for Sotos (orange) and control (grey). Each sample is represented by one point. The yellow line represents the linear model $EAA \sim Age$, with the standard error shown in the light yellow shade. **c.** Scatterplot showing the relationship between the score for the epigenetic mitotic clock (*pcgtAge*) [185] and chronological age of the samples for Sotos (orange) and control (grey). Each sample is represented by one point. A higher value of *pcgtAge* is associated with a higher number of cell divisions in the tissue. **d.** Scatterplot showing the relationship between the epigenetic mitotic clock (*pcgtAge*) acceleration (with CCC) and chronological age of the samples for Sotos (orange) and control (grey). Each sample is represented by one point. The yellow line represents the linear model $pcgtAge_EAA_{with\ CCC} \sim Age$, with the standard error shown in the light yellow shade.

for both conditions, using the models that account for cell composition correction (see equations 2.10 and 3.1). Ageing DMPs (aDMPs) were calculated in this case using the healthy samples in the age range 0-55 years. aDMPs were composed almost equally of CpG sites that gain methylation with age (i.e. become hypermethylated, 51.69%) and CpG sites that lose methylation with age (i.e. become hypomethylated, 48.31%, barplot in Fig. 3.5a), a picture that resembles previous studies [152]. It is worth mentioning that in this case less aDMPs were identified when compared with the full lifespan analysis presented in section 2.1.4, where the hypomethylated aDMPs were also slightly more frequent when compared with the hypermethylated ones. This highlights the importance of the age range and/or the sample size when calculating aDMPs. On the contrary, DMPs in Sotos were clearly dominated by CpGs that decrease their methylation level in individuals with the syndrome (i.e. hypomethylated, 99.27%, barplot in Fig. 3.5a), consistent with previous reports [197].

Then, I compared the intersections between the hypermethylated and hypomethylated DMPs in ageing and Sotos. Most of the DMPs were specific for ageing or Sotos (i.e. they did not overlap), but a subset of them were shared (table in Fig. 3.5a). Interestingly, there were 1728 DMPs that became hypomethylated both during ageing and in Sotos (**‘Hypo-Hypo DMPs’**). This subset of DMPs is of special interest because it could be used to understand in more depth some of the mechanisms that drive hypomethylation during physiological ageing. Thus, I tested whether the different subsets of DMPs are found in specific genomic contexts (Fig. S2.4, Fig. S2.5). DMPs that are hypomethylated during ageing and in Sotos were both enriched (odds ratio >1) in enhancer categories (such as ‘active enhancer 1’ or ‘weak enhancer 1’, see the chromatin state model used, from the K562 cell line, in section 3.7) and depleted (odds ratio <1) for active transcription categories (such as ‘active TSS’ or ‘strong transcription’), which was also observed in the ‘Hypo-Hypo DMPs’ subset (Fig. 3.5b). Interestingly, age-related hypomethylation in enhancers seems to be a characteristic of both humans [153, 154] and mice [207]. Furthermore, both *de novo* DNA methyltransferases (DNMT3A and DNMT3B) have been shown to bind in an H3K36me3-dependent manner to active enhancers [208], consistent with these results.

When looking at the levels of total RNA expression (depleted for rRNA) in blood, I confirmed a significant reduction in the RNA levels around these hypomethylated DMPs when compared with the controls sets (Fig. 3.5c, see section 3.7 for more details on how the control sets were defined). Interestingly, hypomethylated DMPs in both ageing and Sotos were depleted from gene bodies (Fig. 3.5b) and were located in areas with lower levels of H3K36me3 when compared with the control sets (Fig. 3.5d, Fig. S2.5). Moreover,




Fig. 3.5 Comparison between the DNA methylation changes during physiological ageing and in Sotos. **a.** On the left: barplot showing the total number of differentially methylated positions (DMPs) found during physiological ageing and in Sotos syndrome. CpG sites that increase their methylation levels with age in the healthy population or those that are elevated in Sotos patients (when compared with a control) are displayed in red. Conversely, those CpG sites that decrease their methylation levels are displayed in blue. On the right: table that represents the intersection between the ageing (aDMPs) and the Sotos DMPs. The subset resulting from the intersection between the hypomethylated DMPs in ageing and Sotos is called the ‘Hypo-Hypo DMPs’ subset ($N=1728$). **b.** Enrichment for the categorical (epi)genomic features considered when comparing the different genome-wide subsets of differentially methylated positions (DMPs) in ageing and Sotos against a control (see section 3.7). The y-axis represents the odds ratio (OR), the error bars show the 95% confidence interval for the OR estimate and the colour of the points codes for $-\log_{10}(p\text{-value})$ obtained after testing for enrichment using Fisher’s exact test. An OR > 1 shows that the given feature is enriched in the subset of DMPs considered, whilst an OR < 1 shows that it is found less than expected. In grey: features that did not reach significance using a significance level of $\alpha = 0.01$ after Bonferroni correction. **c.** Boxplots showing the distributions of the ‘normalised RNA expression’ (NRE) when comparing the different genome-wide subsets of differentially methylated positions (DMPs) in ageing and Sotos against a control (see section 3.7). NRE represents normalised mean transcript abundance in a window of ± 200 bp from the CpG site coordinate (DMP) being considered. The p-values (two-sided Wilcoxon’s test, before multiple testing correction) are shown above the boxplots. The number of DMPs belonging to each subset (in green) and the median value of the feature score (in dark red) are shown below the boxplots. **d.** As in c., but showing the ‘normalised fold change’ (NFC) for the H3K36me3 histone modification (representing normalised mean ChIP-seq fold change for H3K36me3 in a window of ± 200 bp from the DMP being considered).

hypomethylated aDMPs and hypomethylated Sotos DMPs where both generally enriched or depleted for the same histone marks in blood (Fig. S2.5), which adds weight to the hypothesis that they share the same genomic context and could become hypomethylated through similar molecular mechanisms.

Intriguingly, I also identified a subset of DMPs (2550) that were hypermethylated during ageing and hypomethylated in Sotos (Fig. 3.5a). These '**Hyper-Hypo DMPs**' seem to be enriched for categories such as 'bivalent promoter' and 'repressed polycomb' (Fig. S2.4), which are normally associated with developmental genes [209, 210]. These categories are also a defining characteristic of the hypermethylated aDMPs, highlighting that even though the direction of the DNA methylation changes is different in some ageing and Sotos DMPs, the genomic context in which they happen is shared.

Finally, I looked at the DNA methylation patterns in the 353 **Horvath's epigenetic clock CpG sites for the Sotos samples**. For each clock CpG site, I modelled the changes of DNA methylation with age in the healthy control individuals (0-55 years) and then calculated the deviations from these patterns for the Sotos samples (Fig. 3.6, see equation 3.3). As expected, the landscape of clock CpG sites is dominated by hypomethylation in the Sotos samples, although only a small fraction of the clock CpG sites seems to be significantly affected (Fig. 3.6c). Overall, I confirmed the trends reported for the genome-wide analysis (Fig. S2.6, Fig. S2.7, Fig. S2.8). However, given the much smaller number of CpG sites to consider in this analysis, very few comparisons reached significance.

I have demonstrated that the ageing process and Sotos syndrome share a subset of hypomethylated CpG sites that is characterised by an enrichment in enhancer features and a depletion of active transcription activity. This highlights the usefulness of **developmental disorders as a model to study the mechanisms that may drive the changes in the methylome with age**, since they permit stratification of the ageing DMPs into different functional categories that are associated with alterations in the function of specific genes and hence specific molecular components of the epigenetic ageing clock.

3.5 Methylation Shannon entropy and the epigenetic clock

In section 2.1.5 I have discussed how Shannon entropy can be applied in the context of DNA methylation data in order to measure the genome-wide epigenetic information loss that happens during ageing. It is possible to apply a methodology similar to the one described in section 2.2.2 to compare the methylation Shannon entropy in healthy controls (0-55 years)




Fig. 3.6 The landscape of Horvath's epigenetic clock CpG sites in Sotos syndrome. **a.** and **b.** DNA methylation (β -value) profiles for two of the clock CpG sites (cg02071305 and cg18328933). A linear model (displayed in dark grey, see equation 3.3) can be fitted to each CpG site to model the changes in β -value with chronological age in the controls (grey). Afterwards, the difference of the Sotos samples β -values (orange) with the controls can be estimated. **c.** Heatmap displaying the differential methylation patterns for Sotos samples (rows) when compared with controls in each one of the 353 epigenetic clock CpGs (columns). Hierarchical clustering was performed in both rows and columns. RNA refers to the 'normalised RNA expression' (NRE). H3K36me3 refers to the H3K36me3 histone modification 'normalised fold change' (NFC). aDMPs: differentially methylated positions during ageing. EAA: epigenetic age acceleration. CCC: cell composition correction. PBMC: peripheral blood mononuclear cells.

and Sotos patients (i.e. using a linear model similar to equation 2.16, although in this case the dependent variable is the entropy value). This allows testing whether Sotos syndrome patients present genome-wide Shannon entropy acceleration i.e. deviations from the expected genome-wide Shannon entropy for their age. Despite detailed analysis, I did not find evidence that this was the case when looking genome-wide ($p\text{-value} = 0.71$, Fig. 3.7a,b, Fig. S2.9a).

When I considered only the 353 Horvath's epigenetic clock CpG sites for the entropy calculations, the picture was different. Shannon entropy for the 353 clock sites slightly decreased with age in the controls when I included all the batches, showing the opposite direction when compared with the genome-wide entropy ($\text{SCC} = -0.1223$, $p\text{-value} = 3.8166 \cdot 10^{-5}$, Fig. 3.7c). However, when I removed the 'Europe' batch (which was an outlier even after pre-processing, Fig. S2.10), this trend was reversed and I observed a weak increase of clock Shannon entropy with age ($\text{SCC} = 0.1048$, $p\text{-value} = 8.6245 \cdot 10^{-5}$). This shows that Shannon entropy calculations are very sensitive to batch effects, especially when considering a small number of CpG sites, and the results must be interpreted carefully, as already discussed in section 2.1.5.

Interestingly, the mean Shannon entropy across all the control samples was higher in the epigenetic clock sites (mean = 0.4726, Fig. 3.7c) with respect to the genome-wide entropy (mean = 0.3913, Fig. 3.7a). Sotos syndrome patients displayed a lower clock Shannon entropy when compared with the control ($p\text{-value} = 5.0449 \cdot 10^{-12}$, Fig. 3.7d, Fig. S2.9b), which is probably driven by the hypomethylation of the clock CpG sites. Furthermore, this highlights that the **Horvath's epigenetic clock sites could have slightly different characteristics in terms of the methylation entropy associated with them** when compared with the genome as a whole, something that to my knowledge has not been reported before.

3.6 Discussion

The epigenetic ageing clock has emerged as the most accurate biomarker of the ageing process and it seems to be a conserved property in mammalian genomes [211, 212]. However, it is still unknown whether the age-related DNA methylation changes measured are functional at all or whether they are related to some fundamental process of the biology of ageing. Developmental disorders in humans represent an interesting framework to look at the biological effects of mutations in genes that are fundamental for the integrity of the epigenetic landscape and other core processes, such as growth or neurodevelopment [110, 193]. Therefore, using a reverse genetics approach, I aimed to identify genes that disrupt aspects of the behaviour of the epigenetic ageing clock in humans.




Fig. 3.7 Analysis of methylation Shannon entropy during physiological ageing and in Sotos syndrome. **a.** Scatterplot showing the relation between genome-wide Shannon entropy (i.e. calculated using the methylation levels of all the CpG sites in the array) and chronological age of the samples for Sotos (orange) and healthy controls (grey). Each sample is represented by one point. **b.** Boxplots showing the distributions of genome-wide Shannon entropy acceleration (i.e. deviations from the expected genome-wide Shannon entropy for their age) for the control and Sotos samples. The p-value displayed on top of the boxplots was derived from a two-sided Wilcoxon's test. **c.** As in a., but using the Shannon entropy calculated only for the 353 CpG sites in the Horvath's epigenetic clock. **d.** As in b., but using the Shannon entropy calculated only for the 353 CpG sites in the Horvath's epigenetic clock.

Most of the studies have looked at the epigenetic ageing clock using Horvath's epigenetic clock [102], and I decided to employ it as a tool to measure the epigenetic age of my samples. The results from the screen strongly suggest that Sotos syndrome accelerates epigenetic ageing. Sotos syndrome is caused by loss-of-function mutations in the NSD1 gene [197, 206], which encodes a histone H3 lysine 36 (H3K36) methyltransferase. This leads to a phenotype which can include pre-natal and post-natal overgrowth, facial gestalt, advanced bone age, developmental delay, higher cancer predisposition and, in some cases, heart defects [205]. Remarkably, many of these characteristics could be interpreted as ageing-like, identifying **Sotos syndrome as a potential human model of accelerated physiological ageing.**

NSD1 catalyses the addition of either monomethyl (H3K36me) or dimethyl groups (H3K36me2) and indirectly regulates the levels of trimethylation (H3K36me3) by altering the availability of the monomethyl and dimethyl substrates for the trimethylation enzymes (SETD2 in humans, whose mutations cause a 'Sotos-like' overgrowth syndrome) [213, 214]. H3K36 methylation has a complex role in the regulation of transcription [213] and has been shown to regulate nutrient stress response in yeast [215]. Moreover, experiments in model organisms (yeast and worm) have demonstrated that **mutations in H3K36 methyltransferases decrease lifespan and, remarkably, mutations in H3K36 demethylases increase it** [216–218].

In humans, DNA methylation patterns are established and maintained by three conserved enzymes: the maintenance DNA methyltransferase DNMT1 and the *de novo* DNA methyltransferases DNMT3A and DNMT3B [219]. Both DNMT3A and DNMT3B contain PWWP domains that can read the H3K36me3 histone mark [220, 221]. Therefore, the H3K36 methylation landscape can influence DNA methylation levels in specific genomic regions through the recruitment of the *de novo* DNA methyltransferases. Mutations in the PWWP domain of DNMT3A impair its binding to H3K36me2 and H3K36me3 and cause an undergrowth disorder in humans (microcephalic dwarfism) [222]. This redirects DNMT3A, which is normally targeted to H3K36me2 and H3K36me3 throughout the genome, to DNA methylation valleys (DMVs, aka DNA methylation canyons), which become hypermethylated [222]; a phenomenon that also seems to happen during physiological ageing in humans [153, 223, 224] and mice [207]. DMVs are hypomethylated domains conserved across cell types and species, often associated with Polycomb-regulated developmental genes and marked by bivalent chromatin (with H3K27me3 and H3K4me3) [225–228]. Therefore, I suggest a model (Fig. 3.8) where the **reduction in the levels of H3K36me2 and/or H3K36me3, caused by a proposed decrease in H3K36 methylation maintenance during ageing or NSD1 function in Sotos syndrome, could lead to hypomethylation in many**

genomic regions (because DNMT3A is recruited less efficiently) and hypermethylation in DMVs (because of the higher availability of DNMT3A). Indeed, I observe enrichment for categories such as ‘bivalent promoter’ or ‘repressed polycomb’ in the hypermethylated DMPs in Sotos and ageing (Fig. S2.4), which is also supported by higher levels of Polycomb Repressing Complex 2 (PRC2, represented by EZH2) and H3K27me3, the mark deposited by PRC2 (Fig. S2.5). This is also consistent with the results obtained for the epigenetic mitotic clock [185], where I observe a trend towards increased hypermethylation of Polycomb-bound regions in Sotos patients.

A recent preprint has shown that loss-of-function mutations in DNMT3A, which cause Tatton-Brown-Rahman overgrowth syndrome, also lead to a higher ticking rate of the epigenetic ageing clock [231]. They also report positive epigenetic age acceleration in Sotos syndrome and negative acceleration in Kabuki syndrome, consistent with my results. Furthermore, they observe a DNA methylation signature in the DNMT3A mutants characterised by widespread hypomethylation, with a modest enrichment of DMPs in regions upstream of the transcription start site, shores and enhancers [231], which I also detect in the ‘Hypo-Hypo DMPs’ (those that become hypomethylated both during physiological ageing and in Sotos). Therefore, **the hypomethylation observed in the ‘Hypo-Hypo DMPs’ is consistent with a reduced methylation activity of DNMT3A**, which in my analysis could be a consequence of the decreased recruitment of DNMT3A to genomic regions that have lost H3K36 methylation (Fig. 3.8).

Interestingly, H3K36me3 is required for the selective binding of the *de novo* DNA methyltransferase DNMT3B to the bodies of highly transcribed genes [221]. Furthermore, DNMT3B loss reduces gene-body methylation, which leads to intragenic spurious transcription (aka cryptic transcription) [232]. An increase in this so-called cryptic transcription seems to be a conserved feature of the ageing process [217]. Therefore, the changes observed in the ‘Hypo-Hypo DMPs’ could theoretically be a consequence of the loss of H3K36me3 and the concomitant inability of DNMT3B to be recruited to gene bodies. However, the ‘Hypo-Hypo DMPs’ were depleted for H3K36me3, active transcription and gene bodies when compared with the rest of the probes in the array (Fig. 3.5b-d), prompting me to suggest that the DNA methylation changes observed are likely mediated by DNMT3A instead (Fig. 3.8). Nevertheless, it is worth mentioning that the different biological replicates for the blood H3K36me3 ChIP-seq datasets were quite heterogeneous and that the absolute difference in the case of the hypomethylated Sotos DMPs, although significant due to the big sample sizes, is quite small. Thus, I cannot exclude the existence of this mechanism during human ageing




Fig. 3.8 Proposed model that highlights the role of H3K36 methylation maintenance on epigenetic ageing. The H3K36me2/3 mark allows recruiting *de novo* DNA methyltransferases DNMT3A (in green) and DNMT3B (not shown) through their PWWP domain (in blue) to different genomic regions (such as gene bodies or pericentric heterochromatin) [221, 229, 230], which leads to the methylation of the cytosines in the DNA of these regions (5mC, black lollipops). On the contrary, DNA methylation valleys (DMVs) are conserved genomic regions that are normally found hypomethylated and associated with Polycomb-regulated developmental genes [225–228]. During ageing, the H3K36 methylation machinery could become less efficient at maintaining the H3K36me2/3 landscape. This would lead to a relocation of *de novo* DNA methyltransferases from their original *genomic reservoirs* (which would become hypomethylated) to other non-specific regions such as DMVs (which would become hypermethylated and potentially lose their normal boundaries), with functional consequences for the tissues. This is also partially observed in patients with Sotos syndrome, where mutations in NSD1 potentially affect H3K36me2/3 patterns and accelerate the epigenetic ageing clock as measured with the Horvath's model [102]. Given that DNMT3B is enriched in the gene bodies of highly transcribed genes [221] and that I found these regions depleted in the differential methylation analysis, I hypothesise that the hypermethylation of DMVs could be mainly driven by DNMT3A instead. However, it is important to mention that my analysis does not discard a role of DNMT3B during epigenetic ageing.

and an exhaustive study on the prevalence of cryptic transcription in humans and its relation to the ageing methylome should be carried out.

H3K36me3 has also been shown to guide deposition of the N⁶-methyladenosine mRNA modification (m⁶A), an important post-transcriptional mechanism of gene regulation [233]. Interestingly, a decrease in overall m⁶A during human ageing has been previously reported in PBMCs [234], suggesting another biological route through which an alteration of the H3K36 methylation landscape could have functional consequences for the organism.

Because of the way that the Horvath epigenetic clock was trained [102], it is likely that its constituent 353 CpG sites are a **low-dimensional representation of the different genome-wide processes that are eroding the epigenome with age**. My analysis has shown that these 353 CpG sites are characterised by a higher Shannon entropy when compared with the rest of the genome, which is dramatically decreased in the case of Sotos patients. This could be related to the fact that Horvath's clock CpGs are enriched in regions of bivalent chromatin (marked by H3K27me3 and H3K4me3), conferring a more dynamic or plastic regulatory state with levels of DNA methylation deviated from the collapsed states of 0 or 1. Interestingly, EZH2 (part of Polycomb Repressing Complex 2, responsible for H3K27 methylation) is an interacting partner of DNMT3A and NSD1, with mutations in NSD1 affecting the genome-wide levels of H3K27me3 [235]. Furthermore, Kabuki syndrome was weakly identified in my screen as having an epigenome younger than expected, which could be related to the fact that they show post-natal dwarfism [194, 196]. Kabuki syndrome is caused by loss-of-function mutations in KMT2D [194, 196], a major mammalian H3K4 mono-methyltransferase [236]. Additionally, H3K27me3 and H3K4me3 levels can affect lifespan in model organisms [237]. It will be interesting to test whether bivalent chromatin is a general feature of multi-tissue epigenetic ageing clocks.

Thus, **DNMT3A, NSD1 and the machinery in control of bivalent chromatin (such as EZH2 and KMT2D) contribute to an emerging picture on how the mammalian epigenome is regulated during ageing**, which could open new avenues for anti-ageing drug development. Mutations in these proteins lead to different developmental disorders with impaired growth defects [193], with DNMT3A, NSD1 and potentially KMT2D also affecting epigenetic ageing. Interestingly, EZH2 mutations (which cause Weaver syndrome, Table 3.1) do not seem to affect the epigenetic clock in my screen. However, this syndrome has the smallest number of samples ($N = 7$) and this could limit the power to detect any changes.

My screen has also revealed that **Rett syndrome and fragile X syndrome (FXS) could potentially have an accelerated epigenetic age**. It is worth noting that FXS is caused by

an expansion of the CGG trinucleotide repeat located in the 5' UTR of the FMR1 gene [198]. Interestingly, Huntington's disease, caused by a trinucleotide repeat expansion of CAG, has also been shown to accelerate epigenetic ageing of human brain [177], pointing towards trinucleotide repeat instability as an interesting molecular mechanism to look at from an ageing perspective. It is important to notice that the conclusions for Rett syndrome, FXS and Kabuki syndrome were very dependent on the age range used in the healthy control (Fig. S2.2) and these results must therefore be treated with caution.

This study has several **limitations that I tried to address in the best possible way**. First of all, given that DNA methylation data for patients with developmental disorders is relatively rare, some of the sample sizes were quite small. It is thus possible that some of the other developmental disorders assessed are epigenetically accelerated but I lack the power to detect this. Furthermore, people with the disorders tend to get sampled when they are young i.e. before reproductive age. Horvath's clock adjusts for the different rates of change in the DNA methylation levels of the clock CpGs before and after adult/reproductive age (20 years in humans) [102], but this could still have an effect on the predictions, especially if the control is not properly age-matched. My solution was to discard those developmental disorders with less than 5 samples and I required them to have at least 2 samples with an age ≥ 20 years, which reduced the list of final disorders included to the ones listed in Table 3.1.

Future studies should increase the sample size and follow the patients during their entire lifespan in order to confirm these findings. Furthermore, it would be interesting to identify mutations that affect, besides the mean, the variance of epigenetic age acceleration, since changes in methylation variability at single CpG sites with age have been associated with fundamental ageing mechanisms [153]. Finally, testing the influence of H3K36 methylation on the epigenetic clock and lifespan in mice will provide deeper mechanistic insights.

3.7 Additional methods

Sample generation and annotation

I collected DNA methylation data generated with the Illumina Infinium HumanMethylation450 BeadChip (450K array) from human blood. In the case of the developmental disorder samples, I combined public data with data generated in-house by my collaborators in Canada (Table S2.1, Fig. S2.1). The wet-lab protocols used in the public datasets can be found in their respective GEO repositories. DNA methylation data from my Canadian collaborators was generated according to the manufacturer's protocol [238, 239].

Basic metadata (including the chronological age) was also stored. All the mutations in the developmental disorder samples were manually curated using Variant Effect Predictor [240] in the GRCh37 (hg19) human genome assembly. Those samples with a variant of unknown significance that had the characteristic DNA methylation signature of the disease were also included (they are labelled as ‘YES_predicted’ in Fig. S2.1). In the case of fragile X syndrome (FXS), only male samples with full mutation (>200 repeats) [198] were included in the final screen. As a consequence, only samples with a clear molecular and clinical diagnosis were kept for the final screen.

Identifying differentially methylated positions in Sotos syndrome

Following a strategy similar to the one outlined in section 2.1.4, I identified those array probes that were differentially methylated in patients with Sotos syndrome. I compared the Sotos samples ($N=20$) against the internal control samples ($N=51$) from the same dataset (GSE74432) [197], fitting the following linear model to each one of the array probes:

$$\text{Beta} \sim \text{Disease_status} + \text{Age} + \text{Sex} + \text{Gran} + \text{CD4T} + \text{CD8T} + \text{B} + \text{Mono} + \text{NK} + \text{PC1} + \dots + \text{PC17} \quad (3.1)$$

where *Beta* is the β -value for the array probe being evaluated; *Disease_status* indicates whether a sample comes from a healthy individual (0) or a Sotos syndrome patient (1); *Age* is the chronological age (in years) of the samples; *Sex* encodes for the sex of the samples (0/1); *Gran*, *CD4T*, *CD8T*, *B*, *Mono* and *NK* are the cell type proportions from the samples as calculated with my cell-type deconvolution strategy and *PCN* is the N th principal component that captures technical variance and accounts for potential batch effects (see section 2.2.3 for more details).

P-values and regression coefficients were extracted for the *Disease_status* covariate. I selected as my final Sotos DMPs those CpG probes that survived the analysis after Bonferroni multiple testing correction with a significance level of $\alpha = 0.01$.

(Epi)genomic annotation of the CpG sites

Different (epi)genomic features were extracted for the CpG sites of interest. All the data were mapped to the *hg19* assembly of the human genome. The **continuous features** were calculated by extracting the mean value in a window of ± 200 bp from the CpG site coordinate using the *pyBigWig* package [241]. I chose this window value based on the

methylation correlation observed between neighbouring CpG sites in previous studies [242]. The continuous features included (Fig. S2.11):

- ChIP-seq data from ENCODE (histone modifications from peripheral blood mononuclear cells or PBMC; EZH2, as a marker of Polycomb Repressing Complex 2 binding, from B cells; RNF2, as a marker of Polycomb Repressing Complex 1 binding, from the K562 cell line). I obtained Z-scores (using the *scale* function in R) for the values of ‘fold change over control’ as calculated in ENCODE [93]. When needed, biological replicates of the same feature were aggregated by taking the mean of the Z-scores in order to obtain the ‘normalised fold change’ (NFC).
- ChIP-seq data for LaminB1 (GSM1289416, quantified as ‘normalised read counts’ or NRC) and Repli-seq data for replication timing (GSM923447, quantified as ‘wavelet-transformed signals’ or WTS). I used the same data from the IMR90 cell line as in [243].
- Total RNA-seq data (rRNA depleted, from PBMC) from ENCODE. I calculated Z-scores after aggregating the ‘signal of unique reads’ (*sur*) for both strands (+ and -) in the following manner:

$$RNA_i = \log_2(1 + sur_{i+} + sur_{i-}) \quad (3.2)$$

where RNA_i represents the RNA signal (that then needs to be scaled to obtain the ‘normalised RNA expression’ or NRE) for the i th CpG site.

The **categorical features** were obtained by looking at the overlap (using the *pybedtools* package) [244] of the CpG sites with the following:

- Gene bodies, from protein-coding genes as defined in the basic gene annotation of GENCODE release 29 [245].
- CpG islands (CGIs) were obtained from the UCSC Genome Browser [246]. Shores were defined as regions 0 to 2 kb away from CGIs in both directions and shelves as regions 2 to 4 kb away from CGIs in both directions as previously described [242, 247].
- Chromatin states were obtained from the K562 cell line in the Roadmap Epigenomics Project (based on imputed data, 25 states, 12 marks) [248]. A visualisation for the association between chromatin marks and chromatin states can be found in [249].

When needed for visualisation purposes, the 25 states were manually collapsed to a lower number of them.

I compared the different genomic features for each one of the subsets of CpG sites (hypomethylated aDMPs, hypomethylated Sotos DMPs, ...) against a control set. This control set was composed of all the probes from the background set from which I removed the subset that I was testing. In the case of the comparisons against the 353 Horvath clock CpG sites, a background set of the 21368 (21K) CpG probes used to train the original Horvath model [102] was used. In the case of the genome-wide comparisons for ageing and Sotos syndrome, a background set containing all 428266 probes that passed my pre-processing pipeline was used (see section 2.1.2).

For each continuous feature, the feature score distributions for a given subset of CpG sites and the control set were compared using the non-parametric two-sided Wilcoxon's test. For each categorical feature, I first created a 2×2 contingency table, with the two variables indicating whether a given CpG site overlaps with the categorical feature under consideration (Yes/No) and whether the CpG site is in the subset (e.g. hypomethylated aDMPs) being considered (Yes/No). Using Fisher's exact test (as implemented in the *fisher.test* function in R) I calculated the p-value and the odds ratio (OR), which allows determining whether the categorical feature under consideration is enriched in the CpGs subset.

Differences in the epigenetic clock CpGs β -values for Sotos syndrome

To compare the β -values of the Horvath clock CpG sites between the healthy samples and Sotos samples I fitted the following linear model to each array probe from the Horvath's epigenetic clock (353 in total) in the healthy individuals samples (Fig. 3.6a,b):

$$\text{Beta} \sim \text{Age} + \text{Age}^2 + \text{Sex} + \text{Gran} + \text{CD4T} + \text{CD8T} + \text{B} + \text{Mono} + \text{NK} + \text{PC1} + \dots + \text{PC17} \quad (3.3)$$

where *Beta* is the β -value for the clock array probe being evaluated; *Age* is the chronological age (in years) of the samples; *Sex* encodes for the sex of the samples (0/1); *Gran*, *CD4T*, *CD8T*, *B*, *Mono* and *NK* are the cell type proportions from the samples as calculated with my cell-type deconvolution strategy and *PCN* is the *N*th principal component that captures technical variance and accounts for potential batch effects (see section 2.2.3 for more details). The Age^2 covariate allows accounting for non-linear relationships between chronological age and the β -values.

Finally, I calculated the difference between the β -values in Sotos samples and the predictions from the models in equation 3.3 and displayed these differences in an annotated heatmap (Fig. 3.6c).

Chapter 4

Technological aspects of epigenetic clocks

4.1 Background

With the advent of next-generation sequencing, scientists are studying the biology of life at unprecedented resolution [250]. Unfortunately, owing to the large size of many commonly studied genomes (human, mouse and tobacco plant for example are all > 2.5 Gbp in size) [251–253], it is often still prohibitively expensive to conduct whole genome sequencing at high coverage. This creates a trade-off that negatively impacts the number of replicates that can be included and, therefore, it challenges the statistical power and the reproducibility of the studies [254, 255]. This is true in particular for DNA methylation, where differentially methylated regions (DMRs) are typically called by identifying changes as small as 10% and where 70 – 80% of the reads of Whole Genome Bisulfite Sequencing (WGBS) methods contain little to no relevant information on the DNA methylation status [256].

To address these cost inefficiencies, many methods have been developed to **reduce the number of genomic fragments that need to be sequenced** for a given biological system [257–261]. These methods can be broadly split into those that positively select for genomic fragments of interest and those that deplete for fragments that are not of interest. Positive selection-based methods involve the sites of interest being enriched from the background. This usually occurs through pull-down of these sites via an antibody (e.g. anti-5mC antibody) [262], a recombinant binding protein (e.g. methyl-CpG-binding domains or MBD) [263], covalent biotin tagging [264], capture probes/baits for the sites of interest [265–267], array-based approaches (e.g. 27K, 450K and EPIC arrays in human) [111–113, 268] or PCR-based approaches [269–274]. These methods have many limitations, including enrichment biases, complex protocols and difficulties in quantification [257, 259].

Current evidence shows that depletion-based methods do not have enrichment biases, tend to be simpler and are more readily quantifiable [257, 260]. The most common depletion-based approaches use restriction enzymes to exploit the fact that the nucleotide composition in a given genome is non-random and that the fragment lengths produced from a given digestion will thus reflect this [275–279]. In the case of 5-methylcytosine (5mC), the most common depletion-based method is Reduced Representation Bisulfite Sequencing (RRBS) using the methylation-insensitive restriction enzyme MspI (with the recognition sequence C|CGG) [280, 281], although enzymes such as BglII [282], XmaI [283], Taq α I [284, 285], MspJI [286], ApeKI [287], HpyCH4IV or HpaII [288] have also been used. RRBS has proven extremely useful for cost-effective, global studies of DNA methylation [172, 280, 284, 289], capturing around 10% of CpG sites within mammalian genomes but with up to a 30-fold reduction in the number of fragments sequenced in comparison to WGBS [290].

In the context of epigenetic clocks, most studies have used methylation arrays in humans [102, 160, 291] and MspI-based RRBS in mice, dogs and wolves [172, 103, 292, 104, 293]. The utility of the MspI-based RRBS approach is limited to a specific subset of CpG sites in the genome, mainly found within CpG islands and promoters [280]. Nevertheless, it is known that many age-related changes in the methylome occur in other genomic regions (such as enhancers) [153, 154, 207, 294], and current technologies could be biasing our discoveries. Furthermore, epigenetic clocks could be used in the near future to perform high-throughput screenings of anti-ageing drugs or employed as ageing biomarkers in clinical trials [295]. However, the current assay costs could preclude the use of epigenetic clocks in this context.

Given that restriction enzyme-based approaches are versatile and simple, we developed a new computational method called **customised Reduced Representation Bisulfite Sequencing** (cuRRBS), which allows researchers to optimise the RRBS protocol for a specific experiment. cuRRBS generalises the problem of genomic enrichment with restriction enzymes by allowing the user to define both the genome and the particular sites of interest, before outputting the optimal enzyme combinations and size ranges to target these sites. In addition, cuRRBS provides the user with a variety of metrics to compare the various suggested protocols, including an estimate of the fold-reduction in sequencing costs compared to WGBS and a robustness value to assess the impact of experimental error in the size selection step.

Here, we have tested the enrichment ability of cuRRBS in several biological systems (including the Horvath epigenetic clock), with sites in both CpG and CHG contexts and multiple species, to showcase the generalisability and utility of the software [102, 296–301]. In addition, we take advantage of two recently published independent RRBS datasets to

demonstrate the accuracy of the software predictions in both single and double enzyme experimental settings [283, 285]. We hope that cuRRBS will be useful as a tool for designing cost-effective, genome-wide studies in the future, to help in the development of new epigenetic-based predictors and to validate previous results from whole genome approaches in a simple, cheap and timely fashion.

4.2 Restriction enzyme digestion as a tool for genomic enrichment

Restriction enzymes represent an incredibly effective tool for the enrichment of certain sites of interest in a genome. This is possible due to the wide variety of motifs that commercially-available restriction enzymes can recognise (Fig. 4.1) combined with the non-random nature of the genome composition itself. Fig. 4.1 highlights that this motif diversity is driven both by the sequence composition (GC content) and the length of the recognition sequence. Thus, different restriction enzymes will generate different fragment length distributions, dependent upon how frequently their recognition site is present in a given genome (Fig. 4.2a, Fig. S3.1).




Fig. 4.1 The landscape of restriction enzyme motifs. **a.** Phylogenetic analysis of the motifs that are recognised by the different commercially-available restriction enzymes which are insensitive to CpG methylation. Each sequence represents a different isoschizomer family considered in this study. A neighbour-joining method was used to construct the tree. Motifs with different GC content are shown with different colours. **b.** Principal component analysis (PCA) performed on the matrix of pairwise distances from the aligned motifs. Each circle represents a different motif. The coordinates of the different motifs on the first two principal components are plotted on the x- and y-axes. Motifs with different GC content are shown with different colours (same as in a.) and the motif length is represented by the diameter of the circle.

In DNA methylation studies the most common application is the use of MspI (cutting at C|CGG) in RRBS (Reduced Representation Bisulfite Sequencing), which is used to enrich for CG dinucleotides (CpGs) contained in promoters and CpG islands [280] (Fig. 4.2b). However, in many cases, MspI is by no means the most effective restriction enzyme that could be used. For instance, MspI would be a poor restriction enzyme to choose for the enrichment of CpGs found in intergenic regions or non-coding RNA genes, which would be far better enriched for using BsmI or MfeI respectively (Fig. 4.2c). In fact, it turns out that across many genomic features MspI is rarely the most optimal methylation-insensitive restriction enzyme (Fig. S3.2).

Previous studies have tested the potential of other restriction enzymes and enzyme combinations to expand the range of CpG sites that can be targeted in a genome [275, 277–279, 283, 284, 287, 288]. However, to our knowledge, there is currently no computational method that systematically explores the capacity of all commercially-available restriction enzymes to generate ‘personalised’ reduced-representations of the genome whilst minimising the experimental cost (Fig. S3.3).

4.3 cuRRBS: customised Reduced Representation Bisulfite Sequencing

We have developed a novel computational method (cuRRBS) that determines the optimal combination of restriction enzymes and size range to enrich for any given set of sites of interest in any genome. In other words, by modifying two of the steps in the original RRBS protocol (Fig. 4.3a), cuRRBS generalises RRBS.

The software takes as input the genomic coordinates that the user wants to target (Fig. 4.3b, Fig. S3.4a). Afterwards, cuRRBS assesses *in silico* the potential of all single enzymes and double-enzyme combinations to enrich for the sites of interest using the following variables:

- NF , which reflects the theoretical number of genomic fragments that will be sequenced after the size selection step (i.e. those whose lengths after the *in silico* digestion are within the size range). Assuming that the sequencing cost is proportional to NF , cuRRBS attempts to minimise this value.
- *Score*, which reflects the theoretical number of sites of interest that will be sequenced after the size selection step. cuRRBS attempts to maximise this value, which can be calculated as:




Fig. 4.2 Restriction enzyme digestion as a tool for genomic enrichment. **a.** Heatmap showing the fragment length distributions generated by different restriction enzymes in the human genome (hg38). Each column represents the distribution for an isoschizomer family of restriction enzymes that contains at least one member which is methylation-insensitive in a CpG context. The distributions are binned in size ranges of 200 bp, ordered as they would appear in an electrophoretic gel. Additional row annotations on top of the heatmap contain information regarding the total number of fragments (in red) and the median fragment length (in blue) produced by each in silico digestion, together with the GC content of the recognition motif in the isoschizomer family (in green). Legend is displayed on the right hand side. **b.** Scatterplot showing the percentage of cleavage sites from different restriction enzymes that overlaps with CpG islands (x-axis) and promoters (y-axis) in the human genome (hg38). The size of the circles represents the total number of cleavage sites generated by each enzyme. The enzymes MspI and BssAI are highlighted in red and blue respectively. Legend is displayed on the right hand side. **c.** Scatterplot showing the percentage of cleavage sites from different restriction enzymes that overlaps with intergenic regions (x-axis) and non-coding RNA genes (y-axis) in the human genome (hg38). The size of the circles represents the total number of cleavage sites generated by each enzyme. The enzyme MspI is highlighted in red. The enzymes BsmI and MfeI are both highlighted in blue. Legend is displayed on the right hand side.

$$Score = \sum_{i=1}^n w_i \cdot \gamma_i \quad (4.1)$$

where n is the total number of sites of interest, w_i is the weight of the i th site of interest and γ_i is 1 if the i th site would be theoretically sequenced (i.e. present in a size selected fragment and \leq *read length* base pairs away from one of the ends of the fragment) and 0 otherwise.

- *Enrichment Value (EV)*, which combines both NF and $Score$ into a single number. The objective of cuRRBS is to minimise EV , which can be calculated as:

$$EV = -\log_{10} \left(\frac{Score}{NF} \cdot \frac{n}{max_Score} \right) \quad (4.2)$$

where *max_Score* is the *Score* obtained if all the sites of interest were sequenced.

The NF and $Score$ variables are positively correlated with one another, such that the more genomic fragments sequenced, the more sites of interest are likely to be contained within the reduced representation (Fig. 4.3c, Fig. S3.4b). However, this relationship disappears at higher NF values, where the $Score$ variable becomes saturated such that any additional fragments sequenced will result in a reduction in the overall enrichment of the sites of interest. This $Score$ saturation at high NF is mainly due to additional sites of interest being buried within long fragments that will not be sequenced due to limitations in the read length (cuRRBS parameter $-r$, see Table 4.1). For a given enzyme or enzyme combination, the NF and the $Score$ variables depend on the *size range* chosen, since only the genomic fragments within the size range will be present in the reduced representation of the genome.

cuRRBS requires that the user sets *thresholds* for the maximum NF (i.e. minimum *CRF*, see below) and minimum $Score$ that would be acceptable for a given application (Fig. 4.3b, Fig. S3.4a). These *thresholds* allow cuRRBS to search through all possible *size ranges* for a given enzyme or enzyme combination and to find the one that minimises the *Enrichment Value (EV)*. cuRRBS repeats this procedure for every single enzyme and enzyme combination and reports those with the best hits (i.e. those with the lowest *EVs*) (Fig. S3.4a).

The output file contains the best scoring enzymes with their correspondent size ranges and some other useful variables for each one of the hits, such as:

- *Cost Reduction Factor (CRF)*, which estimates the theoretical fold-reduction in sequencing costs for the cuRRBS protocol when compared to Whole Genome Bisulfite Sequencing (WGBS). The *CRF* for a given cuRRBS protocol can be calculated as:

$$CRF = \frac{NF_{ref}}{NF} = \frac{g/r}{NF} \quad (4.3)$$

where NF_{ref} is the estimated number of fragments that would be sequenced in a WGBS experiment, that can be roughly calculated as the genome size (g) divided by the read length (r).

- *Robustness (R)*. This assesses how much the cuRRBS prediction varies if a slightly different size range is used (Fig. 4.3d). The results for robust enzymes will not be greatly affected as a consequence of experimental error during the size selection step. This will help the user to make an informed decision on which enzyme combination to choose for the system of interest (Fig. S3.4c). The *robustness* of a given enzyme (combination) is calculated as:

$$R = e^{-\theta} \quad (4.4)$$

with

$$\theta = \frac{\sum_{x \in \{a-\delta, a, a+\delta\}} \sum_{y \in \{b-\delta, b, b+\delta\}} |EV_{x,y} - EV_{a,b}|}{EV_{a,b}} \quad (4.5)$$

where $EV_{a,b}$ is the EV for the optimal size range (a : lower limit in size range, b : breadth) and δ is the experimental error (in bp) that is assumed during the size selection step. The *robustness* will take values in the interval $(0, 1]$, with higher values identifying robust cuRRBS protocols.

4.4 Running cuRRBS in different biological systems

cuRRBS provides a way to effectively interrogate DNA methylation in any biological system (including the CpG sites that constitute different epigenetic clocks) for which the reference




Fig. 4.3 cuRRBS overview. **a.** Outline of an RRBS protocol. Highlighted are the two steps that would be modified according to the output produced by cuRRBS (i.e. the restriction enzymes used for the genomic digestion and the size selection). Legend is displayed on the bottom left. **b.** Schematic of cuRRBS. Highlighted are the two main inputs required for the software and the two *thresholds* that the user has to define (red and purple tags). The default output for cuRRBS is a table containing the top hits (restriction enzyme combination and size range) along with additional information that might be useful to the user (such as *Cost Reduction Factor* and *robustness*). **c.** Scatterplot showing the trade-off between the number of fragments (*NF*) and the *Score* for the best enzyme combination (BsaWI & BssAI) that targets the CpGs present in the human placental-specific imprinted regions [296]. *NF* is divided by 1000 for visualization purposes. Each point represents a different *size range*. Shown in dark blue and grey are the size ranges that would and would not pass filtering respectively. Shown in orange is the optimal size range in the filtered search space. The dotted lines depict the *thresholds* that need to be specified by the user (red: maximum *NF*; purple: minimum percentage of the maximum *Score*). In this mock example we specified an *NF threshold* of 150000 fragments and a *Score threshold* of 25% of the maximum *Score*. Legend is displayed below the plot title. **d.** Contour plot that depicts how the *robustness* (*R*) variable is calculated for the optimal enzyme combination (BsaWI & BssAI; size range: 60-540 bp) that targets the CpGs present in the human placental-specific imprinted regions [296]. *Enrichment values* (EVs) are calculated for all possible size ranges in order to create an *EV ‘landscape’*. In this landscape, cuRRBS finds the size range with the lowest *EV* that still satisfies the *thresholds* (asterisk in green). Afterwards, cuRRBS samples *EVs* around the optimum (asterisks in black). The points that are sampled depend on the experimental error (in this case, $\delta = 20$ bp). A high *robustness* value means that the sampled *EVs* do not change a lot when compared to the optimum, which implies that cuRRBS prediction will not be greatly affected by experimental errors during the size selection step.

genome is available. Besides reducing the cost for organisms currently under intensive study (e.g. human, mouse), cuRRBS opens the door to the cost-effective study of DNA methylation in species with large genomes or where DNA methylation in non-CpG contexts is common, such as plants [302], which currently lack an MspI-based RRBS protocol, owing to the enzyme's CHG methylation sensitivity [303].

We decided to test the ability of cuRRBS to enrich for genomic sites that have important functional roles in different systems. Some of the systems that we tested *in silico* include genomic regions whose methylation status is important during cellular reprogramming [297], Horvath's epigenetic clock [102], transcription factor binding sites that are affected by DNA methylation [299, 301], imprinted loci [296], CpGs found in the exon-intron boundaries [300] and CHG sites that are differentially methylated between different arabidopsis accessions [298] (Fig. S3.5). For these *in silico* systems we chose to run the software with the threshold set to 25% of the maximum *Score*.

In all cases, cuRRBS is able to dramatically reduce the cost associated with the sequencing by several orders of magnitude compared to WGBS, which is assessed using the *Cost Reduction Factor (CRF)* (Fig. 4.4). In addition, for cases where a comparison to MspI-based RRBS could be made, cuRRBS is able to improve the *CRF*, again, by orders of magnitude. As an example, for the placental-specific imprints, the sequencing costs are reduced by approximately 400-fold when compared to WGBS and by 12.5-fold when compared to the traditional MspI-based RRBS.

Furthermore, we have also observed that many of the top hits reported by cuRRBS are digestions of two restriction enzymes (Fig. S3.5), highlighting the combinatorial power of restriction enzymes to produce optimal reduced representations of the genome [277]. Excitingly, we are able to show that using cuRRBS it is possible to assay a far larger number of target sites, in a far simpler experimental design than would normally be achieved using amplicon-based bisulfite sequencing.

4.5 Experimental validation of cuRRBS

To assess in an unbiased manner how well predictions from cuRRBS perform in an experimental setting, we employed two independent non-canonical RRBS datasets: one generated from a single enzyme (XmaI) and the other from a combination of two restriction enzymes (MspI and Taq α I) [283, 285]. By evaluating the predictive power of cuRRBS in these two




Fig. 4.4 Running cuRRBS in different biological systems. Barplot showing the values for the *Cost Reduction Factor* (*CRF*) in the different biological systems that were tested (see Fig. S3.5) [102, 296–301]. The colours in the bars represent the different species interrogated (green: *Arabidopsis thaliana*, blue: *Mus musculus*, red: *Homo sapiens*). The *CRF* for the traditional RRBS protocol (*MspI* in the human genome, using a bead size selection step of 20–800 bp, *CRF* = 30.65) is displayed as a grey area, which is not compared with the *A. thaliana* system (since *MspI* is sensitive to CHG methylation).

datasets, we were able to observe cuRRBS' performance in both single and double enzyme contexts and across different genomes.

To test the accuracy of cuRRBS predictions in the context of a single enzyme digestion, we utilised the non-canonical RRBS dataset generated from human DNA using the restriction enzyme *XmaI* [283]. This dataset was previously used to show that *XmaI* could enrich for CpG islands (CGIs), while reducing the overall sequencing cost relative to *MspI*, making the protocol more cost-effective. To validate cuRRBS using this system, we therefore chose to enrich for all CpG sites that overlapped with a CGI (CGI-CpGs) in the human genome using a predetermined theoretical size range equivalent to the 'reproducible library fragment lengths' reported in [283] (i.e. 90–185 bp). cuRRBS predicted with high accuracy the CpG sites that were observed in the experimental *XmaI*-RRBS dataset (Fig. 4.5a). In particular, only a small proportion of the total number of CGI-CpGs should be theoretically sequenced (102253 out of 2164614), and this was indeed the case (Fig. 4.5a). Furthermore, upon filtering out sites with low depth of coverage, which commonly represent noise in RRBS datasets, the sensitivity increased up to approximately 80%. Importantly, the specificity remained constant at almost 100% independent of the threshold set for depth of coverage (Fig. 4.5b). Thus,

cuRRBS produces a prediction that is relatively conservative, as highlighted by the low numbers of false positives (Fig. 4.5a), at the expense of a small decrease in sensitivity.

Interestingly, the original theoretical size range that the study was aiming for (110-200 bp) was slightly different to the one achieved in the actual experiments (90-185 bp) [283]. We ran cuRRBS using the original size range target and obtained slightly worse results for the sensitivity but not the specificity of the prediction (Fig. S3.6). This demonstrates that the correct execution of the size selection step during the experimental protocol is key for obtaining the sites predicted by cuRRBS and highlights the importance of the *robustness* variable as part of the cuRRBS output in order to judge the consequences of these experimental errors.

To test the accuracy of cuRRBS predictions in the context of a double enzyme digestion, we utilised the non-canonical RRBS dataset generated from mouse DNA using the restriction enzymes MspI and Taq α I [285]. To compare the accuracy of cuRRBS prediction in this double enzyme system to that of the XmaI-RRBS system, we again ran cuRRBS for CGI-CpGs, this time in the mouse genome with a theoretical size range of 80-160 bp [285]. cuRRBS predicted with high accuracy the CpG sites that were observed in this double enzyme experiment (Fig. 4.5c). In addition, the results for sensitivity and specificity were very similar to the ones reported for the XmaI-RRBS dataset (Fig. 4.5d). Therefore, we conclude that cuRRBS produces robust predictions for the sites of interest that will be sequenced in RRBS protocols both for single and double enzyme combinations independent of the genome under study.

Lastly, the number of fragments that were theoretically recoverable in each of our experimental systems ranged from $NF = 12780$ (for XmaI) to $NF = 331058$ (for MspI and Taq α I). This represents approximately a 30-fold difference in the number of recoverable fragments and demonstrates that cuRRBS predictions, even for low NF values, are experimentally feasible. Importantly, in the nine theoretical examples that we report (Fig. S3.5), the number of fragments required by each cuRRBS protocol ranges from 107248 to 974050. Thus, the number of fragments required to achieve the stated *CRF* comfortably exceeds the minimum experimentally validated NF value (>8-fold).

4.6 Conclusions and future directions

cuRRBS provides a new framework that allows the user to optimise RRBS for the biological system of interest by using novel combinations of restriction enzymes. Therefore, cuRRBS




Fig. 4.5 Experimental validation of cuRRBS. **a.** Barplots showing the number of true positives (TP, in green), true negatives (TN, in blue), false positives (FP, in red) and false negatives (FN, in orange) when comparing cuRRBS theoretical prediction with the actual XmaI-RRBS experimental data [283]. The number of sites in each category is calculated for different thresholds in the depth of coverage (number of reads covering a CpG site as reported by Bismark). cuRRBS prediction for the CpG sites in human CpG islands was obtained enforcing a theoretical size range of 90-185 bp and running the software for XmaI with all the default parameters (with a *read length* of 200 bp). Legend is displayed on the right hand side. **b.** Plot showing values of cuRRBS sensitivity (in light green) and specificity (in cyan) as a function of the depth of coverage threshold employed to filter the experimental data [283]. The number of true positives (TP), true negatives (TN), false positives (FP) and false negatives (FN) are the same as in a. Legend is displayed below the plot curves. **c.** Same as in a. but for the MspI&Taq α I-RRBS experimental data [285]. cuRRBS prediction for the CpG sites in mouse CpG islands was obtained enforcing a theoretical size range of 80-160 bp and running the software for MspI&Taq α I with all the default parameters (with a *read length* of 75 bp). **d.** Same as in b. but for the MspI&Taq α I-RRBS experimental data [285].

makes the study of DNA methylation more affordable across all species for which genomic sequences are available. Furthermore, it can open the door to the design of future studies in a clinical context [284], which require cost-effective and robust protocols.

Currently, cuRRBS only considers combinations of up to two restriction enzymes. However, in the future, it would be possible to adapt the software to explore combinations that contain higher numbers of enzymes, which could theoretically allow targeting the sites of interest even more efficiently [277]. Moreover, there are several methods that are able to impute DNA methylation levels in sites that are not covered experimentally [242, 304]. These methods could expand the set of sites of interest that are finally measured by making use of the additional DNA methylation information that is retrieved in a cuRRBS experiment.

Finally, the potential of restriction enzymes to target different genomic coordinates is not limited to DNA methylation. As such, it would be conceivable for cuRRBS to be adapted to enrich for SNPs of interest [305, 306] or to optimise chromosome conformation capture techniques [307, 308]. By reducing the cost associated with sequencing, we believe that cuRRBS will help to democratise high-throughput genomic studies.

4.7 Additional methods

Restriction enzymes annotation

All the information regarding the commercially-available restriction enzymes that are used by cuRRBS was extracted from REBASE [309, 310]. Restriction enzymes were grouped in isoschizomer families (i.e. enzymes that recognise the same sequence and generate identical fragment length distributions) and each enzyme was manually annotated for different types of methylation-sensitivity (CpG, CHG, CHH). Only isoschizomer families that contained at least one methylation-insensitive enzyme were considered for the examples described here.

Genome assemblies and genomic annotation

All the analyses presented here were performed in the following genome assemblies: *Homo sapiens* (hg38), *Mus musculus* (mm10) and *Arabidopsis thaliana* (TAIR10). Scaffolds not assembled into the main chromosomes were discarded. Genomic annotation for the human genome (hg38) was obtained from GENCODE (v25, basic gene annotation) [311], with the exception of CpG islands (CGIs), which were extracted from the UCSC Genome Browser [246]. GC content and CpG content were calculated, around each restriction enzyme cleavage

site, taking windows of ± 25 bp and ± 500 bp respectively. For each enzyme, the mean of all cleavage sites was calculated to obtain the mean GC content and the mean CpG content. Intron regions were defined as those regions within ± 2.5 kb of a protein-coding gene, whilst the rest of the genome was considered to be intergenic. CpG shores were defined as regions 0 to 2 kb away from CGIs in both directions and CpG shelves as regions 2 to 4 kb away from CGIs in both directions [242]. Promoters were defined as encompassing a 3 kb region (2.5 kb upstream and 0.5 kb downstream of the TSS) relative to the TSS of all protein-coding transcripts in GENCODE, similar to the strategy used in Taher *et al.* [312]. Genomic annotation for the CGIs in the mouse genome (mm10) was also obtained from the UCSC Genome Browser [246]. All annotations were handled using the *pybedtools* library [244, 313].

Performing *in silico* digestions of a given genome

We used the *Restriction* package from Biopython v1.68 to digest the different genomes with the appropriate restriction enzymes *in silico* [314]. Only the first member of a given isoschizomer family (which contained at least one methylation-insensitive enzyme) was processed to avoid redundant computations. The output of the *in silico* digestions was stored (pre-computed files) and subsequently read by cuRRBS when needed to reduce the computational time (see ‘cuRRBS heuristics and computational efficiency’). When assessing enzyme combinations, the information from the appropriate individual pre-computed files (i.e. the genomic coordinates where the enzyme theoretically cuts) were combined by the software to compute all the necessary variables.

cuRRBS’ enzyme flexibility

To ensure the user has full control over the enzymes that cuRRBS will use to derive the desired enrichments, one of the inputs given to cuRRBS is an enzyme annotation file. This file contains the desired isoschizomer families that the user wishes to be tested by cuRRBS. In my GitHub repository we have already defined enzyme annotation files for enzymes that are methylation-insensitive in a CG context and in CG, CHG and CHH contexts [315]. However, it is also possible for the user to define a personalised set of enzymes by providing a self-generated annotation file. This can be useful, for instance, to reduce the chance of any star activity in the reported cuRRBS protocols.

In addition, the output file from cuRRBS contains, by default, 30 cuRRBS protocols that would enrich for the user’s sites of interest. Therefore, the user can determine which

cuRRBS parameter (abbrev.)	Significance	Default	Range
Enzymes to check (-e)	Defines the enzymes (isoschizomer families) that cuRRBS will look at	-	-
Annotation for the sites of interest (-a)	Allows identification and weighting of the sites of interest	-	-
Read length (-r)	Defines the positions in the theoretical fragments that can be ‘seen’ after sequencing	-	30-300
Adapters size (-s)	Ensures correct experimental size selection	-	-
C_Score constant (-c)	Sets the minimum acceptable <i>Score</i>	-	0-1
Genome size (-g)	Needed to calculate the <i>CRF</i>	-	-
C_NF/1000 constant (-k)	Sets the minimum acceptable <i>CRF</i>	0.2	0-1
Experimental error (-d)	Sets the assumed experimental error (δ)	20	5-500
Size range breadth (-b)	Constrains the breadth of the size range	980	-
Output size (-t)	Defines the number of cuRRBS protocols the user can compare	30	-
Site IDs (-i)	Enables the identification of the recovered sites of interest	No	-

Table 4.1 Flexible user-defined cuRRBS parameters. This table details the flexible user-defined parameters that cuRRBS will accept as arguments. The cuRRBS parameter full name and command line abbreviation (in brackets) are provided alongside a simplified description of the significance of these arguments to the user. Where applicable, the defaults and ranges of these arguments are also detailed.

enzyme combination and size range would be the simplest and most appropriate for the given application. This provides the user with the opportunity to consider experimental factors that may complicate the protocol, such as buffer compatibility and whether consecutive digestions would be required.

Flexible user-defined cuRRBS parameters

cuRRBS contains a number of user-defined parameters to ensure the greatest possible flexibility and ease of use. A table of these parameters is provided to highlight the versatility that the user has and why such versatility is useful (Table 4.1).

cuRRBS heuristics and computational efficiency

cuRRBS employs several strategies to reduce the computational time needed in each run:

- Restriction enzymes are grouped in isoschizomer families. Since isoschizomers generate the same genomic digestions, only one member of each family needs to be processed.

- *In silico* digestions are read from pre-computed files. Digesting the genomes would be a limiting factor in the cuRRBS pipeline. The user can download the pre-computed files [315] and the information that they contain is read every time that an enzyme needs to be assessed.
- The number of size ranges that are sampled is minimised. Since the experimental size selection step is generally imperfect, size ranges are sampled with a sliding window whose ‘resolution’ is equivalent to the experimental error specified by the user.
- Parallelization. cuRRBS can use several cores to decrease the CPU time.

Moreover, we have observed that, in many enzyme combinations, one of the enzymes is providing most of the enrichment for the sites of interest, while the second one complements the targeting. Therefore, it would be possible to implement a ‘heuristic’ mode, where only those enzymes that perform well individually are used as ‘seeds’ to construct combinations (as opposed to the current implementation, where all the enzyme combinations are checked exhaustively). This could further reduce the computational time, especially if combinations of more than two enzymes were being evaluated.

The CPU time required by cuRRBS depends on several parameters, including the number of enzymes checked, the experimental error, the number of sites of interest or the genome size (Fig. S3.7). The RAM used will be approximately equal to the size of the pre-computed files that are read by the software. A standard cuRRBS run (e.g. for a few thousand sites of interest in the human genome, checking 128 CpG methylation-insensitive isoschizomer families) takes around 0.5-1 hours and uses around 4 GB RAM, which allows the user to easily run it on a dual-core laptop or desktop computer.

Obtaining the sites of interest for different biological systems

We have tested *in silico* the ability of cuRRBS to enrich for the sites of interest in a selection of different biological systems where DNA methylation has an important functional role. In some of these systems, described below, previous analysis was performed in order to obtain the genomic coordinates for the sites:

- Exon-intron boundaries in human. Exons and introns were obtained from protein-coding genes using GENCODE annotation data. Those CpG sites that were found within ± 5 bp of a canonical splice site (5'-GT, 3'-AG) were selected.
- Epigenetic clock in human. These sites were obtained from the Horvath epigenetic clock [102] and were lifted over to hg38 [316] before running cuRRBS.

- Canonical and placental imprints in human. These loci were obtained from Hanna *et al.* [296]. The sites were lifted over to hg38 [316] and the CpG sites were then extracted for the analysis.
- CTCF binding sites in human. We obtained the CpG sites that overlap with *in vivo* CTCF binding sites. Peaks from sites that seem to be affected by methylation (upregulated, reactivated) were kindly provided by Dr. M. T. Maurano [299]. We scanned the peaks for high-scoring motifs according to the CTCF JASPAR model [317]. Finally, we extracted those CpGs that were found in positions 5 and 15 of the motif, whose methylation status is supposed to influence the binding of the transcription factor [299].
- Induced pluripotent stem cells (iPSCs) demethylated and maintained sites in mouse. These were obtained by comparing mouse embryonic fibroblasts (MEFs) to iPSCs as described previously [297], with an additional filter for magnitude of methylation change (>50% methylation change).
- NRF1 binding sites in mouse. We obtained the CpG sites that overlap with *in vivo* NRF1 binding sites in mouse. ChIP-seq data was processed as described in the original publication [301], where peaks were called using Peakzilla [318]. We took as our final set of peaks the overlap between the two TKO replicates. Next, we scanned the peaks for high-scoring motifs according to the NRF1 JASPAR model [317]. Finally, we extracted those CpGs that were found in positions 2 and 8 of the motif, whose methylation status is supposed to influence the binding of the transcription factor [317].
- CHG sites in *Arabidopsis thaliana*. Non-CpG DMRs arising from the epigenomic diversity between *Arabidopsis thaliana* accessions were obtained from Kawakatsu *et al.* [298]. The coordinates for C sites in non-CpG context were extracted.

In all the cases the sites were equally weighted ($w_i = 1$), with the exception of the human epigenetic clock system, where the sites were assigned the absolute value of the weights in the linear model [102]. All the site annotation files can be found in my GitHub repository [315]

Running cuRRBS for the different biological systems

cuRRBS was run in the different systems described above using the default parameters ($k = 0.2$, $d = 20$, $b = 980$, $t = 30$), for a *read length* (r) of 75 bp and a *Score threshold* (c) of 0.25. In the mouse and human examples we considered 128 isoschizomer families that contained enzymes that were not sensitive to CpG methylation. In the case of *Arabidopsis*

thaliana we used 28 isoschizomer families that contained enzymes that were not sensitive to 5mC in any context (CG, CHG, CHH).

Mapping of RRBS samples

XmaI-RRBS data generated on the Ion Torrent platform [283] and MspI&Taq α I -RRBS data generated on the Illumina HiSeq platform [285] were quality trimmed using Trim Galore (www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and had base pairs removed from the 3' end to avoid including filled-in nucleotides with artificial methylation states (the filled-in XmaI, MspI and Taq α I cut sites include the nucleotide sequence CCGG, CG and CG respectively). The data was then mapped to the human genome (for XmaI data, parameters: –non_directional) or the mouse genome (for MspI&Taq α I data, parameters: –directional) using Bismark (0.18.0) [319]. In each of the two cases data from different experiments or replicates was merged into the same FASTQ file prior to quality trimming.

Estimating cuRRBS' sensitivity and specificity

We assessed the performance of cuRRBS predictions in two independent experimental datasets [283, 285] (see section 4.5). We ran cuRRBS fixing the theoretical size ranges tested to the ones reported in the publications [283, 285] and we used as our sites of interest the CpGs that overlapped with CpG islands (CGI-CpGs) in the human [283] and the mouse genomes [285] respectively. From the cuRRBS output files we recovered the IDs of the sites that should be theoretically sequenced. Moreover, using the experimental RRBS data [283, 285], we could obtain the IDs of the sites that were actually sequenced (filtered by a given depth of coverage threshold). Afterwards, we calculated the following variables for each one of the datasets:

- True positives (TP): number of CGI-CpGs that cuRRBS predicted to be sequenced and were indeed found in the RRBS data.
- True negatives (TN): number of CGI-CpGs that cuRRBS predicted to be absent and were not found in the RRBS data.
- False positives (FP): number of CGI-CpGs that cuRRBS predicted to be sequenced but were not found in the RRBS data.
- False negatives (FN): number of CGI-CpGs that cuRRBS predicted to be absent but were found in the RRBS data.

Finally, we estimated the sensitivity and specificity, for a given dataset, as follows:

$$\text{Sensitivity} = \frac{TP}{TP + FN} \cdot 100 \quad (4.6)$$

$$\text{Specificity} = \frac{TN}{FP + TN} \cdot 100 \quad (4.7)$$

Software availability

cuRRBS and its documentation are freely distributed under GNU General Public License v3.0 and can be accessed in my GitHub repository [315].

Appendix

Supplementary figures

S.1 Statistical aspects of the epigenetic clock




Fig. S1.1 Effects of *noob* background correction on the array fluorescence intensities. Distributions of the array fluorescence intensities for the **a.** methylated signals (M_i) before background correction; **b.** unmethylated signals (U_i) before background correction; **c.** methylated signals (M_i) after background correction and **d.** unmethylated signals (U_i) after background correction. Each curve represents a DNA methylation sample from the GSE41273 batch. In grey: 51 samples that passed quality control (QC). In red: 2 samples that failed QC.




Fig. S1.2 Quality control (QC) strategy to identify outlier samples, according to their global intensity values, in the GSE41273 batch. Those samples with low median intensity values (see criteria in section 2.1.2) were discarded from downstream analyses (2/53, in red). Each sample is represented by one point. The dashed line represents the intensity threshold. M_i and U_i represent the background-corrected methylated and unmethylated intensity measurements for the different 450K array probes in a given sample.




Fig. S1.3 M-value distributions in the samples of the GSE41273 batch, after all the pre-processing steps have been carried out (background correction, quality control, probe filtering and BMIQ normalisation). M-values were calculated applying the logistic transformation to the β -values, as described in Du *et al.* [122]. Each curve represents a different sample.

Strategy name	Reference	Gold-standard preprocessing	Reference preprocessing	Probes in reference	Algorithm	Mean RMSE	Mean MAE	Mean R^2
minfi	minfi	SQN*	SQN*	600	Houseman CP/QP	2.3246	2.0137	0.9473
dhs_dif1_houseman	DHS-DMCs	Noob+BMIQ	Default	333	Houseman CP/QP	4.8039	3.843	0.7783
dhs_NB_houseman	DHS-DMCs	Noob+BMIQ	Noob+BMIQ	333	Houseman CP/QP	4.9398	4.1559	0.8062
dhs_dif2_houseman	DHS-DMCs	Noob+Filtering+ BMIQ	Default	316	Houseman CP/QP	6.1731	5.2469	0.7779
dhs_NFB_houseman	DHS-DMCs	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	316	Houseman CP/QP	6.1194	5.3185	0.7816
dhs_dif1_cibersort	DHS-DMCs	Noob+BMIQ	Default	333	CIBERSORT	2.3914	1.9502	0.8702
dhs_NB_cibersort	DHS-DMCs	Noob+BMIQ	Noob+BMIQ	333	CIBERSORT	2.8578	2.3833	0.8453
dhs_dif2_cibersort	DHS-DMCs	Noob+Filtering+ BMIQ	Default	316	CIBERSORT	2.9751	2.4714	0.8552
dhs_NFB_cibersort	DHS-DMCs	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	316	CIBERSORT	3.0684	2.5403	0.8571
dhs_dif1_rpc	DHS-DMCs	Noob+BMIQ	Default	333	RPC	2.0421	1.7032	0.8873
dhs_NB_rpc	DHS-DMCs	Noob+BMIQ	Noob+BMIQ	333	RPC	2.5289	2.1689	0.8705
dhs_dif2_rpc	DHS-DMCs	Noob+Filtering+ BMIQ	Default	316	RPC	2.9653	2.3887	0.8722
dhs_NFB_rpc	DHS-DMCs	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	316	RPC	3.0755	2.5266	0.8611
idol_NB_houseman	IDOL	Noob+BMIQ	Noob+BMIQ	300	Houseman CP/QP	2.0347	1.6778	0.9632
idol_NFB_houseman	IDOL	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	281	Houseman CP/QP	1.927	1.5498	0.9672
idol_NB_cibersort	IDOL	Noob+BMIQ	Noob+BMIQ	300	CIBERSORT	2.1997	1.7958	0.9626
idol_NFB_cibersort	IDOL	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	281	CIBERSORT	1.9818	1.6216	0.9704
idol_NB_rpc	IDOL	Noob+BMIQ	Noob+BMIQ	300	RPC	2.26	1.8812	0.9679
idol_NFB_rpc	IDOL	Noob+Filtering+ BMIQ	Noob+Filtering+ BMIQ	281	RPC	2.0122	1.6288	0.9692

Fig. S1.4 Table showing the different cell-type deconvolution strategies that were benchmarked. BMIQ: beta-mixture quantile normalisation. CP/QP: constrained projection/quadratic programming. MAE: mean absolute error. Noob: noob background correction. R²: coefficient of determination. RMSE: root mean squared error. RPC: robust partial correlations. SQN: stratified quantile normalisation. ‘Default’ refers to the pre-processing strategy employed in the original DHS-DMCs publication, as implemented in the *EpiDISH* R package (*centDHSbloodDMC.m*) [141, 145]. See section 2.1.3 in the main text for more details on what the different references refer to.




Fig. S1.5 Benchmarking of the cell-type deconvolution strategies in blood. The x-axis shows the different strategies that were tested (for a detailed description see Fig. S1.4). The y-axis shows the results for the coefficient of determination (R^2) when comparing the predictions with the real proportions of cells in a gold-standard dataset (GSE77797) [144]. The grey horizontal solid lines represent the mean for the R^2 across cell types and the grey dashed line the maximum of these values.

ProbeID	Chromosome	Coordinate	Intercept	Slope	T statistic	p-value	Methylation change	In Horvath model	Gene(s)
cg16867657	chr6	11044877	0.5458189	0.0053562	96.7079	0	Hypermethylated	No	ELOVL2
cg06639320	chr2	106015739	-0.18099	0.0040751	68.4826	0	Hypermethylated	No	FHL2
cg21572722	chr6	11044894	0.4485118	0.0029979	67.7891	0	Hypermethylated	No	ELOVL2
cg22454769	chr2	106015767	-0.37256	0.0054721	65.4459	0	Hypermethylated	No	FHL2
cg07547549	chr20	44658225	-0.109895	0.0039332	60.4444	0	Hypermethylated	No	SLC12A5
cg24724428	chr6	11044888	0.1715795	0.003787	60.3559	0	Hypermethylated	No	ELOVL2
cg17110586	chr19	36454623	-0.076933	0.0027991	59.6101	0	Hypermethylated	No	
cg19283806	chr18	66389420	1.1244081	-0.0052494	-55.5368	0	Hypomethylated	No	CCDC102B
cg10501210	chr1	207997020	-0.767615	-0.0071941	-54.848	0	Hypomethylated	No	
cg24079702	chr2	106015771	-0.239806	0.0037027	54.5055	0	Hypermethylated	No	FHL2
cg22796704	chr10	49673534	0.5923358	-0.0038938	-54.2818	0	Hypomethylated	No	ARHGAP22
cg04875128	chr15	31775895	-0.29584	0.0048949	53.8691	0	Hypermethylated	No	OTUD7A
cg23606718	chr2	131513927	-0.192302	0.0024361	53.8427	0	Hypermethylated	No	FAM123C
cg00059225	chr5	151304357	0.2564821	0.0023987	52.8361	0	Hypermethylated	No	GLRA1
cg23500537	chr5	140419819	0.2019473	0.0029768	52.4657	0	Hypermethylated	No	
cg07553761	chr3	160167977	-0.085898	0.0030009	52.1708	0	Hypermethylated	No	TRIM59
cg14674720	chr2	219827930	-0.15175	0.0022723	52.1475	0	Hypermethylated	No	
cg16419235	chr8	57360613	-0.110675	0.0021004	52.087	0	Hypermethylated	No	PENK
cg07082267	chr16	85429035	-0.234831	-0.0024153	-51.9394	0	Hypomethylated	No	
cg11970349	chr4	8582287	0.4395301	0.0024517	51.7603	0	Hypermethylated	No	GPR78
cg14556683	chr19	15342982	-0.354214	0.0030292	51.4444	0	Hypermethylated	No	EPHX3
cg06493994	chr6	25652602	-0.281467	0.0018639	51.2747	0	Hypermethylated	Yes	SCGN
cg19560758	chr1	8086721	0.123634	0.0017654	51.0739	0	Hypermethylated	No	ERRF1
cg22736354	chr6	18122719	-0.328228	0.0023877	50.7215	0	Hypermethylated	Yes	NHLRC1
cg17885226	chr6	105388731	-0.011797	0.0030608	50.2096	0	Hypermethylated	No	
cg08262002	chr4	16575323	0.448234	-0.0036267	-50.1807	0	Hypomethylated	No	LDB2
cg18933331	chr1	110186418	0.1394501	-0.0026901	-49.3592	0	Hypomethylated	No	
cg00329615	chr3	118706648	0.3767479	-0.0049889	-49.1687	0	Hypomethylated	No	IGSF11
cg08097417	chr7	130419133	-0.212277	0.0018305	48.9874	0	Hypermethylated	No	KLF14
cg00748589	chr12	11653486	0.1822405	0.0024207	48.2695	0	Hypermethylated	No	
cg11084334	chr3	9594264	-0.022951	0.0027848	47.6682	0	Hypermethylated	No	LHFPL4
cg11071401	chr17	48637194	0.3081191	0.0023875	47.6374	0	Hypermethylated	No	CACNA1G
cg06784991	chr1	53308768	0.0728526	0.0021442	47.4979	0	Hypermethylated	No	ZYG11A
cg00439658	chr17	72848669	-0.187047	0.0019148	47.3396	0	Hypermethylated	No	GRIN2C
cg16054275	chr1	169556022	-0.308762	-0.0031404	-47.2773	0	Hypomethylated	No	F5
cg14692377	chr17	28562685	-0.319816	0.0019735	47.2725	0	Hypermethylated	No	SLC6A4
cg13649056	chr9	136474626	0.0939199	0.0018608	47.0121	0	Hypermethylated	No	
cg11693709	chr15	40542019	0.4398948	-0.0041179	-46.6849	0	Hypomethylated	No	PAK6
cg07080372	chr11	796607	-0.044385	-0.0020517	-46.5748	0	Hypomethylated	No	SLC25A22
cg19671120	chr2	98962974	0.2917162	0.0019275	46.5463	0	Hypermethylated	No	CNGA3
cg16219603	chr8	57360586	-0.243393	0.001599	46.4953	0	Hypermethylated	No	PENK
cg11705975	chr10	120354248	0.1345631	0.0025062	46.1335	0	Hypermethylated	No	PRLHR
cg15480367	chr14	93389485	0.1737257	0.0020641	46.1196	0	Hypermethylated	No	CHGA
cg24466241	chr1	53308908	-0.192473	0.0028258	45.9054	5.9288E-323	Hypermethylated	No	ZYG11A
cg02650266	chr4	147558239	-0.028284	0.0018604	45.5452	2.5444E-319	Hypermethylated	No	

cg03738025	chr6	105388694	0.1325219	0.0037303	45.5435	2.6480E-319	Hypermethylated	No	
cg08160331	chr11	75140865	0.1225186	0.0024513	45.5115	5.5982E-319	Hypermethylated	No	KLHL35
cg14361627	chr7	130419116	-0.029613	0.0024426	45.4145	5.4238E-318	Hypermethylated	No	KLF14
cg08128734	chr1	206685423	0.5891423	-0.0054386	-45.0487	2.8384E-314	Hypomethylated	No	RASSF5
cg26290632	chr8	91094847	0.2029635	0.0020152	45.0401	3.4695E-314	Hypermethylated	No	CALB1
cg01974375	chr1	151298954	0.0385361	-0.0019059	-45.0297	4.4226E-314	Hypomethylated	No	PI4KB
cg23479922	chr5	16179633	-0.5691	0.0045894	44.9595	2.2879E-313	Hypermethylated	No	MARCH11
cg09809672	chr1	236557682	0.175291	-0.0040059	-44.8504	2.9374E-312	Hypomethylated	Yes	EDARADD
cg00481951	chr3	187387650	0.1841224	0.0023342	44.6878	1.3200E-310	Hypermethylated	No	SST
cg03545227	chr2	220173100	0.0832971	0.0013552	44.5825	1.5491E-309	Hypermethylated	No	PTPRN
cg18618815	chr17	48275324	-0.292108	-0.0031805	-44.5025	1.0061E-308	Hypomethylated	No	COL1A1
cg11649376	chr12	81473234	0.1177648	-0.0025894	-44.4751	1.9099E-308	Hypomethylated	No	ACSS3
cg11436113	chr20	19191145	-0.245529	-0.0028774	-44.446	3.7798E-308	Hypomethylated	No	
cg20591472	chr1	110008990	0.2290873	0.0029438	44.3726	2.1018E-307	Hypermethylated	No	SYPL2
cg12757011	chr2	162281111	-0.036861	0.0022385	44.3402	4.4864E-307	Hypermethylated	No	TBR1
cg06570224	chr3	157812475	-0.255113	0.0021525	44.3003	1.1387E-306	Hypermethylated	No	
cg12878812	chr12	119419696	-0.152434	0.0017975	44.1946	1.3495E-305	Hypermethylated	No	SRRM4
cg07931844	chr15	72102213	-0.347225	-0.0020941	-44.1556	3.363E-305	Hypomethylated	No	NR2E3
cg15341124	chr14	102027734	0.1822515	0.0021014	43.8202	8.5279E-302	Hypermethylated	No	DIO3; MIR1247
cg12534424	chr7	127992316	-0.038607	0.0019362	43.5602	3.7086E-299	Hypermethylated	No	PRRT4
cg25410668	chr1	28241577	0.5378571	0.0033963	43.5204	9.4093E-299	Hypermethylated	No	RPA2
cg19392831	chr10	120355756	0.1002692	0.0017162	43.3469	5.4065E-297	Hypermethylated	No	PRLHR
cg16008966	chr1	114761794	0.2872323	-0.0024427	-43.054	5.0499E-294	Hypomethylated	No	
cg05308819	chr1	155959156	-0.383566	-0.0018965	-43.0379	7.3568E-294	Hypomethylated	No	
cg08468401	chr3	14303131	-0.481126	-0.0045074	-43.0226	1.0497E-293	Hypomethylated	No	
cg19855470	chr22	40060836	-0.111118	0.0015512	42.913	1.3565E-292	Hypermethylated	No	CACNA1I
cg11220950	chr16	2042693	0.0102849	0.0019377	42.8543	5.3374E-292	Hypermethylated	No	SYNGR3
cg16717122	chr15	51973920	0.3252301	0.00151	42.8415	7.1833E-292	Hypermethylated	No	SCG3
cg22156456	chr17	39844239	-0.229764	-0.0018499	-42.8279	9.8668E-292	Hypomethylated	No	EIF1
cg06335143	chr1	53308654	-0.088651	0.0022272	42.8111	1.4619E-291	Hypermethylated	No	ZYG11A
cg23746497	chr6	105388668	0.072451	0.0034686	42.7311	9.4375E-291	Hypermethylated	No	
cg08234504	chr5	139013317	-0.235634	-0.0015863	-42.72	1.2233E-290	Hypomethylated	No	
cg24436906	chr2	242498081	0.4803492	0.0019615	42.6333	9.2401E-290	Hypermethylated	No	BOK
cg13848598	chr10	115804578	-0.111233	0.0024786	42.4955	2.2983E-288	Hypermethylated	No	ADRB1
cg10804656	chr10	22623460	-0.950746	0.0028943	42.4594	5.3272E-288	Hypermethylated	No	
cg13135455	chr2	241860318	0.0059196	-0.0022231	-42.4071	1.8043E-287	Hypomethylated	No	
cg23078123	chr1	68577796	0.759047	-0.0026555	-42.3732	3.9744E-287	Hypomethylated	No	GPR177
cg13327545	chr10	22623548	-0.358846	0.0022651	42.3019	2.0954E-286	Hypermethylated	No	
cg03431918	chr17	77716367	0.1575907	-0.0017119	-42.2827	3.2734E-286	Hypomethylated	No	
cg01820374	chr12	6882083	-0.47997	-0.0022168	-42.2819	3.3323E-286	Hypomethylated	Yes	LAG3
cg20747538	chr3	137838021	-0.227794	-0.0019417	-42.2727	4.1287E-286	Hypomethylated	No	
cg27320127	chr2	47798396	0.3532211	0.0019054	42.2074	1.8912E-285	Hypermethylated	No	KCNK12
cg20273670	chr17	21356245	-0.202763	0.0032538	42.1546	6.4709E-285	Hypermethylated	No	
cg19702785	chr20	43727089	-0.307403	0.0016088	42.1542	6.5405E-285	Hypermethylated	No	KCNS1
cg14583999	chr3	10019040	0.051048	-0.0038329	-42.1149	1.6328E-284	Hypomethylated	No	TMEM111
cg01844642	chr3	51989764	-0.160677	0.0021369	42.1066	1.9788E-284	Hypermethylated	No	GPR62

cg00602811	chr2	145278564	-0.192604	-0.0038479	-42.1046	2.0743E-284	Hypomethylated	No	ZEB2
cg01770755	chr15	41914122	-0.106172	0.0017079	42.0334	1.089E-283	Hypermethylated	No	
cg00484358	chr1	110610995	0.2396367	0.0016647	42.0065	2.0361E-283	Hypermethylated	No	ALX3
cg18064714	chr7	20824556	-0.082174	0.00167	41.9065	2.0891E-282	Hypermethylated	No	SP8
cg16512661	chr5	2743620	0.2799574	0.0020114	41.717	1.7193E-280	Hypermethylated	No	
cg11741201	chr11	35638398	-0.069447	-0.0023228	-41.523	1.5688E-278	Hypomethylated	No	FJX1
cg22016779	chr2	230452311	-0.370728	-0.0023361	-41.4895	3.4156E-278	Hypomethylated	No	DNER
cg18473521	chr12	54448265	0.1111276	0.0041993	41.3931	3.2188E-277	Hypermethylated	No	HOXC4
cg01528542	chr12	81468232	-0.352352	-0.0036075	-41.3691	5.6171E-277	Hypomethylated	No	

Fig. S1.6 Table showing the characteristics of the top 100 differentially methylated positions during ageing (aDMPs) in the blood of the healthy individuals, ordered by p-value and the absolute value of the T statistic. The chromosome and coordinate refer to the *hg19* human genome assembly. The reported genes are the closest genes associated with the array probe, as specified by the 450K array annotation. In this case, cell composition correction (CCC) was applied during modelling (see section 2.1.4).




Fig. S1.7 Plot showing how the median absolute error (MAE) of the prediction in the healthy individual samples, that should tend to zero, is reduced when the PCs capturing the technical variation are included as part of the modelling strategy (see equations 2.16 and 2.17). The dashed line represents the optimal number of PCs (11) that was finally used. The optimal mean MAE is calculated as the average MAE between the green and purple lines. In this case, no background correction was applied to the methylation data before calculating the epigenetic ages according to Horvath's epigenetic clock [102].




Fig. S1.8 Correcting for batch effects in the context of the epigenetic clock. **a.** Distribution of the epigenetic age acceleration (EAA) for the different batches of healthy individual samples, using the control model without cell composition correction (CCC) and before applying batch effect correction. The dashed black line represents $EAA = 0$, where the distributions should be centred around. **b.** As in a., but after applying batch effect correction (i.e. equivalent to equation 2.17).




Fig. S1.9 Scatterplot showing the values of the first two principal components (PCs) for the samples with developmental disorders (cases, see Chapter 3) after performing PCA on the control probes of the 450K arrays. Each point corresponds to a different sample and the colours represent the different batches. The different batches cluster together in the PCA space, showing that the control probes indeed capture technical variation. Please note that all the PCA calculations were done using samples from both healthy individuals (full lifespan, $N = 2218$) and cases from developmental disorders ($N = 666$).




Fig. S1.10 Plot showing the percentages of technical variance explained by the different PCs from the control probes. The dashed line represents the optimal number of PCs (17) that was finally used.

S.2 Biological aspects of the epigenetic clock

Batch name	$N_{\text{♀}}$	$N_{\text{♂}}$	N	Median age (years)	Other comments
Europe	0	119	119	7.73	
Feb_2016	20	20	40	6	
GSE116300	4	5	9	3	
GSE41273	0	9	9	7.75	
GSE74432	11	16	27	10	
GSE97362	4	9	13	15	Samples from the ‘validation cohort’ were not included in the analysis, since they all seemed outliers on close examination
Jun_2015	1	1	2	3.5015	
Mar_2014	11	6	17	8	
May_2015	17	49	66	14	
Nov_2015	35	30	65	6.7	
Total	103	264	367	8	-

Table S2.1 Overview of the blood DNA methylation dataset from individuals with developmental disorders. The batches ‘Europe’, ‘Feb_2016’, ‘Jun_2015’, ‘Mar_2014’, ‘May_2015’ and ‘Nov_2015’ were generated in-house by our collaborators in Canada (see Chapter 3). The rest of the batches were downloaded from GEO [109]. $N_{\text{♀}}$: number of samples from females. $N_{\text{♂}}$: number of samples from males. N: total number of samples. These numbers correspond to the samples left after applying quality control and filtering (see section 3.2).

Batch name	Developmental disorder	Gene	Mutation (DNA)	Mutation (protein)	Mutation effect	Pathogenic	Sex	Age (years)	DNAmAge
Europe	ASD	NA	NA	NA	NA	NA	Male	23.25	29.94120469
Europe	ASD	NA	NA	NA	NA	NA	Male	25.75	23.66579727
Europe	ASD	NA	NA	NA	NA	NA	Male	23.75	22.89490773
Europe	ASD	NA	NA	NA	NA	NA	Male	26.58	31.33521081
Europe	ASD	NA	NA	NA	NA	NA	Male	11.83	13.55540994
Europe	ASD	NA	NA	NA	NA	NA	Male	12.33	12.62567804
Europe	ASD	NA	NA	NA	NA	NA	Male	11.67	11.91444556
Europe	ASD	NA	NA	NA	NA	NA	Male	12.67	15.1433583
Europe	ASD	NA	NA	NA	NA	NA	Male	15.92	20.69231419
Europe	ASD	NA	NA	NA	NA	NA	Male	16.92	18.37736076
Europe	ASD	NA	NA	NA	NA	NA	Male	15.92	14.74270021
Europe	ASD	NA	NA	NA	NA	NA	Male	19	28.69942806
Europe	ASD	NA	NA	NA	NA	NA	Male	16.75	20.84761017
Europe	ASD	NA	NA	NA	NA	NA	Male	20.16	17.69509361
Europe	ASD	NA	NA	NA	NA	NA	Male	12.92	18.28693655
Europe	ASD	NA	NA	NA	NA	NA	Male	13.25	12.24924728
Europe	ASD	NA	NA	NA	NA	NA	Male	13	15.27709141
Europe	ASD	NA	NA	NA	NA	NA	Male	13.25	15.93247357
Europe	ASD	NA	NA	NA	NA	NA	Male	13.16	17.97126245
Europe	ASD	NA	NA	NA	NA	NA	Male	13.67	18.5985271
Europe	ASD	NA	NA	NA	NA	NA	Male	7.67	9.834525429
Europe	ASD	NA	NA	NA	NA	NA	Male	7.92	8.819610809
Europe	ASD	NA	NA	NA	NA	NA	Male	7.73	10.53639331
Europe	ASD	NA	NA	NA	NA	NA	Male	8	8.782413174
Europe	ASD	NA	NA	NA	NA	NA	Male	7.83	8.331080792
Europe	ASD	NA	NA	NA	NA	NA	Male	8	8.412508081
Europe	ASD	NA	NA	NA	NA	NA	Male	10.83	12.94110542
Europe	ASD	NA	NA	NA	NA	NA	Male	11.5	16.52427744
Europe	ASD	NA	NA	NA	NA	NA	Male	10.83	9.546814402
Europe	ASD	NA	NA	NA	NA	NA	Male	11.5	10.75219435
Europe	ASD	NA	NA	NA	NA	NA	Male	10.83	11.7226536
Europe	ASD	NA	NA	NA	NA	NA	Male	6	8.750320884
Europe	ASD	NA	NA	NA	NA	NA	Male	5.75	8.069349936
Europe	ASD	NA	NA	NA	NA	NA	Male	6	8.205893972
Europe	ASD	NA	NA	NA	NA	NA	Male	5.83	8.765912407
Europe	ASD	NA	NA	NA	NA	NA	Male	6.33	6.903468104
Europe	ASD	NA	NA	NA	NA	NA	Male	5.25	5.648518225
Europe	ASD	NA	NA	NA	NA	NA	Male	5.67	5.896253109
Europe	ASD	NA	NA	NA	NA	NA	Male	5.42	6.160793858
Europe	ASD	NA	NA	NA	NA	NA	Male	5.75	8.719005258
Europe	ASD	NA	NA	NA	NA	NA	Male	5.42	6.49657694
Europe	ASD	NA	NA	NA	NA	NA	Male	3.92	4.884904225
Europe	ASD	NA	NA	NA	NA	NA	Male	4.08	4.766905985
Europe	ASD	NA	NA	NA	NA	NA	Male	4	5.462162993

Europe	ASD	NA	NA	NA	NA	NA	Male	4.08	4.557194499
Europe	ASD	NA	NA	NA	NA	NA	Male	4	4.383741212
Europe	ASD	NA	NA	NA	NA	NA	Male	4.25	5.321367013
Europe	ASD	NA	NA	NA	NA	NA	Male	3.25	2.797437125
Europe	ASD	NA	NA	NA	NA	NA	Male	3.42	3.906912403
Europe	ASD	NA	NA	NA	NA	NA	Male	3.33	4.703272329
Europe	ASD	NA	NA	NA	NA	NA	Male	3.5	3.223456196
Europe	ASD	NA	NA	NA	NA	NA	Male	3.42	4.024449964
Europe	ASD	NA	NA	NA	NA	NA	Male	3.58	4.662665584
Europe	ASD	NA	NA	NA	NA	NA	Male	5.16	7.931806871
Europe	ASD	NA	NA	NA	NA	NA	Male	5.16	6.144088681
Europe	ASD	NA	NA	NA	NA	NA	Male	5.16	5.423886319
Europe	ASD	NA	NA	NA	NA	NA	Male	5.25	6.873520458
Europe	ASD	NA	NA	NA	NA	NA	Male	5.16	6.828746343
Europe	ASD	NA	NA	NA	NA	NA	Male	5.25	6.287392617
Europe	ASD	NA	NA	NA	NA	NA	Male	6.5	7.549817595
Europe	ASD	NA	NA	NA	NA	NA	Male	6.83	5.310188113
Europe	ASD	NA	NA	NA	NA	NA	Male	6.67	8.807848811
Europe	ASD	NA	NA	NA	NA	NA	Male	7.16	7.314048584
Europe	ASD	NA	NA	NA	NA	NA	Male	6.83	7.143809294
Europe	ASD	NA	NA	NA	NA	NA	Male	7.25	4.888587648
Europe	ASD	NA	NA	NA	NA	NA	Male	10.08	11.01168613
Europe	ASD	NA	NA	NA	NA	NA	Male	10.08	9.091817984
Europe	ASD	NA	NA	NA	NA	NA	Male	10.08	12.00962928
Europe	ASD	NA	NA	NA	NA	NA	Male	10.5	11.89814401
Europe	ASD	NA	NA	NA	NA	NA	Male	10.08	10.85200361
Europe	ASD	NA	NA	NA	NA	NA	Male	10.58	15.97655481
Europe	ASD	NA	NA	NA	NA	NA	Male	14.67	19.40830372
Europe	ASD	NA	NA	NA	NA	NA	Male	15.25	17.28948864
Europe	ASD	NA	NA	NA	NA	NA	Male	14.83	18.99313794
Europe	ASD	NA	NA	NA	NA	NA	Male	15.25	17.40182035
Europe	ASD	NA	NA	NA	NA	NA	Male	15.08	20.74719227
Europe	ASD	NA	NA	NA	NA	NA	Male	15.83	17.66494621
Europe	ASD	NA	NA	NA	NA	NA	Male	1.83	2.332369997
Europe	ASD	NA	NA	NA	NA	NA	Male	2.33	2.079645877
Europe	ASD	NA	NA	NA	NA	NA	Male	2.08	3.093728905
Europe	ASD	NA	NA	NA	NA	NA	Male	2.5	3.327332717
Europe	ASD	NA	NA	NA	NA	NA	Male	2.08	3.081702301
Europe	ASD	NA	NA	NA	NA	NA	Male	2.5	3.640188937
Europe	ASD	NA	NA	NA	NA	NA	Male	27.67	5.315328746
Europe	ASD	NA	NA	NA	NA	NA	Male	32.92	35.79080593
Europe	ASD	NA	NA	NA	NA	NA	Male	31.83	35.12415194
Europe	ASD	NA	NA	NA	NA	NA	Male	35.16	34.8152863
Europe	ASD	NA	NA	NA	NA	NA	Male	32.33	33.47894995
Europe	ASD	NA	NA	NA	NA	NA	Male	11.58	14.81256772
Europe	ASD	NA	NA	NA	NA	NA	Male	4.5	3.982793413

Europe	ASD	NA	NA	NA	NA	NA	Male	4.75	6.632731853
Europe	ASD	NA	NA	NA	NA	NA	Male	4.5	5.453577973
Europe	ASD	NA	NA	NA	NA	NA	Male	5	6.0536493
Europe	ASD	NA	NA	NA	NA	NA	Male	4.67	4.665684936
Europe	ASD	NA	NA	NA	NA	NA	Male	5	5.538833496
Europe	ASD	NA	NA	NA	NA	NA	Male	4.33	6.826640979
Europe	ASD	NA	NA	NA	NA	NA	Male	4.42	5.074848057
Europe	ASD	NA	NA	NA	NA	NA	Male	4.33	4.069969605
Europe	ASD	NA	NA	NA	NA	NA	Male	4.5	2.914915908
Europe	ASD	NA	NA	NA	NA	NA	Male	4.33	4.177855824
Europe	ASD	NA	NA	NA	NA	NA	Male	4.5	5.359046992
Europe	ASD	NA	NA	NA	NA	NA	Male	7.33	4.981096393
Europe	ASD	NA	NA	NA	NA	NA	Male	7.5	7.521560211
Europe	ASD	NA	NA	NA	NA	NA	Male	7.33	5.632014057
Europe	ASD	NA	NA	NA	NA	NA	Male	7.58	5.381195679
Europe	ASD	NA	NA	NA	NA	NA	Male	7.42	7.07596058
Europe	ASD	NA	NA	NA	NA	NA	Male	7.58	6.118788705
Europe	ASD	NA	NA	NA	NA	NA	Male	8.83	8.225301829
Europe	ASD	NA	NA	NA	NA	NA	Male	9.08	9.139517533
Europe	ASD	NA	NA	NA	NA	NA	Male	8.83	7.154970232
Europe	ASD	NA	NA	NA	NA	NA	Male	9.67	9.966260719
Europe	ASD	NA	NA	NA	NA	NA	Male	8.92	8.69481855
Europe	ASD	NA	NA	NA	NA	NA	Male	9.67	12.84219838
Europe	ASD	NA	NA	NA	NA	NA	Male	8.08	10.35219735
Europe	ASD	NA	NA	NA	NA	NA	Male	8.25	8.849774575
Europe	ASD	NA	NA	NA	NA	NA	Male	8.16	9.464032218
Europe	ASD	NA	NA	NA	NA	NA	Male	8.33	10.51799454
Europe	ASD	NA	NA	NA	NA	NA	Male	8.16	9.41622481
Europe	ASD	NA	NA	NA	NA	NA	Male	8.75	13.39598874
May_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	7	5.473183736
May_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	13	15.48878288
May_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	55	59.49787491
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	1	2.790549766
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	4	3.956276247
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	15	17.87817565
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	1	2.320603044
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	4	4.348249902
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	1	0.959598999
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	1	1.994091886
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	10	8.697172131
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	14	15.7410421
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Female	6	5.13374965
Nov_2015	Angelman	UBE3A	NA	NA	NA	YES	Male	25	32.45470863
May_2015	ATR-X	ATRX	c.6254G>A	p.Arg2085His	Missense	YES	Male	6.3	6.19432086
May_2015	ATR-X	ATRX	c.736C>T	p.Arg246Cys	Missense	YES	Male	18	13.11825849
May_2015	ATR-X	ATRX	c.6593A>G	p.His2198Arg	Missense	YES	Male	1.4	2.604328944

May_2015	ATR-X	<i>ATRX</i>	c.758T>C	p.Leu253Ser	Missense	YES	Male	18.5	6.108170831
May_2015	ATR-X	<i>ATRX</i>	c.4817G>A	p.Ser1606Asn	Missense	YES	Male	21	24.74309568
May_2015	ATR-X	<i>ATRX</i>	c.5786A>G	p.Lys1929Arg	Missense	YES	Male	0.7	-0.14552632
May_2015	ATR-X	<i>ATRX</i>	c.730A>C	p.Ile244Leu	Missense	YES	Male	14	11.30064691
May_2015	ATR-X	<i>ATRX</i>	c.7156C>T	p.Arg2386*	Nonsense	YES	Male	4.6	6.236506951
May_2015	ATR-X	<i>ATRX</i>	c.536A>G	p.Asn179Ser	Missense	YES	Male	4.6	33.54375298
May_2015	ATR-X	<i>ATRX</i>	Exon 207 deletion	NA	Exonic deletion	YES	Male	4.4	4.821921423
May_2015	ATR-X	<i>ATRX</i>	c.7366_7367insA	p.Met2456Asnfs*42	Frameshift	YES	Male	27	39.19917395
May_2015	ATR-X	<i>ATRX</i>	c.109C>T	p.Arg37*	Nonsense	YES	Male	14.5	5.274937882
May_2015	ATR-X	<i>ATRX</i>	c.736C>T	p.Arg246Cys	Missense	YES	Male	2.5	1.113449871
May_2015	ATR-X	<i>ATRX</i>	c.109C>T	p.Arg37*	Nonsense	YES	Male	17.5	22.71435784
May_2015	ATR-X	<i>ATRX</i>	c.109C>T	p.Arg37*	Nonsense	YES	Male	14	11.21597332
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.1510G>A	p.Val504Met	Missense	YES	Male	30	42.69659356
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.1439C>T	p.Pro480Leu	Missense	YES_predicted	Male	6	8.103173952
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.4439_4440delAG	p.Arg1481Glyfs*	Frameshift	YES	Male	26	28.25654272
Nov_2015	Claes_Jensen	<i>KDM5C</i>	Intron 11:+5G>A	NA	Splice site mutation	YES	Male	42	54.3236723
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.1510G>A	p.Val504Met	Missense	YES	Male	8	10.07007313
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.1439C>T	p.Pro480Leu	Missense	YES	Male	2	3.619189097
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.229G>A	p.Ala77Thr	Missense	YES	Male	37	48.42002598
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.4439_4440delAG	p.Arg1481Glyfs*	Frameshift	YES	Male	28	31.61445991
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.229G>A	p.Ala77Thr	Missense	YES	Male	13	16.50827759
Nov_2015	Claes_Jensen	<i>KDM5C</i>	c.1510G>A	p.Val504Met	Missense	YES	Male	26	38.69008936
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.1520insA	p.Arg507fs	Frameshift	YES	Female	6	4.093225848
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.2065C>T	p.Gln689*	Nonsense	YES	Male	11.5	10.63296406
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.2186G>A	p.Arg729Gln	Missense	YES_predicted	Male	4	4.62981308
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.631_772del142 and c.774+5G>A	NA	Frameshift and intronic mutation	YES_predicted	Male	7	5.068637974
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.340C>T	p.Arg114Trp	Missense	YES_predicted	Male	1.3	8.170755226
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.727C>T	p.Arg243*	Nonsense	YES	Male	13	14.17141748
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	Intron 14:+1G>A	NA	Splice site mutation	YES	Male	22.8	25.56720654
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	NA	NA	Exonic and intronic deletion	YES	Male	12	10.17620766
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.386_387insCTT	p.Phe130Phefs*141	Frameshift	YES	Male	2	1.808104516
May_2015	Coffin_Lowry	<i>RPS6KA3</i>	c.1155delT	p.Phe385fs*40	Frameshift	YES	Male	8	7.406603271
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7303C>T	p.Arg2435*	Nonsense	YES	Female	8	11.29885487
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	15	16.23135534
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7282dupC	p.Arg2428Profs*15	Frameshift	YES	Female	6	5.620915174
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	10	42.55562244
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.8117C>G	p.Ser2706*	Nonsense	YES	Male	4	2.815335426
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	5	4.112348915
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	42	43.43022309
Mar_2014	Floating_Harbour	<i>SRCAP</i>	c.7330C>T	p.Arg2444*	Nonsense	YES	Male	12	12.37257473

Mar_2014	Floating_Harbour	SRCAP	c.7316dupC	p.Ala2440Serfs*3	Frameshift	YES	Male	10	4.424381743
Mar_2014	Floating_Harbour	SRCAP	c.7165G>T	p.Glu2389*	Nonsense	YES	Female	8	1.524333568
Mar_2014	Floating_Harbour	SRCAP	c.7218_7219delTC	p.Gln2407Argfs*35	Frameshift	YES	Male	12	19.26251425
Mar_2014	Floating_Harbour	SRCAP	c.7330C>T	p.Arg2444*	Nonsense	YES	Male	5	4.902256866
Mar_2014	Floating_Harbour	SRCAP	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	35	38.47378886
Mar_2014	Floating_Harbour	SRCAP	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	15	14.81418145
Mar_2014	Floating_Harbour	SRCAP	c.7549delC	p.Gln2517Lysfs*5	Frameshift	YES	Male	4	3.645524918
Mar_2014	Floating_Harbour	SRCAP	c.7330C>T	p.Arg2444*	Nonsense	YES	Female	6	7.201471688
Mar_2014	Floating_Harbour	SRCAP	c.7219C>T	p.Gln2407*	Nonsense	YES	Female	6	6.552720685
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	5	-0.26537653
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	10.41667	4.620596743
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	7.75	9.380603836
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	4.333333	7.378290152
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	0.083333	7.256745087
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	4.166667	6.582911793
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	21	32.38418863
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	34.58333	46.41126929
GSE41273	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	48	58.89975733
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	27	32.354974
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	12	11.03917455
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	42	40.85689027
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	28	31.89965321
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	15	15.3286979
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	17	13.98190146
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	21	21.42017869
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	30	35.16564816
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	28	27.14880628
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	21	24.03936596
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	33	37.84060062
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	29	35.17133434
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	25	25.67600147
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	17	14.45573451
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	33	36.37082822
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	29	34.45261333
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	20	24.86340454
May_2015	FXS	FMR1	NA	NA	CGG repeat expansion	YES	Male	41	46.76222649

May_2015	FXS	<i>FMR1</i>	NA	NA	CGG repeat expansion	YES	Male	31	34.61968346
May_2015	FXS	<i>FMR1</i>	NA	NA	CGG repeat expansion	YES	Male	27	29.78714348
May_2015	FXS	<i>FMR1</i>	NA	NA	CGG repeat expansion	YES	Male	17	19.72629863
May_2015	FXS	<i>FMR1</i>	NA	NA	CGG repeat expansion	YES	Male	15	11.78896917
May_2015	FXS	<i>FMR1</i>	NA	NA	CGG repeat expansion	YES	Male	14	12.80759084
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Pro443fs	Frameshift	YES	Female	1	0.790826048
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Tyr2199fs	Frameshift	YES	Female	3	4.448848163
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Ser5307fs	Frameshift	YES	Male	5	11.49079359
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Asn4403fs	Frameshift	YES	Male	4.33	6.325934863
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Gln4102*	Nonsense	YES	Male	2	5.566745677
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Gln3934*	Nonsense	YES	Male	3.75	4.443224079
GSE116300	Kabuki	<i>KMT2D</i>	c.14515+1G>T	NA	Splice site mutation	YES	Male	2.5	16.55101592
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Gln4090*	Nonsense	YES	Female	1.42	3.379081974
GSE116300	Kabuki	<i>KMT2D</i>	NA	p.Thr1708fs	Frameshift	YES	Female	11.5	10.71344707
GSE97362	Kabuki	<i>KMT2D</i>	c.15061C>T	p.Arg5021*	Nonsense	YES	Female	14	8.946680052
GSE97362	Kabuki	<i>KMT2D</i>	c.16318delG	p.Glu5440Argfs*16	Frameshift	YES	Male	1	0.664960442
GSE97362	Kabuki	<i>KMT2D</i>	c.15030dup	p.Glu5011Argfs*13	Frameshift	YES	Male	18	24.00757516
GSE97362	Kabuki	<i>KMT2D</i>	c.8172_8173del	p.Pro2724Glnfs*5	Frameshift	YES	Female	16	4.540501556
GSE97362	Kabuki	<i>KMT2D</i>	c.6595delT	p.Tyr2199Ilefs*65	Frameshift	YES	Male	15	6.279894046
GSE97362	Kabuki	<i>KMT2D</i>	c.14055_14056delCA	p.His4685Glnfs*4	Frameshift	YES	Male	11	9.2260079
GSE97362	Kabuki	<i>KMT2D</i>	c.6295C>T	p.Arg2099*	Nonsense	YES	Male	14	6.594838599
GSE97362	Kabuki	<i>KMT2D</i>	c.4135delA	p.Met1379Valfs*52	Frameshift	YES	Male	20	10.04269734
GSE97362	Kabuki	<i>KMT2D</i>	c.12592C>T	p.Arg4198*	Nonsense	YES	Male	18	9.095825776
GSE97362	Kabuki	<i>KMT2D</i>	c.4135delA	p.Met1379Valfs*52	Frameshift	YES	Male	6	8.462691919
GSE97362	Kabuki	<i>KMT2D</i>	c.11710C>T	p.Gln3904*	Nonsense	YES	Male	16	12.68670209
GSE97362	Kabuki	<i>KMT2D</i>	c.15143G>A	p.Arg5048His	Missense	YES_predicted	Female	7	0.627461504
GSE97362	Kabuki	<i>KMT2D</i>	c.16522-5_16522-4delTT	NA	Splice site mutation	YES_predicted	Female	15	12.75508563
Jun_2015	Kabuki	<i>KMT2D</i>	c.1801_1822dup22	NA	Frameshift	YES	Male	7	6.044371299
Nov_2015	Kabuki	<i>KMT2D</i>	c.13059delG	p.Pro4353fs	Frameshift	YES	Female	6.7	5.526369466
Nov_2015	Kabuki	<i>KMT2D</i>	c.839+1delG	NA	Splice site mutation	YES	Male	1.9	2.51325414
Nov_2015	Kabuki	<i>KMT2D</i>	c.15844C>T	p.Arg5282*	Nonsense	YES	Female	3.9	3.752004426
Nov_2015	Kabuki	<i>KMT2D</i>	c.16294C>T	p.Arg5432Trp	Missense	YES_predicted	Male	21.6	30.3375233
Nov_2015	Kabuki	<i>KMT2D</i>	c.8488C>T	p.Arg2830*	Nonsense	YES	Female	0	-0.1055224
Nov_2015	Kabuki	<i>KMT2D</i>	c.4168dupG	p.Ala1390fs	Frameshift	YES	Female	3.8	4.177253095
Nov_2015	Kabuki	<i>KMT2D</i>	c.15289C>T	p.Arg5097*	Nonsense	YES	Male	4.3	6.455955113
Nov_2015	Kabuki	<i>KMT2D</i>	c.4419-2A>G	NA	Splice site mutation	YES	Male	2.6	3.387623395
Nov_2015	Kabuki	<i>KMT2D</i>	c.16048A>T	p.Lys5350*	Nonsense	YES	Female	19.1	19.2926115
Nov_2015	Kabuki	<i>KMT2D</i>	c.10201C>T	p.Gln3401*	Nonsense	YES	Male	7.1	8.838432826
Nov_2015	Kabuki	<i>KMT2D</i>	c.16360C>T	p.Arg5454*	Nonsense	YES	Male	3.4	5.199197126
Nov_2015	Kabuki	<i>KMT2D</i>	c.8692C>T	p.Gln2898*	Nonsense	YES	Male	3.1	3.423420462

Nov_2015	Kabuki	<i>KMT2D</i>	c.14878C>T	p.Arg4960*	Nonsense	YES	Female	4.1	4.752807097
Nov_2015	Kabuki	<i>KMT2D</i>	c.6265A>T	p.Lys2089*	Nonsense	YES	Female	23.1	25.95907184
Nov_2015	Kabuki	<i>KMT2D</i>	c.10740+1G>A	NA	Splice site mutation	YES	Female	6.9	6.253113479
Nov_2015	Kabuki	<i>KMT2D</i>	c.13652T>A	p.Leu4551*	Nonsense	YES	Male	2.2	3.757460909
Nov_2015	Kabuki	<i>KMT2D</i>	c.11596G>T	p.Gln3866*	Nonsense	YES	Female	1	1.193509229
Nov_2015	Kabuki	<i>KMT2D</i>	c.548delC	p.Pro183fs	Frameshift	YES	Female	16.6	8.413539447
Nov_2015	Kabuki	<i>KMT2D</i>	c.7411C>T	p.Arg2471*	Nonsense	YES	Female	3.3	3.541604601
Nov_2015	Kabuki	<i>KMT2D</i>	c.1966dupC	p.Leu656fs	Frameshift	YES	Female	24.1	28.78927404
Nov_2015	Kabuki	<i>KMT2D</i>	c.6200delA	p.Asn2067fs	Frameshift	YES	Female	9.5	6.485224166
Nov_2015	Kabuki	<i>KMT2D</i>	c.7933C>T	p.Arg2645*	Nonsense	YES	Female	9.3	8.701999271
Nov_2015	Kabuki	<i>KMT2D</i>	c.13450C>T	p.Arg4484*	Nonsense	YES	Female	5.8	5.430619578
Feb_2016	Noonan	<i>PTPN11</i>	c.1403C>T	p.Thr468Met	Missense	YES	Male	9	10.53231848
Feb_2016	Noonan	<i>PTPN11</i>	c.1391G>C	p.Gly464Ala	Missense	YES	Female	28	25.06455423
Feb_2016	Noonan	<i>PTPN11</i>	c.1493G>T	p.Arg498Leu	Missense	YES	Male	0.4	1.069462128
Feb_2016	Noonan	<i>PTPN11</i>	c.836A>G	p.Tyr279Cys	Missense	YES	Male	0.2	0.145725107
Feb_2016	Noonan	<i>PTPN11</i>	c.1493G>T	p.Arg498Leu	Missense	YES	Male	7	7.125930003
Feb_2016	Noonan	<i>PTPN11</i>	c.1528C>G	p.Gln510Glu	Missense	YES	Female	2	4.906928458
Feb_2016	Noonan	<i>PTPN11</i>	c.228G>C	p.Glu76Asp	Missense	YES	Male	17	17.52765019
Feb_2016	Noonan	<i>PTPN11</i>	c.215C>G	p.Ala72Gly	Missense	YES	Female	13	9.011977393
Feb_2016	Noonan	<i>PTPN11</i>	c.1391G>C	p.Gly464Ala	Missense	YES	Female	0.7	1.172244358
Feb_2016	Noonan	<i>PTPN11</i>	c.922A>G	p.Asn308Asp	Missense	YES	Male	15	14.68576639
Feb_2016	Noonan	<i>PTPN11</i>	c.836A>G	p.Tyr279Cys	Missense	YES	Male	0.3	0.576697185
Feb_2016	Noonan	<i>PTPN11</i>	c.214G>T	p.Ala72Ser	Missense	YES	Male	0.9	1.080594238
Feb_2016	Noonan	<i>PTPN11</i>	c.178G>A	p.Gly60Ser	Missense	YES	Male	2	3.079510066
Feb_2016	Noonan	<i>PTPN11</i>	c.172A>G	p.Asn58Asp	Missense	YES	Male	37	42.63784241
Feb_2016	Noonan	<i>PTPN11</i>	c.174C>A	p.Asn58Lys	Missense	YES	Female	27	32.19911243
Feb_2016	Noonan	<i>RAF1</i>	c.781C>T	p.Pro261Ser	Missense	YES	Male	9	11.76954478
Feb_2016	Noonan	<i>RAF1</i>	c.770C>T	p.Ser257Leu	Missense	YES	Female	4	6.836828788
Feb_2016	Noonan	<i>RAF1</i>	c.788T>G	p.Val263Gly	Missense	YES	Male	8	10.54386119
Feb_2016	Noonan	<i>RAF1</i>	c.782C>T	p.Pro261Leu	Missense	YES	Male	3	5.956377653
Feb_2016	Noonan	<i>RAF1</i>	c.786T>A	p.Asn262Lys	Missense	YES	Female	3	3.603073783
Feb_2016	Noonan	<i>RAF1</i>	c.768G>T	p.Arg256Ser	Missense	YES	Male	20	21.09275241
Feb_2016	Noonan	<i>RAF1</i>	c.524A>G	p.His175Arg	Missense	YES	Female	0.7	0.815080545
Feb_2016	Noonan	<i>RAF1</i>	c.1837C>G	p.Leu613Val	Missense	YES	Female	10	7.425274033
Feb_2016	Noonan	<i>RAF1</i>	c.775T>A	p.Ser259Thr	Missense	YES	Female	8	8.883918263
Feb_2016	Noonan	<i>RAF1</i>	c.1472C>T	p.Thr491Ile	Missense	YES	Female	26	29.82312626
Feb_2016	Noonan	<i>RAF1</i>	c.781C>A	p.Pro261Thr	Missense	YES	Female	11	12.25565712
Feb_2016	Noonan	<i>SOS1</i>	c.2536G>A	p.Glu846Lys	Missense	YES	Female	3	2.62618922
Feb_2016	Noonan	<i>SOS1</i>	c.1654A>G	p.Arg552Gly	Missense	YES	Male	16	12.47288243
Feb_2016	Noonan	<i>SOS1</i>	c.1310T>C	p.Ile437Thr	Missense	YES	Female	7	7.309199493
Feb_2016	Noonan	<i>SOS1</i>	c.806T>C	p.Met269Thr	Missense	YES	Female	35	25.04627009
Feb_2016	Noonan	<i>SOS1</i>	c.1642A>C	p.Ser548Arg	Missense	YES	Female	3	4.372134286
Feb_2016	Noonan	<i>SOS1</i>	c.925G>T	p.Asp309Tyr	Missense	YES	Female	49	45.20434465
Feb_2016	Noonan	<i>SOS1</i>	c.1655G>C	p.Arg552Thr	Missense	YES	Male	1	2.41372048
Feb_2016	Noonan	<i>SOS1</i>	c.508A>G	p.Lys170Glu	Missense	YES	Male	0.3	0.944100935
Feb_2016	Noonan	<i>SOS1</i>	c.1294T>C	p.Trp432Arg	Missense	YES	Female	14	17.03491762

Feb_2016	Noonan	<i>SOS1</i>	c.1322G>A	p.Cys441Tyr	Missense	YES	Female	0.6	0.555111083
Feb_2016	Noonan	<i>SOS1</i>	c.806T>G	p.Met269Arg	Missense	YES	Female	0.4	0.844087032
Feb_2016	Noonan	<i>SOS1</i>	c.797C>A	p.Thr266Lys	Missense	YES	Male	1	2.133506512
Feb_2016	Noonan	<i>SOS1</i>	c.1297G>A	p.Glu433Lys	Missense	YES	Male	1	1.481217449
Feb_2016	Noonan	<i>SOS1</i>	c.1300G>A	p.Gly434Arg	Missense	YES	Male	5	8.558246566
May_2015	Rett	<i>MECP2</i>	NA	p.Arg106Trp	Missense	YES	Female	1	1.835127123
May_2015	Rett	<i>MECP2</i>	NA	p.Arg168*	Nonsense	YES	Female	25	29.34649481
May_2015	Rett	<i>MECP2</i>	NA	p.Pro302Arg	Missense	YES	Female	34	35.17904908
May_2015	Rett	<i>MECP2</i>	NA	NA	Exonic deletion	YES	Female	2	2.581071992
May_2015	Rett	<i>MECP2</i>	NA	p.Thr158Met	Missense	YES	Female	1	2.210005617
May_2015	Rett	<i>MECP2</i>	Deletion in exon 4	NA	Exonic deletion	YES	Female	3	5.225511336
May_2015	Rett	<i>MECP2</i>	NA	p.Thr158Met	Missense	YES	Female	1	2.510753024
May_2015	Rett	<i>MECP2</i>	NA	p.Pro225Arg	Missense	YES	Female	4	6.160921221
May_2015	Rett	<i>MECP2</i>	c.1157_1197del41	p.Glu374fs	Frameshift	YES	Female	6	6.2636907
May_2015	Rett	<i>MECP2</i>	NA	p.Arg255*	Nonsense	YES	Female	1.5	1.084382282
May_2015	Rett	<i>MECP2</i>	Deletion in exons 3 and 4	NA	Exonic deletion	YES	Female	6	6.883663479
May_2015	Rett	<i>MECP2</i>	NA	p.Arg106Trp	Missense	YES	Female	29	38.83647398
May_2015	Rett	<i>MECP2</i>	NA	p.Thr158Met	Missense	YES	Female	3	4.77442952
May_2015	Rett	<i>MECP2</i>	NA	p.Arg255*	Nonsense	YES	Female	11	11.74653291
May_2015	Rett	<i>MECP2</i>	Partial deletion of exon 4	NA	Exonic deletion	YES	Female	4	3.072948979
Jun_2015	Saethre_Chotzen	<i>TWIST1</i>	c.385_405dup21	NA	In-frame insertion	YES	Female	0.003	-0.35722332
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.149delC	p.Ala50fs	Frameshift	YES	Male	0.02	0.16785508
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.149delC	p.Ala50fs	Frameshift	YES	Female	0.1	13.96937513
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.376G>T	p.Glu126*	Nonsense	YES	Male	38	41.56611411
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.406_407ins21	NA	In-frame insertion	YES	Male	30	29.61790422
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.156delC	p.Pro52fs	Frameshift	YES	Female	33.5	27.76671901
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.418_419ins21	NA	In-frame insertion	YES	Male	17.7	15.97052177
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.211C>T	p.Gln71*	Nonsense	YES	Female	20.7	18.347741
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.325C>T	p.Gln109*	Nonsense	YES_predicted	Male	0.7	0.45749609
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.396_416dup21	NA	In-frame insertion	YES	Male	0.1	0.386967314
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.193G>T	p.Glu65*	Nonsense	YES	Female	0.01	0.049927484
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.472T>C	p.Phe158Leu	Missense	YES	Female	23.3	0.174364646
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	NA	NA	Full gene deletion	YES	Female	0.35	0.404844597
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	NA	NA	Full gene deletion	YES	Female	0.003	7.069271322
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.160G>T	p.Gly54*	Nonsense	YES	Female	0.7	0.830512167
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.397_417dup21	NA	In-frame insertion	YES_predicted	Female	20.5	25.83177177
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.120_145del26	NA	Frameshift	YES	Male	0.6	0.491449014
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.149delC	p.Ala50fs	Frameshift	YES	Female	23.5	18.94806941
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.394_414del21	NA	In-frame deletion	YES	Female	12.3	10.10722932
Nov_2015	Saethre_Chotzen	<i>TWIST1</i>	c.352C>G	p.Arg118Gly	Missense	YES_predicted	Female	21.5	23.41800184

Nov_2015	Saethre_Chetzen	<i>TWIST1</i>	c.376G>T	p.Glu126*	Nonsense	YES	Female	0.8	0.92117994
Nov_2015	Saethre_Chetzen	<i>TWIST1</i>	c.490C>T	p.Gln164*	Nonsense	YES	Female	28.7	28.56296158
GSE74432	Sotos	<i>NSD1</i>	chr5:175,366,0 08- 177,470,488	NA	Long deletion	YES	Female	9	8.442111023
GSE74432	Sotos	<i>NSD1</i>	chr5:175,764,2 62- 177,059,256	NA	Long deletion	YES	Female	7	16.4840396
GSE74432	Sotos	<i>NSD1</i>	Exons 15-19 deletion	NA	Exonic deletion	YES	Male	10	26.70242296
GSE74432	Sotos	<i>NSD1</i>	c.1716delC	p.Cys573Valfs*26	Frameshift	YES	Female	10	14.59121875
GSE74432	Sotos	<i>NSD1</i>	c.6454C>T	p.Arg2152*	Nonsense	YES	Female	3.5	9.371834336
GSE74432	Sotos	<i>NSD1</i>	c.5445C>G	p.Tyr1815*	Nonsense	YES	Female	13.2	22.67264348
GSE74432	Sotos	<i>NSD1</i>	c.4843delT	p.Tyr1615Thrfs*2 7	Frameshift	YES	Male	3	7.039068162
GSE74432	Sotos	<i>NSD1</i>	NA	NA	Microdeletion	YES	Male	2.2	15.1797238
GSE74432	Sotos	<i>NSD1</i>	c.6349C>T	p.Arg2117*	Nonsense	YES	Female	12	26.9093016
GSE74432	Sotos	<i>NSD1</i>	c.1492C>T	p.Arg498*	Nonsense	YES	Male	2.2	8.399587071
GSE74432	Sotos	<i>NSD1</i>	c.6454C>T	p.Arg2152*	Nonsense	YES	Male	18	32.23853498
GSE74432	Sotos	<i>NSD1</i>	c.1583delA	p.Lys528Argfs*8	Frameshift	YES	Male	19.7	27.25531484
GSE74432	Sotos	<i>NSD1</i>	c.2014_2018del ACAGA	p.Thr672Glufs*9	Frameshift	YES	Male	8	26.46585423
GSE74432	Sotos	<i>NSD1</i>	c.2014_2018del ACAGA	p.Thr672Glufs*9	Frameshift	YES	Male	41	67.36442178
GSE74432	Sotos	<i>NSD1</i>	c.2014_2018del ACAGA	p.Thr672Glufs*9	Frameshift	YES	Female	2	11.34495985
GSE74432	Sotos	<i>NSD1</i>	c.1810C>T	p.Arg604*	Nonsense	YES	Female	1.6	6.2471485
GSE74432	Sotos	<i>NSD1</i>	c.1801A>T	p.Lys601*	Nonsense	YES	Male	10.6	30.82670587
GSE74432	Sotos	<i>NSD1</i>	c.4977_4978ins G	p.Arg1660Alafs*1 3	Frameshift	YES	Male	20	41.38296452
GSE74432	Sotos	<i>NSD1</i>	c.6437G>C	p.Cys2146Ser	Missense	YES_predicted	Male	2	9.83036953
GSE74432	Sotos	<i>NSD1</i>	c.6412T>C	p.Cys2138Arg	Missense	YES_predicted	Male	7	29.0788673
GSE74432	Weaver	<i>EZH2</i>	c.457_459delTA T	p.Tyr153del	In-frame deletion	YES	Male	30	40.6786865
GSE74432	Weaver	<i>EZH2</i>	c.2080C>T	p.His694Tyr	Missense	YES	Female	10.9167	17.28626931
GSE74432	Weaver	<i>EZH2</i>	c.2050C>T	p.Arg684Cys	Missense	YES	Male	2.5833	2.611103643
GSE74432	Weaver	<i>EZH2</i>	c.398A>G	p.Tyr133Cys	Missense	YES	Female	17	7.870608634
GSE74432	Weaver	<i>EZH2</i>	c.553G>C	p.Asp185His	Missense	YES	Male	15.4167	18.04003584
GSE74432	Weaver	<i>EZH2</i>	c.394C>T	p.Pro132Ser	Missense	YES	Female	19.75	21.09459251
GSE74432	Weaver	<i>EZH2</i>	c.1876G>A	p.Val626Met	Missense	YES	Male	43	42.37721085

Fig. S2.1 Table showing information for the samples from individuals with developmental disorders (total $N = 367$). Mutation information was annotated for the human genome assembly *hg19*. ASD: autism spectrum disorder; ATR-X: alpha thalassemia/mental retardation X-linked syndrome; FXS: fragile X syndrome.






Fig. S2.2 Effect of changing the median age of the controls when performing the screening for epigenetic age acceleration (EAA) in the different developmental disorders. The dashed green line displays the significance level of $\alpha = 0.01$ after Bonferroni correction. The dashed orange line displays the median age for the samples in the developmental disorder considered. In blue: EAA model without cell composition correction (CCC). In red: EAA model with CCC. ASD: autism spectrum disorder; ATR-X: alpha thalassemia/mental retardation X-linked syndrome; FXS: fragile X syndrome.








Fig. S2.3 Screening for epigenetic age acceleration (EAA) in developmental disorders. Left panel: scatterplot showing the relation between epigenetic age (DNAmAge) according to Horvath's model and chronological age of the samples for a given developmental disorder (orange) and control (grey). Each sample is represented by one point. The black dashed line represents the diagonal to aid visualisation. Middle and right panels: scatterplots showing the relation between the epigenetic age acceleration (EAA) (without and with CCC respectively) and chronological age of the samples for a given developmental disorder (orange) and control (grey). Each sample is represented by one point. The yellow line represents the linear model $EAA \sim Age$, with the standard error shown in the light yellow shade.




Fig. S2.4 Enrichment for the categorical (epi)genomic features considered when comparing the different genome-wide subsets of differentially methylated positions (DMPs) in ageing and Sotos against a control (see section 3.7). The y-axis represents the odds ratio (OR), the error bars show the 95% confidence interval for the OR estimate and the colour of the points codes for $-\log_{10}(p\text{-value})$ obtained after testing for enrichment using Fisher's exact test. An OR > 1 shows that the given feature is enriched in the subset of DMPs considered, whilst an OR < 1 shows that it is found less than expected. The 'Hyper-Hypo DMPs' subset results from the intersection between the hypermethylated DMPs in ageing and the hypomethylated DMPs in Sotos. The 'Hypo-Hypo DMPs' subset results from the intersection between the hypomethylated DMPs in ageing and Sotos. In grey: features that did not reach significance using a significance level of $\alpha = 0.01$ after Bonferroni correction.



Fig. S2.5 Boxplots showing the distributions of scores for the continuous (epi)genomic features considered when comparing the different genome-wide subsets of differentially methylated positions (DMPs) in ageing and Sotos against a control (see section 3.7). The p-values (two-sided Wilcoxon's test, before multiple testing correction) are shown above the boxplots. The number of DMPs belonging to each subset (in green) and the median value of the feature score (in dark red) are shown below the boxplots. NFC: ‘normalised fold change’; NRE: ‘normalised RNA expression’; WTS: ‘wavelet-transformed signals’; NRC: ‘normalised read counts’.




Fig. S2.6 Heatmap displaying the scores for the different continuous (epi)genomic features (rows) in each one of the 353 Horvath's epigenetic clock CpGs (columns). The names of the features include the ENCODE ID (see Fig. S2.11). Hierarchical clustering was performed in both rows and columns. RNA refers to the ‘normalised RNA expression’ (NRE). aDMPs: differentially methylated positions during ageing. PBMC: peripheral blood mononuclear cells.




Fig. S2.7 As in Fig. S2.4., but focused on the 353 Horvath's epigenetic clock CpG sites.




Fig. S2.8 As in Fig. S2.5., but focused on the 353 Horvath's epigenetic clock CpG sites.




Fig. S2.9 Methylation Shannon entropy acceleration. **a.** Scatterplot showing the relationship between the genome-wide Shannon entropy acceleration (gSEA) and chronological age of the samples for Sotos (orange) and healthy controls (grey). Each sample is represented by one point. The yellow line represents the linear model $\text{gSEA} \sim \text{Age}$, with the standard error shown in the light yellow shade. **b.** As in a., but using the Shannon entropy acceleration calculated only for the 353 CpG sites in the Horvath's epigenetic clock (cSEA).




Fig. S2.10 Scatterplot showing the effects of the different batches on the methylation Shannon entropy calculations for the 353 Horvath's epigenetic clock sites. Each sample is represented by one point and coloured according to the batch that they belong to.

File ID	Feature type	Data type	Tissue	Age (years)	Sex	Source
ENCFF516PTT	EZH2	fold change over control	B cell	27	Female	ENCODE
ENCFF071CIY	RNF2	fold change over control	K562	NA	NA	ENCODE
ENCFF857HEZ	RNF2	fold change over control	K562	NA	NA	ENCODE
ENCFF320VKN	RNF2	fold change over control	K562	NA	NA	ENCODE
ENCFF847TGB	RNF2	fold change over control	K562	NA	NA	ENCODE
ENCFF737OJY	H3K27ac	fold change over control	PBMC	32	Male	ENCODE
ENCFF303YKC	H3K4me3	fold change over control	PBMC	32	Male	ENCODE
ENCFF643USH	H3K36me3	fold change over control	PBMC	32	Male	ENCODE
ENCFF249WVX	H3K36me3	fold change over control	PBMC	28	Male	ENCODE
ENCFF759GIZ	H3K27ac	fold change over control	PBMC	28	Female	ENCODE
ENCFF412KUE	H3K27me3	fold change over control	PBMC	32	Male	ENCODE
ENCFF455IGC	H3K9ac	fold change over control	PBMC	28	Male	ENCODE
ENCFF457WMB	H3K4me1	fold change over control	PBMC	32	Male	ENCODE
ENCFF211ORP	H3K9ac	fold change over control	PBMC	27	Male	ENCODE
ENCFF171WZC	H3K9me3	fold change over control	PBMC	27	Male	ENCODE
ENCFF573QMJ	H3K4me3	fold change over control	PBMC	27	Male	ENCODE
ENCFF150RIG	H3K27me3	fold change over control	PBMC	28	Female	ENCODE
ENCFF033IPJ	H3K9me3	fold change over control	PBMC	28	Female	ENCODE
ENCFF796FFT	H3K4me3	fold change over control	PBMC	28	Female	ENCODE
ENCFF100NYH	H3K4me1	fold change over control	PBMC	27	Male	ENCODE
ENCFF713QZB	H3K9me3	fold change over control	PBMC	32	Male	ENCODE
ENCFF265VZG	H3K27me3	fold change over control	PBMC	28	Male	ENCODE
ENCFF319EBK	H3K9me3	fold change over control	PBMC	28	Male	ENCODE
ENCFF754LBN	RNA-seq	minus strand signal of unique reads	PBMC	52	Female	ENCODE
ENCFF398HDS	RNA-seq	plus strand signal of unique reads	PBMC	52	Female	ENCODE
GSM923447	Replication timing	Wavelet-transformed signals	IMR90	NA	Female	GEO
GSM1289416	LaminB1	Normalised read counts	IMR90	NA	NA	GEO

Fig. S2.11 Information (including the source) about the continuous (epi)genomic features (ChIP-seq and RNA-seq data) that were included in my analysis to annotate the different sets of CpG sites. All the data were mapped to the hg19 assembly of the human genome. PBMC: peripheral blood mononuclear cells.

S.3 Technological aspects of epigenetic clocks




Fig. S3.1 Scatterplot which summarises the fragment length distributions for the same isoschizomer families portrayed in Fig 4.2a. The red dots represent the actual values of median fragment length and total number of fragments for each family. The black lines assign each name label to the correspondent red point for visualization purposes.





Fig. S3.2 Matrix of scatterplots showing the percentages of cleavage sites from different restriction enzymes that overlap with several genomic features (listed on the diagonal) in the human genome (hg38). The red dot in each scatterplot represents the values for MspI. The numbers above the diagonal are the Pearson correlation coefficients between all the possible pairs of genomic features.

First author(s)	Title	Date	Single enzymes checked	Double enzymes checked	Size ranges interrogated	Genomic regions targeted	Organism(s)	Read lengths tested	For sequencing	Code available
Cedar H	Direct detection of methylated cytosine in DNA by use of the restriction enzyme MspI	1979	YES	NO	NA	NA	<i>Neurospora crassa</i> , herpes virus, fly, bovine	NA	N	N
Yu L	A NotI–EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies	2004	YES	YES	NA	CpG islands, protein-coding genes	Human (hg16), mouse (mm4)	NA	Y	N
Wang J and Xia Y	Double restriction-enzyme digestion improves the coverage and accuracy of genome-wide CpG methylation profiling by reduced representation bisulfite sequencing	2013	YES	YES	2	Increase CpG coverage genome-wide	Human (hg18), mouse(mm9)	50 bp PE, 90 bp PE	Y	N
Bystrykh L	A combinatorial approach to the restriction of a mouse genome	2013	YES	YES	NA	NA	Mouse (mm10)	NA	N	N
Martinez-Arguelles DB	In silico analysis identifies novel restriction enzyme combinations that expand reduced representation bisulfite sequencing CpG coverage	2014	YES	YES	1	Increase CpG coverage genome-wide	Human (hg38), mouse (mm10), rat (NCBI build 4.2)	50 bp PE	Y	N
Lee YK and Jin S	Improved reduced representation bisulfite sequencing for epigenomic profiling of clinical samples	2014	YES	YES	1	Increase CpG coverage genome-wide	Human (hg19)	36 bp PE	Y	N
Kirschner SA	Focussing reduced representation CpG sequencing through judicious restriction enzyme choice	2016	YES	YES	2	Increase CpG coverage genome-wide	Mouse (mm10)	NA	Y	N
Tanas AS	Rapid and affordable genome-wide bisulfite DNA sequencing by XmaI-reduced representation bisulfite sequencing	2017	YES	NO	1	CpG islands	Human (hg19)	NA	Y	N
Martin-Herranz DE and Stubbs TM	cuRRBS	2017	YES	YES	Defined by the user	Defined by the user	Defined by the user	Defined by the user	Y	Y

Fig. S3.3 Table showing the comparison of different studies that have attempted to use restriction enzymes to target different regions in the genome.

a

OUTPUT



b**c**

Fig. S3.4 Additional insights into cuRRBS. **a.** Detailed flowchart showing the input, main steps in cuRRBS and the output of the software. **b.** Violin plots showing the distribution of Pearson's correlation coefficients between the number of fragments (NF) and the *Score* for all the different enzymes tested with cuRRBS (single-enzyme, double-enzyme, all). In this example we used the Horvath epigenetic clock system [102], checking all the size ranges between 20 and 1000 bp, with an *experimental error* of 10 bp and a *read length* of 75 bp. Each yellow point represents the median for the Pearson's correlation coefficients under consideration. **c.** Density plot showing the distribution of the *robustness* (R) values when assuming an *experimental error* (δ) of 20 bp. cuRRBS was run for all the biological systems under study (Fig. S3.5) [102, 296–301] with the same parameters as described in ‘Running cuRRBS for different *in silico* systems’ in section 4.7 (all the hits that satisfied the thresholds were reported in this case). The dashed blue line represents the median (0.9734). The different colours provide a way to judge the *robustness* values: bad (in red, $R < Q_1 = 0.9580$), medium (in orange, $Q_1 \leq R \leq Q_3 = 0.9834$) and good (in green, $R > Q_3$); where Q_1 and Q_3 represent the first and the third quartiles respectively.

Species	System	PMID where applicable	Additional information about the system	Total number of sites targeted	Optimal restriction enzyme combination	Optimal theoretical size range (in bp)	% max Score	NF /1000	Enrichment Value (EV)	Cost Reduction Factor (CRF)	Robustness (R)
<i>Homo sapiens</i>	Exon-intron boundaries		DNA methylation has been shown to affect alternative splicing. Therefore, we focused on targeting CpGs close to canonical splicing sites.	26211	(BsiSI OR MspI) AND (SbfI OR Sdal OR Sse8387I)	80_500	25.4	772.23	2.06446811	53.32	0.94704403
<i>Homo sapiens</i>	Horvath epigenetic clock	24138928	The Horvath epigenetic clock is the best predictor of biological age available in humans. We have attempted to target the 353 CpG sites that are used in the model in order to reduce the cost associated with the assay.	353	(BsiSI OR MspI) AND (BspQI OR Lgul OR SapI)	60_160	27.57	442.456	3.65771916	93.06	0.91305072
<i>Homo sapiens</i>	Imprinted loci	26769960	Genomic imprinting is an epigenetic phenomenon that results in gene expression occurring in a parent-of-origin fashion. We have attempted to target Cs in CpG context that are found within the canonical human imprints.	2810	(BmeT110I OR BsoBI) AND (BsaWI)	60_540	25.12	336.88	2.67867053	122.23	0.98085689
<i>Homo sapiens</i>	Placental imprinted loci	26769960	Genomic imprinting is an epigenetic phenomenon that results in gene expression occurring in a parent-of-origin fashion. However, until recently many extraembryonic imprints were still unknown. We have targeted Cs in CpG context that are found within these novel human placental imprints.	7591	(BsaWI) AND (BssAI)	60_540	26.41	107.248	1.72827483	383.94	0.93382453
<i>Homo sapiens</i>	CTCF sites	26257180	CTCF is an important architectural protein that helps to organise chromatin domains. Since its binding has been shown to be dependent on DNA methylation in some of its recognition sequences, we have targeted the Cs in CpG sites within these regions of the genome.	2000	(BmeT110I OR BsoBI) AND (BssAI)	40_360	25.5	314.079	2.78946872	131.1	0.88798165
<i>Mus musculus</i>	iPSCs demethylated	28147265	iPSC reprogramming in mouse is characterised by global changes in DNA methylation. Sites that tend to undergo demethylation faster than the genome average tend to be within ESC-Super Enhancers. We targeted the Cs in CpG context in these regions, as they are interesting for the reprogramming field.	1449	(BmeT110I OR BsoBI) AND (BsiSI OR MspI)	80_980	25.19	974.05	3.42628839	37.31	0.96792238
<i>Mus musculus</i>	iPSCs maintained	28147265	iPSC reprogramming in mouse is characterised by global changes in DNA methylation. Sites that tend to be resistant to the genome-wide demethylation tend to be within intercisinal A-particle containing regions. We targeted the Cs in CpG context in these regions, as they are interesting for the reprogramming field.	3896	(BmeT110I OR BsoBI) AND (BsiSI OR MspI)	80_560	25.85	690.088	2.835875	52.66	0.94227711
<i>Mus musculus</i>	NRF1 sites	26675734	NRF1 is a transcription factor whose binding to the DNA is dependent on the methylation status of its recognition sequences. We have tried to enrich for those CpG sites that overlap with <i>in vivo</i> NRF1 binding sites.	17018	(BmeT110I OR BsoBI) AND (PaeI OR SphI)	20_760	25.04	445.36	2.01909776	81.6	0.99634045
<i>Arabidopsis thaliana</i>	CHG sites	27419873	Non-CpG methylation is an important epigenetic modification in plants. In this study a huge number of regions containing non-CpG methylation were found to vary between different <i>Arabidopsis</i> accessions in the 1001 Epigenomes Project. We targeted Cs in non-CpG context within these non-CpG DMRs.	21801	(AanI OR PsII) AND (Csp6I OR CviQI)	100_520	25.05	165.313	1.48095531	9.65	0.94999336

Fig. S3.5 Table showing the information regarding the different biological systems [102, 296–301] for which cuRRBS was run *in silico*. Some variables from the top hits in cuRRBS output are also reported.




Fig. S3.6 Effect of experimental errors during size selection in cuRRBS predictions. **a.** Barplots showing the difference in the number of true positives (TP, in green), true negatives (TN, in blue), false positives (FP, in red) and false negatives (FN, in yellow) derived from cuRRBS theoretical predictions for the XmaI-RRBS data [283] using two different size ranges: 110–200 bp (aimed size range) and 90–185 bp (real size range). The difference observed between the two size ranges (aimed - real) is expressed as the percentage of the total number of sites considered (i.e. all CGI- CpGs). The number of sites in each category is calculated for different thresholds in the depth of coverage (number of reads covering a CpG site as reported by Bismark). cuRRBS was run for XmaI with all the default parameters (with a *read length* of 200 bp). Legend is displayed on the right hand side. **b.** Plot showing values of cuRRBS sensitivity and specificity as a function of the depth of coverage threshold employed to filter the experimental data [283]. The two size ranges considered in a. (aimed: 110–200 bp; real: 90–185 bp) are used for the calculations. Legend is displayed below the plot curves.




Fig. S3.7 cuRRBS computational efficiency. **a.** Plot showing the dependency between the number of enzymes checked and the computational (real) time required by the software (mean between 3 independent runs). cuRRBS was run for the Horvath epigenetic clock system [102] with a *read length* of 75 bp, a *Score threshold* of 25% and an *experimental error* of 10 bp. A laptop with an Intel® Core™ i7-6600U CPU was used, which allowed cuRRBS to employ 4 parallel threads. The red error bars display the mean \pm SD for the 3 independent runs. **b.** Plot showing the dependency between the *experimental error* (which determines how many size ranges are sampled) and the computational (real) time required by the software (mean between 3 independent runs). cuRRBS was run for the Horvath epigenetic clock system [102] with a *read length* of 75 bp, a *Score threshold* of 25% and a list with 40 enzymes. A laptop with an Intel® Core™ i7-6600U CPU was used, which allowed cuRRBS to employ 4 parallel threads. The red error bars display the mean \pm SD for the 3 independent runs. **c.** Plot showing the dependency between the number of sites of interest and the computational (real) time required by the software (mean between 3 independent runs). cuRRBS was run with a *read length* of 75 bp, a *Score threshold* of 25%, an *experimental error* of 10 bp and a list with 40 enzymes. A laptop with an Intel® Core™ i7-6600U CPU was used, which allowed cuRRBS to employ 4 parallel threads. The red error bars display the mean \pm SD for the 3 independent runs. **d.** Plot showing the dependency between genome size (measured as the size in GB of all the pre-computed files) and the computational (real) time required by the software (mean between 3 independent runs). cuRRBS was run with a *read length* of 75 bp, a *Score threshold* of 25%, an experimental error of 10 bp and a list with 40 enzymes. A laptop with an Intel® Core™ i7-6600U CPU was used, which allowed cuRRBS to employ 4 parallel threads. The red error bars display the mean \pm SD for the 3 independent runs.

References

- [1] Colin Renfrew, Michael J. Boyd, and Iain Morley. *Death Rituals, Social Order and the Archeology of Immortality in the Ancient World*. 2016.
- [2] Carlos Lopez-Otin, Maria A Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer. The hallmarks of aging. *Cell*, 153(6):1194–1217, 2013.
- [3] Zhores A Medvedev. An attempt at a rational classification of theories of ageing. *Biological Reviews*, 65:375–398, 1990.
- [4] Matthew Witten. Information content of biological survival curves arising in aging experiments: some further thoughts. In *Evolution of longevity in animals: a comparative approach.*, pages 295–317. 1986.
- [5] Owen R Jones, Alexander Scheuerlein, Roberto Salguero-Gómez, Carlo Giovanni Camarda, Ralf Schaible, Brenda B Casper, Johan P Dahlgren, Johan Ehrlén, María B García, Eric S Menges, Pedro F Quintana-Ascencio, Hal Caswell, Annette Baudisch, and James W Vaupel. Diversity of ageing across the tree of life. *Nature*, 505:169, 2013.
- [6] J P DE MAGALHÃES and J COSTA. A database of vertebrate longevity records and their relation to other life-history traits. *Journal of Evolutionary Biology*, 22(8):1770–1774, 2009.
- [7] C E Finch. Update on Slow Aging and Negligible Senescence – A Mini-Review. *Gerontology*, 55(3):307–313, 2009.
- [8] Leonard Hayflick. Biological aging is no longer an unsolved problem. In *Annals of the New York Academy of Sciences*, volume 1100, pages 1–13, 2007.
- [9] Leonard Hayflick. Entropy Explains Aging, Genetic Determinism Explains Longevity, and Undefined Terminology Explains Misunderstanding Both. *PLOS Genetics*, 3(12):e220, dec 2007.
- [10] T B L Kirkwood. Evolution of ageing. *Nature*, 270(5635):301–304, 1977.
- [11] T. B.L. Kirkwood and M. R. Rose. Evolution of senescence: late survival sacrificed for reproduction. *Philosophical Transactions - Royal Society of London, B*, 332(1262):15–24, 1991.
- [12] Mikhail V. Blagosklonny. Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition, 2006.

- [13] Mikhail V Blagosklonny. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. *Cell Cycle*, 9(16):3171–3176, aug 2010.
- [14] João Pedro de Magalhães. Programmatic features of aging originating in development: aging mechanisms beyond molecular damage? *The FASEB Journal*, 26(12):4821–4826, 2012.
- [15] David Gems. The aging-disease false dichotomy: understanding senescence as pathology. *Frontiers in genetics*, 6(June):212, 2015.
- [16] G. C. Williams. Pleiotropy, Natural Selection, and the Evolution of Senescence. *Evolution*, 11(4):398–411, 1957.
- [17] Robert E Ricklefs. Life-history connections to rates of aging in terrestrial vertebrates. *Proceedings of the National Academy of Sciences*, 107(22):10314–10319, 2010.
- [18] Richard Peto and Richard Doll. There is no such thing as aging. *BMJ*, 315(7115):1030, 1997.
- [19] Adam Freund. Untangling Aging Using Dynamic, Organism-Level Phenotypic Networks. *Cell Systems*, 8(3):172–181, 2019.
- [20] David Gems and Donald L Riddle. Defining Wild-Type Life Span in *Caenorhabditis elegans*. *The Journals of Gerontology: Series A*, 55(5):B215–B219, may 2000.
- [21] Cynthia Kenyon. The plasticity of aging: Insights from long-lived mutants. *Cell*, 120(4):449–460, 2005.
- [22] C M McCay, L A Maynard, and Mary F Crowell. The Effect of Retarded Growth Upon the Length of Life Span and Upon the Ultimate Body Size: One Figure. *The Journal of Nutrition*, 10(1):63–79, 1935.
- [23] Roger B. McDonald and Jon J. Ramsey. Honoring Clive McCay and 75 Years of Calorie Restriction Research. *The Journal of Nutrition*, 140(7):1205–1210, 2010.
- [24] Luigi Fontana and Linda Partridge. Promoting health and longevity through diet: From model organisms to humans. *Cell*, 161(1):106–118, 2015.
- [25] MICHAEL KLASS and DAVID HIRSH. Non-ageing developmental variant of *Caenorhabditis elegans*. *Nature*, 260(5551):523–525, 1976.
- [26] Thomas E Johnson. 25years after age-1: Genes, interventions and the revolution in aging research. *Experimental Gerontology*, 48(7):640–643, 2013.
- [27] Cynthia Kenyon, Jean Chang, Erin Gensch, Adam Rudner, and Ramon Tabtiang. A *C. elegans* mutant that lives twice as long as wild type. *Nature*, 366(6454):461–464, 1993.
- [28] Jason Z Morris, Heidi A Tissenbaum, and Gary Ruvkun. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in *Caenorhabditis elegans*. *Nature*, 382(6591):536–539, 1996.

- [29] Cynthia J Kenyon. The genetics of ageing. *Nature*, 464(7288):504–12, 2010.
- [30] Param Priya Singh, Brittany A Demmitt, Ravi D Nath, and Anne Brunet. The Genetics of Aging: A Vertebrate Perspective. *Cell*, 177(1):200–220, 2019.
- [31] Eric L. Greer and Anne Brunet. Signaling networks in aging. *Journal of Cell Science*, 121:407–412, 2008.
- [32] Leonard Guarente and Cynthia Kenyon. Genetic pathways that regulate ageing in model organisms. *Nature*, 408(6809):255–262, 2000.
- [33] Kui Lin, Honor Hsin, Natasha Libina, and Cynthia Kenyon. Regulation of the *Caenorhabditis elegans* longevity protein DAF-16 by insulin/IGF-1 and germline signaling. *Nature Genetics*, 28:139–145, 2001.
- [34] Rute Martins, Gordon J Lithgow, and Wolfgang Link. Long live FOXO: unraveling the role of FOXO proteins in aging and longevity. *Aging Cell*, 15(2):196–207, 2016.
- [35] Ao-Lin Hsu, Coleen T Murphy, and Cynthia Kenyon. Regulation of Aging and Age-Related Disease by DAF-16 and Heat-Shock Factor. *Science*, 300(5622):1142–1145, 2003.
- [36] Jennifer M A Tullet, Maren Hertweck, Jae Hyung An, Joseph Baker, Ji Yun Hwang, Shu Liu, Riva P Oliveira, Ralf Baumeister, and T Keith Blackwell. Direct Inhibition of the Longevity-Promoting Factor SKN-1 by Insulin-like Signaling in *C. elegans*. *Cell*, 132(6):1025–1038, 2008.
- [37] Sung Hee Um, David D’Alessio, and George Thomas. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. *Cell Metabolism*, 3(6):393–402, 2006.
- [38] David E Harrison, Randy Strong, Zelton Dave Sharp, James F Nelson, Clinton M Astle, Kevin Flurkey, Nancy L Nadon, J Erby Wilkinson, Krystyna Frenkel, Christy S Carter, Marco Pahor, Martin a Javors, Elizabeth Fernandez, and Richard a Miller. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature*, 460(7253):392–395, 2009.
- [39] Maria M Mihaylova and Reuben J Shaw. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. *Nature Cell Biology*, 13:1016–1023, 2011.
- [40] Vladimir N Anisimov, Lev M Berstein, Peter A Egormin, Tatiana S Piskunova, Irina G Popovich, Mark A Zabrezhinski, Margarita L Tyndyk, Maria V Yurova, Irina G Kovalenko, Tatiana E Poroshina, and Anna V Semenchenko. Metformin slows down aging and extends life span of female SHR mice. *Cell Cycle*, 7(17):2769–2773, 2008.
- [41] Alejandro Martin-Montalvo, Evi M Mercken, Sarah J Mitchell, Hector H Palacios, Patricia L Mote, Morten Scheibye-Knudsen, Ana P Gomes, Theresa M Ward, Robin K Minor, Marie-José Blouin, Matthias Schwab, Michael Pollak, Yongqing Zhang, Yingbing Yu, Kevin G Becker, Vilhelm A Bohr, Donald K Ingram, David A Sinclair, Norman S Wolf, Stephen R Spindler, Michel Bernier, and Rafael de Cabo. Metformin improves healthspan and lifespan in mice. *Nature Communications*, 4:2192, 2013.

- [42] Nir Barzilai, Jill P Crandall, Stephen B Kritchevsky, and Mark A Espeland. Metformin as a Tool to Target Aging. *Cell Metabolism*, 23(6):1060–1065, 2016.
- [43] Michael S Bonkowski and David A Sinclair. Slowing ageing by design: the rise of NAD⁺ and sirtuin-activating compounds. *Nature Reviews Molecular Cell Biology*, 17:679–690, 2016.
- [44] Marco Lezzerini and Yelena Budovskaya. A dual role of the Wnt signaling pathway during aging in *Caenorhabditis elegans*. *Aging Cell*, 13(1):8–18, 2014.
- [45] Sean P Curran, Xiaoyun Wu, Christian G Riedel, and Gary Ruvkun. A soma-to-germline transformation in long-lived *Caenorhabditis elegans* mutants. *Nature*, 459:1079–1084, 2009.
- [46] Andrew Dillin, Douglas K Crawford, and Cynthia Kenyon. Timing Requirements for Insulin/IGF-1 Signaling in *C. elegans*. *Science*, 298(5594):830–834, 2002.
- [47] Eric L. Greer, Philip R. Oskoui, Max R. Banko, Jay M. Maniar, Melanie P. Gygi, Steven P. Gygi, and Anne Brunet. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. *Journal of Biological Chemistry*, 282:30107–30119, 2007.
- [48] Nuno Arantes-Oliveira, Jennifer R Berman, and Cynthia Kenyon. Healthy Animals with Extreme Longevity. *Science*, 302(5645):611, 2003.
- [49] Srinivas Ayyadevara, Ramani Alla, John J Thaden, and Robert J Shmookler Reis. Remarkable longevity and stress resistance of nematode PI3K-null mutants. *Aging Cell*, 7(1):13–22, 2008.
- [50] J Graham Ruby, Megan Smith, and Rochelle Buffenstein. Naked mole-rat mortality rates defy Gompertzian laws by not increasing with age. *eLife*, 7:e31157, 2018.
- [51] Toni Fleischer, Jutta Gampe, Alexander Scheuerlein, and Gerald Kerth. Rare catastrophic events drive population dynamics in a bat species with negligible senescence. *Scientific Reports*, 7(1):7370, 2017.
- [52] Iñigo Martincorena, Joanna C Fowler, Agnieszka Wabik, Andrew R J Lawson, Federico Abascal, Michael W J Hall, Alex Cagan, Kasumi Murai, Krishnaa Mahbubani, Michael R Stratton, Rebecca C Fitzgerald, Penny A Handford, Peter J Campbell, Kourosh Saeb-Parsy, and Philip H Jones. Somatic mutant clones colonize the human esophagus with age. *Science*, 362(6417):911–917, 2018.
- [53] Nils-Göran Larsson. Somatic Mitochondrial DNA Mutations in Mammalian Aging. *Annual Review of Biochemistry*, 79(1):683–706, 2010.
- [54] Ludmil B Alexandrov and Michael R Stratton. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. *Current Opinion in Genetics & Development*, 24:52–60, 2014.
- [55] Ludmil B Alexandrov, Philip H Jones, David C Wedge, Julian E Sale, Peter J Campbell, Serena Nik-Zainal, and Michael R Stratton. Clock-like mutational processes in human somatic cells. *Nature Genetics*, 47(12):1402–1407, 2015.

- [56] Philipp Oberdoerffer and David A Sinclair. The role of nuclear architecture in genomic instability and ageing. *Nature Reviews Molecular Cell Biology*, 8:692–702, 2007.
- [57] William C. Orr. Tightening the connection between transposable element mobilization and aging. *Proceedings of the National Academy of Sciences*, 113(40):11069–11070, 2016.
- [58] Roderick J O’Sullivan and Jan Karlseder. Telomeres: protecting chromosomes against genome instability. *Nature Reviews Molecular Cell Biology*, 11:171–181, 2010.
- [59] L Hayflick and P S Moorhead. The serial cultivation of human diploid cell strains. *Experimental Cell Research*, 25(3):585–621, 1961.
- [60] Leonard Hayflick. A Brief History of the Mortality and Immortality of Cultured Cells. *The Keio Journal of Medicine*, 47(3):174–182, 1998.
- [61] Maria A Blasco. Telomere length, stem cells and aging. *Nature Chemical Biology*, 3:640, sep 2007.
- [62] Antonia Tomás-Loba, Ignacio Flores, Pablo J Fernández-Marcos, María L Cayuela, Antonio Maraver, Agueda Tejera, Consuelo Borrás, Ander Matheu, Peter Klatt, Juana M Flores, José Viña, Manuel Serrano, and María A Blasco. Telomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice. *Cell*, 135(4):609–622, 2008.
- [63] Nicolás Herranz and Jesús Gil. Mechanisms and functions of cellular senescence. *The Journal of Clinical Investigation*, 128(4):1238–1246, 2018.
- [64] Darren J Baker, Tobias Wijshake, Tamar Tchkonia, Nathan K LeBrasseur, Bennett G Childs, Bart van de Sluis, James L Kirkland, and Jan M van Deursen. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. *Nature*, 479:232–236, 2011.
- [65] Darren J Baker, Bennett G Childs, Matej Durik, Melinde E Wijers, Cynthia J Sieben, Jian Zhong, Rachel A. Saltness, Karthik B Jeganathan, Grace Casaclang Verzosa, Abdulmohammad Pezeshki, Khashayarsha Khazaie, Jordan D Miller, and Jan M van Deursen. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan. *Nature*, 530:184–189, 2016.
- [66] Ming Xu, Tamar Pirtskhalava, Joshua N Farr, Bettina M Weigand, Allyson K Palmer, Megan M Weivoda, Christina L Inman, Mikolaj B Ogrodnik, Christine M Hachfeld, Daniel G Fraser, Jennifer L Onken, Kurt O Johnson, Grace C Verzosa, Larissa G P Langhi, Moritz Weigl, Nino Giorgadze, Nathan K LeBrasseur, Jordan D Miller, Diana Jurk, Ravinder J Singh, David B Allison, Keisuke Ejima, Gene B Hubbard, Yuji Ikeno, Hajrunisa Cubro, Vesna D Garovic, Xiaonan Hou, S John Weroha, Paul D Robbins, Laura J Niedernhofer, Sundeep Khosla, Tamara Tchkonia, and James L Kirkland. Senolytics improve physical function and increase lifespan in old age. *Nature Medicine*, 24(8):1246–1256, 2018.
- [67] James L Kirkland, Tamara Tchkonia, Yi Zhu, Laura J Niedernhofer, and Paul D Robbins. The Clinical Potential of Senolytic Drugs. *Journal of the American Geriatrics Society*, 65(10):2297–2301, 2017.

- [68] Marco De Cecco, Takahiro Ito, Anna P Petrashen, Amy E Elias, Nicholas J Skvir, Steven W Criscione, Alberto Caligiana, Greta Brocculi, Emily M Adney, Jef D Boeke, Oanh Le, Christian Beauséjour, Jayakrishna Ambati, Kameshwari Ambati, Matthew Simon, Andrei Seluanov, Vera Gorbunova, P Eline Slagboom, Stephen L Helfand, Nicola Neretti, and John M Sedivy. L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature*, 566(7742):73–78, 2019.
- [69] Linda Partridge, Joris Deelen, and P Eline Slagboom. Facing up to the global challenges of ageing. *Nature*, 561(7721):45–56, 2018.
- [70] Xiao Dong, Brandon Milholland, and Jan Vijg. Evidence for a limit to human lifespan. *Nature*, 538:257–259, 2016.
- [71] Benjamin Gompertz. On the Nature of the Function Expressive of the Law of Human Mortality, and on a New Mode of Determining the Value of Life Contingencies. *Philosophical Transactions of the Royal Society of London*, 115:513–583, 1825.
- [72] Elisabetta Barbi, Francesco Lagona, Marco Marsili, James W Vaupel, and Kenneth W Wachter. The plateau of human mortality: Demography of longevity pioneers. *Science*, 360(6396):1459–1461, 2018.
- [73] Vasilis Kontis, James E. Bennett, Colin D. Mathers, Guangquan Li, Kyle Foreman, and Majid Ezzati. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. *The Lancet*, 389(10076):1323–1335, 2017.
- [74] Michael Fine. Intergenerational perspectives on ageing, economics and globalisation. *Australasian Journal on Ageing*, 33(4):220–225, 2014.
- [75] Breanne L Newell Stamper, James R Cypser, Katerina Kechris, David Alan Kitzenberg, Patricia M Tedesco, and Thomas E Johnson. Movement decline across lifespan of *Caenorhabditis elegans* mutants in the insulin/insulin-like signaling pathway. *Aging Cell*, 17(1):e12704, 2018.
- [76] Lori Feldman, Stacy L Andersen, Thomas T Perls, Daniel A Dworkis, and Paola Sebastiani. Health Span Approximates Life Span Among Many Supercentenarians: Compression of Morbidity at the Approximate Limit of Life Span. *The Journals of Gerontology: Series A*, 67A(4):395–405, 2012.
- [77] Orli G Bahcall. UK Biobank — a new era in genomic medicine. *Nature Reviews Genetics*, 19(12):737, 2018.
- [78] Ridho Rahmadi, Perry Groot, Marieke H C van Rijn, Jan A J G van den Brand, Marianne Heins, Hans Knoop, and Tom Heskes. Causality on longitudinal data: Stable specification search in constrained structural equation modeling. *Statistical Methods in Medical Research*, 27(12):3814–3834, 2017.
- [79] Garret FitzGerald, David Botstein, Robert Califff, Rory Collins, Keith Peters, Nick Van Bruggen, and Dan Rader. The future of humans as model organisms. *Science*, 361(6402):552–553, 2018.
- [80] Steven N Austad and Kathleen E Fischer. Sex Differences in Lifespan. *Cell Metabolism*, 23(6):1022–1033, 2016.

- [81] J Graham Ruby, Kevin M Wright, Kristin A Rand, Amir Kermany, Keith Noto, Don Curtis, Neal Varner, Daniel Garrigan, Dmitri Slinkov, Ilya Dorfman, Julie M Granka, Jake Byrnes, Natalie Myres, and Catherine Ball. Estimates of the Heritability of Human Longevity Are Substantially Inflated due to Assortative Mating. *Genetics*, 210(3):1109–1124, 2018.
- [82] Joanna Kaplanis, Assaf Gordon, Tal Shor, Omer Weissbrod, Dan Geiger, Mary Wahl, Michael Gershovits, Barak Markus, Mona Sheikh, Melissa Gymrek, Gaurav Bhatia, Daniel G MacArthur, Alkes L Price, and Yaniv Erlich. Quantitative analysis of population-scale family trees with millions of relatives. *Science*, 360(6385):171–175, 2018.
- [83] Leanne M Redman, Steven R Smith, Jeffrey H Burton, Corby K Martin, Dora Il'yasova, and Eric Ravussin. Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging. *Cell Metabolism*, 27(4):805–815.e4, 2018.
- [84] Min Wei, Sebastian Brandhorst, Mahshid Shelehchi, Hamed Mirzaei, Chia Wei Cheng, Julia Budniak, Susan Groshen, Wendy J Mack, Esra Guen, Stefano Di Biase, Pinchas Cohen, Todd E Morgan, Tanya Dorff, Kurt Hong, Andreas Michalsen, Alessandro Laviano, and Valter D Longo. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. *Science Translational Medicine*, 9(377):eaai8700, 2017.
- [85] Erik A. Richter and Neil B. Ruderman. AMPK and the biochemistry of exercise: implications for human health and disease. *Biochemical Journal*, 418(2):261–275, 2009.
- [86] Jasper Most, Valeria Tosti, Leanne M Redman, and Luigi Fontana. Calorie restriction in humans: An update. *Ageing Research Reviews*, 39:36–45, 2017.
- [87] Yang Claire Yang, Courtney Boen, Karen Gerken, Ting Li, Kristen Schorpp, and Kathleen Mullan Harris. Social relationships and physiological determinants of longevity across the human life span. *Proceedings of the National Academy of Sciences*, 113(3):578–583, 2016.
- [88] Michel Poulaire, Anne Herm, and Gianni Pes. The Blue Zones: areas of exceptional longevity around the world. *Vienna Yearbook of Population Research*, 11:87–108, 2013.
- [89] Conrad H. Waddington. The Epigenotype. *Endeavor*, 1:18–20, 1942.
- [90] Scott F Gilbert. Commentary: ‘The Epigenotype’ by C.H. Waddington. *International Journal of Epidemiology*, 41(1):20–23, 2011.
- [91] Conrad H. Waddington. The cybernetics of development. In *The strategy of the genes*, pages 27–38. 1957.
- [92] Tuuli Lappalainen and John M Greally. Associating cellular epigenetic models with human phenotypes. *Nature Reviews Genetics*, 18:441–451, 2017.

- [93] The ENCODE Project Consortium, Ian Dunham, Anshul Kundaje, Shelley F Aldred, Patrick J Collins, Carrie A Davis, Francis Doyle, Charles B Epstein, Seth Frietze, Jennifer Harrow, Rajinder Kaul, Jainab Khatun, Bryan R Lajoie, Stephen G Landt, Bum-Kyu Lee, Florencia Pauli, Kate R Rosenbloom, Peter Sabo, Alexias Safi, Amartya Sanyal, Noam Shoresh, Jeremy M Simon, Lingyun Song, Nathan D Trinklein, Robert C Altshuler, Ewan Birney, James B Brown, Chao Cheng, Sarah Djebali, Xianjun Dong, Ian Dunham, Jason Ernst, Terrence S Furey, Mark Gerstein, Belinda Giardine, Melissa Greven, Ross C Hardison, Robert S Harris, Javier Herrero, Michael M Hoffman, Sowmya Iyer, Manolis Kellis, Jainab Khatun, Pouya Kheradpour, Anshul Kundaje, Timo Lassmann, Qunhua Li, Xinying Lin, Georgi K Marinov, Angelika Merkel, Ali Mortazavi, Stephen C J Parker, Timothy E Reddy, Joel Rozowsky, Felix Schlesinger, Robert E Thurman, Jie Wang, Lucas D Ward, Troy W Whitfield, Steven P Wilder, Weisheng Wu, Hualin S Xi, Kevin Y Yip, Jiali Zhuang, Bradley E Bernstein, Ewan Birney, Ian Dunham, Eric D Green, Chris Gunter, Michael Snyder, Michael J Pazin, Rebecca F Lowdon, Laura A L Dillon, Leslie B Adams, Caroline J Kelly, Julia Zhang, Judith R Wexler, Eric D Green, Peter J Good, Elise A Feingold, Bradley E Bernstein, Ewan Birney, Gregory E Crawford, Job Dekker, Laura Elnitski, Peggy J Farnham, Mark Gerstein, Morgan C Giddings, Thomas R Gingeras, Eric D Green, Roderic Guigó, Ross C Hardison, Timothy J Hubbard, Manolis Kellis, W James Kent, Jason D Lieb, Elliott H Margulies, Richard M Myers, Michael Snyder, John A Stamatoyannopoulos, Scott A Tenenbaum, Zhiping Weng, Kevin P White, Barbara Wold, Jainab Khatun, Yanbao Yu, John Wrobel, Brian A Risk, Harsha P Gunawardena, Heather C Kuiper, Christopher W Maier, Ling Xie, Xian Chen, Morgan C Giddings, Bradley E Bernstein, Charles B Epstein, Noam Shoresh, Jason Ernst, Pouya Kheradpour, Tarjei S Mikkelsen, Shawn Gillespie, Alon Goren, Oren Ram, Xiaolan Zhang, Li Wang, Robbyn Issner, Michael J Coyne, Timothy Durham, Manching Ku, Thanh Truong, Lucas D Ward, Robert C Altshuler, Matthew L Eaton, Manolis Kellis, Sarah Djebali, Carrie A Davis, Angelika Merkel, Alex Dobin, Timo Lassmann, Ali Mortazavi, Andrea Tanzer, Julien Lagarde, Wei Lin, Felix Schlesinger, Chenghai Xue, Georgi K Marinov, Jainab Khatun, Brian A Williams, Chris Zaleski, Joel Rozowsky, Maik Röder, Felix Kokocinski, Rehab F Abdelhamid, Tyler Alioto, Igor Antoshechkin, Michael T Baer, Philippe Batut, Ian Bell, Kimberly Bell, Sudipto Chakrabortty, Xian Chen, Jacqueline Chrast, Joao Curado, Thomas Derrien, Jorg Drenkow, Erica Dumais, Jackie Dumais, Radha Duttagupta, Megan Fastuca, Kata Fejes-Toth, Pedro Ferreira, Sylvain Foissac, Melissa J Fullwood, Hui Gao, David Gonzalez, Assaf Gordon, Harsha P Gunawardena, Cédric Howald, Sonali Jha, Rory Johnson, Philipp Kapranov, Brandon King, Colin Kingswood, Guoliang Li, Oscar J Luo, Eddie Park, Jonathan B Preall, Kimberly Presaud, Paolo Ribeca, Brian A Risk, Daniel Robyr, Xiaoaan Ruan, Michael Sammeth, Kuljeet Singh Sandhu, Lorain Schaeffer, Lei-Hoon See, Atif Shahab, Jorgen Skancke, Ana Maria Suzuki, Hazuki Takahashi, Hagen Tilgner, Diane Trout, Nathalie Walters, Huaien Wang, John Wrobel, Yanbao Yu, Yoshihide Hayashizaki, Jennifer Harrow, Mark Gerstein, Timothy J Hubbard, Alexandre Raymond, Stylianos E Antonarakis, Gregory J Hannon, Morgan C Giddings, Yijun Ruan, Barbara Wold, Piero Carninci, Roderic Guigó, Thomas R Gingeras, Kate R Rosenbloom, Cricket A Sloan, Katrina Learned, Venkat S Malladi, Matthew C Wong, Galt P Barber, Melissa S Cline, Timothy R Dreszer, Steven G Heitner, Donna Karolchik, W James Kent, Vanessa M Kirkup, Laurence R Meyer, Jeffrey C Long, Morgan Maddren, Brian J Raney, Terrence S Furey, Lingyun Song, Linda L Grasfeder, Paul G

Giresi, Bum-Kyu Lee, Anna Battenhouse, Nathan C Sheffield, Jeremy M Simon, Kimberly A Showers, Alexias Safi, Darin London, Akshay A Bhinge, Christopher Shestak, Matthew R Schaner, Seul Ki Kim, Zhuzhu Z Zhang, Piotr A Mieczkowski, Joanna O Mieczkowska, Zheng Liu, Ryan M McDaniell, Yunyun Ni, Naim U Rashid, Min Jae Kim, Sheera Adar, Zhancheng Zhang, Tianyuan Wang, Deborah Winter, Damian Keefe, Ewan Birney, Vishwanath R Iyer, Jason D Lieb, Gregory E Crawford, Guoliang Li, Kuljeet Singh Sandhu, Meizhen Zheng, Ping Wang, Oscar J Luo, Atif Shahab, Melissa J Fullwood, Xiaoan Ruan, Yijun Ruan, Richard M Myers, Florencia Pauli, Brian A Williams, Jason Gertz, Georgi K Marinov, Timothy E Reddy, Jost Vielmetter, E Partridge, Diane Trout, Katherine E Varley, Clarke Gasper, Anita Bansal, Shirley Pepke, Preti Jain, Henry Amrhein, Kevin M Bowling, Michael Anaya, Marie K Cross, Brandon King, Michael A Muratet, Igor Antoshechkin, Kimberly M Newberry, Kenneth McCue, Amy S Nesmith, Katherine I Fisher-Aylor, Barbara Pusey, Gilberto DeSalvo, Stephanie L Parker, Sreeram Balasubramanian, Nicholas S Davis, Sarah K Meadows, Tracy Eggleston, Chris Gunter, J Scott Newberry, Shawn E Levy, Devin M Absher, Ali Mortazavi, Wing H Wong, Barbara Wold, Matthew J Blow, Axel Visel, Len A Pennachio, Laura Elnitski, Elliott H Margulies, Stephen C J Parker, Hanna M Petrykowska, Alexej Abyzov, Bronwen Aken, Daniel Barrell, Gemma Barson, Andrew Berry, Alexandra Bignell, Veronika Boychenko, Giovanni Bussotti, Jacqueline Chrast, Claire Davidson, Thomas Derrien, Gloria Despacio-Reyes, Mark Diekhans, Iakes Ezkurdia, Adam Frankish, James Gilbert, Jose Manuel Gonzalez, Ed Griffiths, Rachel Harte, David A Hendrix, Cédric Howald, Toby Hunt, Irwin Jungreis, Mike Kay, Ekta Khurana, Felix Kokocinski, Jing Leng, Michael F Lin, Jane Loveland, Zhi Lu, Deepa Manthravadi, Marco Mariotti, Jonathan Mudge, Gaurab Mukherjee, Cedric Notredame, Baikang Pei, Jose Manuel Rodriguez, Gary Saunders, Andrea Sboner, Stephen Searle, Cristina Sisu, Catherine Snow, Charlie Steward, Andrea Tanzer, Elec-tra Tapanari, Michael L Tress, Marijke J van Baren, Nathalie Walters, Stefan Washietl, Laurens Wilming, Amonida Zadissa, Zhengdong Zhang, Michael Brent, David Haussler, Manolis Kellis, Alfonso Valencia, Mark Gerstein, Alexandre Reymond, Roderic Guigó, Jennifer Harrow, Timothy J Hubbard, Stephen G Landt, Seth Frietze, Alexej Abyzov, Nick Addleman, Roger P Alexander, Raymond K Auerbach, Suganthi Bal-asubramanian, Keith Bettinger, Nitin Bhardwaj, Alan P Boyle, Alina R Cao, Philip Cayting, Alexandra Charos, Yong Cheng, Chao Cheng, Catharine Eastman, Ghia Euskirchen, Joseph D Fleming, Fabian Grubert, Lukas Habegger, Manoj Hariharan, Arif Harmancı, Sushma Iyengar, Victor X Jin, Konrad J Karczewski, Maya Kasowski, Phil Lacroute, Hugo Lam, Nathan Lamarre-Vincent, Jing Leng, Jin Lian, Marianne Lindahl-Allen, Renqiang Min, Benoit Miotto, Hannah Monahan, Zarmik Moqtaderi, Xinmeng J Mu, Henriette O'Geen, Zhengqing Ouyang, Dorrelyn Patacsil, Baikang Pei, Debasish Raha, Lucia Ramirez, Brian Reed, Joel Rozowsky, Andrea Sboner, Minyi Shi, Cristina Sisu, Teri Slifer, Heather Witt, Linfeng Wu, Xiaoqin Xu, Koon-Kiu Yan, Xinqiong Yang, Kevin Y Yip, Zhengdong Zhang, Kevin Struhl, Sherman M Weissman, Mark Gerstein, Peggy J Farnham, Michael Snyder, Scott A Tenenbaum, Luiz O Penalva, Francis Doyle, Subhradip Karmakar, Stephen G Landt, Raj R Bhan-vadia, Alina Choudhury, Marc Domanus, Lijia Ma, Jennifer Moran, Dorrelyn Patacsil, Teri Slifer, Alec Victorsen, Xinqiong Yang, Michael Snyder, Kevin P White, Thomas Auer, Lazaro Centanin, Michael Eichenlaub, Franziska Gruhl, Stephan Heermann, Burkhard Hoeckendorf, Daigo Inoue, Tanja Kellner, Stephan Kirchmaier, Claudia Mueller, Robert Reinhardt, Lea Schertel, Stephanie Schneider, Rebecca Sinn, Beate

- Wittbrodt, Jochen Wittbrodt, Zhiping Weng, Troy W Whitfield, Jie Wang, Patrick J Collins, Shelley F Aldred, Nathan D Trinklein, E Christopher Partridge, Richard M Myers, Job Dekker, Gaurav Jain, Bryan R Lajoie, Amartya Sanyal, Gayathri Balasundaram, Daniel L Bates, Rachel Byron, Theresa K Canfield, Morgan J Diegel, Douglas Dunn, Abigail K Ebersol, Tristan Frum, Kavita Garg, Erica Gist, R Scott Hansen, Lisa Boatman, Eric Haugen, Richard Humbert, Gaurav Jain, Audra K Johnson, Ericka M Johnson, Tattyana V Kutyavin, Bryan R Lajoie, Kristen Lee, Dimitra Lotakis, Matthew T Maurano, Shane J Neph, Fiedencio V Neri, Eric D Nguyen, Hongzhu Qu, Alex P Reynolds, Vaughn Roach, Eric Rynes, Peter Sabo, Minerva E Sanchez, Richard S Sandstrom, Amartya Sanyal, Anthony O Shafer, Andrew B Stergachis, Sean Thomas, Robert E Thurman, Benjamin Vernot, Jeff Vierstra, Shinny Vong, Hao Wang, Molly A Weaver, Yongqi Yan, Miaohua Zhang, Joshua M Akey, Michael Bender, Michael O Dorschner, Mark Groudine, Michael J MacCoss, Patrick Navas, George Stamatoyannopoulos, Rajinder Kaul, Job Dekker, John A Stamatoyannopoulos, Ian Dunham, Kathryn Beal, Alvis Brazma, Paul Flicek, Javier Herrero, Nathan Johnson, Damian Keefe, Margus Lukk, Nicholas M Luscombe, Daniel Sobral, Juan M Vaquerizas, Steven P Wilder, Serafim Batzoglou, Arend Sidow, Nadine Hussami, Sofia Kyriazopoulou-Panagiotopoulou, Max W Libbrecht, Marc A Schaub, Anshul Kundaje, Ross C Hardison, Webb Miller, Belinda Giardine, Robert S Harris, Weisheng Wu, Peter J Bickel, Balazs Banfalvi, Nathan P Boley, James B Brown, Haiyan Huang, Qunhua Li, Jingyi Jessica Li, William Stafford Noble, Jeffrey A Bilmes, Orion J Buske, Michael M Hoffman, Avinash D Sahu, Peter V Kharchenko, Peter J Park, Dannon Baker, James Taylor, Zhiping Weng, Sowmya Iyer, Xianjun Dong, Melissa Greven, Xinying Lin, Jie Wang, Hualin S Xi, Jiali Zhuang, Mark Gerstein, Roger P Alexander, Suganthi Balasubramanian, Chao Cheng, Arif Harmanci, Lucas Lochovsky, Renqiang Min, Xinmeng J Mu, Joel Rozowsky, Koon-Kiu Yan, Kevin Y Yip, and Ewan Birney. An integrated encyclopedia of DNA elements in the human genome. *Nature*, 489:57–74, 2012.
- [94] Roadmap Epigenomics Consortium, Anshul Kundaje, Wouter Meuleman, Jason Ernst, Misha Bilenky, Angela Yen, Alireza Heravi-Moussavi, Pouya Kheradpour, Zhizhuo Zhang, Jianrong Wang, Michael J Ziller, Viren Amin, John W Whitaker, Matthew D Schultz, Lucas D Ward, Abhishek Sarkar, Gerald Quon, Richard S Sandstrom, Matthew L Eaton, Yi-Chieh Wu, Andreas Pfenning, Xinchen Wang, Melina Claussnitzer, Yaping Liu, Cristian Coarfa, R Alan Harris, Noam Shores, Charles B Epstein, Elizabetha Gjoneska, Danny Leung, Wei Xie, R David Hawkins, Ryan Lister, Chibo Hong, Philippe Gascard, Andrew J Mungall, Richard Moore, Eric Chuah, Angela Tam, Theresa K Canfield, R Scott Hansen, Rajinder Kaul, Peter J Sabo, Mukul S Bansal, Annaick Carles, Jesse R Dixon, Kai-How Farh, Soheil Feizi, Rosa Karlic, Ah-Ram Kim, Ashwinikumar Kulkarni, Daofeng Li, Rebecca Lowdon, GiNell Elliott, Tim R Mercer, Shane J Neph, Vitor Onuchic, Paz Polak, Nisha Rajagopal, Pradipta Ray, Richard C Sallari, Kyle T Siebenthal, Nicholas A Sinnott-Armstrong, Michael Stevens, Robert E Thurman, Jie Wu, Bo Zhang, Xin Zhou, Nezar Abdennur, Mazhar Adli, Martin Akerman, Luis Barrera, Jessica Antosiewicz-Bourget, Tracy Ballinger, Michael J Barnes, Daniel Bates, Robert J A Bell, David A Bennett, Katherine Bianco, Christoph Bock, Patrick Boyle, Jan Brinchmann, Pedro Caballero-Campo, Raymond Camahort, Marlene J Carrasco-Alfonso, Timothy Charnecki, Huaming Chen, Zhao Chen, Jeffrey B Cheng, Stephanie Cho, Andy Chu, Wen-Yu Chung, Chad Cowan, Qixia Athena Deng, Vikram Deshpande, Morgan Diegel, Bo Ding, Timothy Durham,

Lorigail Echipare, Lee Edsall, David Flowers, Olga Genbacev-Krtolica, Casey Gifford, Shawn Gillespie, Erika Giste, Ian A Glass, Andreas Gnierke, Matthew Gormley, Hongcang Gu, Junchen Gu, David A Hafler, Matthew J Hangauer, Manoj Hariharan, Meital Hatan, Eric Haugen, Yupeng He, Shelly Heimfeld, Sarah Herlofsen, Zhonggang Hou, Richard Humbert, Robbyn Issner, Andrew R Jackson, Haiyang Jia, Peng Jiang, Audra K Johnson, Theresa Kadlecak, Baljit Kamoh, Mirhan Kapidzic, Jim Kent, Audrey Kim, Markus Kleinewietfeld, Sarit Klugman, Jayanth Krishnan, Samantha Kuan, Tanya Kutyavin, Ah-Young Lee, Kristen Lee, Jian Li, Nan Li, Yan Li, Keith L Ligon, Shin Lin, Yingt Lin, Jie Liu, Yuxuan Liu, C John Luckey, Yussanne P Ma, Cecile Maire, Alexander Marson, John S Mattick, Michael Mayo, Michael McMaster, Hayden Metsky, Tarjei Mikkelsen, Diane Miller, Mohammad Miri, Eran Mukame, Raman P Nagarajan, Fidencio Neri, Joseph Nery, Tung Nguyen, Henriette O'Geen, Sameer Paithankar, Thalia Papayannopoulou, Mattia Pelizzola, Patrick Plettnr, Nicholas E Propson, Sriram Raghuraman, Brian J Raney, Anthony Raubitschek, Alex P Reynolds, Hunter Richards, Kevin Riehle, Paolo Rinaudo, Joshua F Robinson, Nicole B Rockweiler, Evan Rosen, Eric Rynes, Jacqueline Schein, Renee Sears, Terrence Sejnowski, Anthony Shafer, Li Shen, Robert Shoemaker, Mahvash Sigaroudinia, Igor Slukvin, Sandra Stehling-Sun, Ron Stewart, Sai Lakshmi Subramanian, Kran Suknuntha, Scott Swanson, Shulan Tian, Hannah Tilden, Linus Tsai, Mark Urich, Ian Vaughn, Jeff Vierstra, Shinny Vong, Ulrich Wagner, Hao Wang, Tao Wang, Yunfei Wang, Arthur Weiss, Holly Whitton, Andre Wildberg, Heather Witt, Kyoung-Jae Won, Mingchao Xie, Xiaoyun Xing, Iris Xu, Zhenyu Xuan, Zhen Ye, Chia-an Yen, Pengzhi Yu, Xian Zhang, Xiaolan Zhang, Jianxin Zhao, Yan Zhou, Jiang Zhu, Yun Zhu, Steven Ziegler, Arthur E Beaudet, Laurie A Boyer, Philip L De Jager, Peggy J Farnham, Susan J Fisher, David Haussler, Steven J M Jones, Wei Li, Marco A Marra, Michael T McManus, Shamil Sunyaev, James A Thomson, Thea D Tlsty, Li-Huei Tsai, Wei Wang, Robert A Waterland, Michael Q Zhang, Lisa H Chadwick, Bradley E Bernstein, Joseph F Costello, Joseph R Ecker, Martin Hirst, Alexander Meissner, Aleksandar Milosavljevic, Bing Ren, John A Stamatoyannopoulos, Ting Wang, Manolis Kellis, Anshul Kundaje, Wouter Meuleman, Jason Ernst, Misha Bilenky, Angela Yen, Alireza Heravi-Moussavi, Pouya Kheradpour, Zhizhuo Zhang, Jianrong Wang, Michael J Ziller, Viren Amin, John W Whitaker, Matthew D Schultz, Lucas D Ward, Abhishek Sarkar, Gerald Quon, Richard S Sandstrom, Matthew L Eaton, Yi-Chieh Wu, Andreas R Pfenning, Xinchen Wang, Melina Claussnitzer, Yaping Liu, Cristian Coarfa, R Alan Harris, Noam Shores, Charles B Epstein, Elizabetha Gjoneska, Danny Leung, Wei Xie, R David Hawkins, Ryan Lister, Chibo Hong, Philippe Gascard, Andrew J Mungall, Richard Moore, Eric Chuah, Angela Tam, Theresa K Canfield, R Scott Hansen, Rajinder Kaul, Peter J Sabo, Mukul S Bansal, Annaick Carles, Jesse R Dixon, Kai-How Farh, Soheil Feizi, Rosa Karlic, Ah-Ram Kim, Ashwinikumar Kulkarni, Daofeng Li, Rebecca Lowdon, GiNell Elliott, Tim R Mercer, Shane J Neph, Vitor Onuchic, Paz Polak, Nisha Rajagopal, Pradipta Ray, Richard C Sallari, Kyle T Sieben-thall, Nicholas A Sinnott-Armstrong, Michael Stevens, Robert E Thurman, Jie Wu, Bo Zhang, Xin Zhou, Arthur E Beaudet, Laurie A Boyer, Philip L De Jager, Peggy J Farnham, Susan J Fisher, David Haussler, Steven J M Jones, Wei Li, Marco A Marra, Michael T McManus, Shamil Sunyaev, James A Thomson, Thea D Tlsty, Li-Huei Tsai, Wei Wang, Robert A Waterland, Michael Q Zhang, Lisa H Chadwick, Bradley E Bernstein, Joseph F Costello, Joseph R Ecker, Martin Hirst, Alexander Meissner, Aleksandar Milosavljevic, Bing Ren, John A Stamatoyannopoulos, Ting Wang, and

- Manolis Kellis. Integrative analysis of 111 reference human epigenomes. *Nature*, 518:317–330, 2015.
- [95] John M Greally. A user’s guide to the ambiguous word ‘epigenetics’. *Nature Reviews Molecular Cell Biology*, 19:207–208, 2018.
- [96] Adrian Bird. Perceptions of epigenetics. *Nature*, 447:396–398, 2007.
- [97] C.-t. Wu and J R Morris. Genes, Genetics, and Epigenetics: A Correspondence. *Science*, 293(5532):1103–1105, 2001.
- [98] C David Allis and Thomas Jenuwein. The molecular hallmarks of epigenetic control. *Nature Reviews Genetics*, 17:487–500, 2016.
- [99] Danny Reinberg and Lynne D Vales. Chromatin domains rich in inheritance. *Science*, 361(6397):33–34, 2018.
- [100] Patrick Trojer and Danny Reinberg. Facultative Heterochromatin: Is There a Distinctive Molecular Signature? *Molecular Cell*, 28(1):1–13, 2007.
- [101] Akina Hoshino, Steve Horvath, Akshayalakshmi Sridhar, Alex Chitsazan, and Thomas A Reh. Synchrony and asynchrony between an epigenetic clock and developmental timing. *Scientific Reports*, 9(1):3770, 2019.
- [102] Steve Horvath. DNA methylation age of human tissues and cell types. *Genome Biology*, 14(10):3156, 2013.
- [103] Daniel A Petkovich, Dmitriy I Podolskiy, Alexei V Lobanov, Sang-Goo Lee, Richard A Miller, and Vadim N Gladyshev. Using DNA Methylation Profiling to Evaluate Biological Age and Longevity Interventions. *Cell Metabolism*, 25(4):954–960.e6, 2017.
- [104] Margarita V Meer, Dmitriy I Podolskiy, Alexander Tyshkovskiy, and Vadim N Gladyshev. A whole lifespan mouse multi-tissue DNA methylation clock. *eLife*, 7:e40675, 2018.
- [105] Thomas A. Rando and Howard Y. Chang. Aging, Rejuvenation, and Epigenetic Reprogramming: Resetting the Aging Clock. *Cell*, 148(1):46–57, 2012.
- [106] Nelly Olova, Daniel J Simpson, Riccardo E Marioni, and Tamir Chandra. Partial reprogramming induces a steady decline in epigenetic age before loss of somatic identity. *Aging Cell*, 18(1):e12877, 2019.
- [107] V K Rakyan, T A Down, D J Balding, and S Beck. Epigenome-wide association studies for common human diseases. *Nat Rev Genet*, 12:529–541, 2011.
- [108] James M Flanagan. Epigenome-Wide Association Studies (EWAS): Past, Present, and Future. In Mukesh Verma, editor, *Cancer Epigenetics: Risk Assessment, Diagnosis, Treatment and Prognosis*, pages 51–63. Springer New York, New York, NY, 2015.
- [109] R Edgar, M Domrachev, and AE Lash. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Research*, 30(1):207–210, 2002.

- [110] Erfan Aref-Eshghi, David I. Rodenhiser, Laila C. Schenkel, Hanxin Lin, Cindy Skinner, Peter Ainsworth, Guillaume Paré, Rebecca L. Hood, Dennis E. Bulman, Kristin D. Kernoohan, Kym M. Boycott, Philippe M. Campeau, Charles Schwartz, and Bekim Sadikovic. Genomic DNA Methylation Signatures Enable Concurrent Diagnosis and Clinical Genetic Variant Classification in Neurodevelopmental Syndromes. *American Journal of Human Genetics*, 102(1):156–174, 2018.
- [111] M Bibikova, J Le, B Barnes, S Saedinia-Melnyk, L Zhou, R Shen, and K L Gunderson. Genome-wide DNA methylation profiling using Infinium® assay. *Epigenomics*, 1(1):177–200, 2009.
- [112] M Bibikova, B Barnes, C Tsan, V Ho, B Klotzle, J M Le, D Delano, L Zhang, G P Schroth, K L Gunderson, J B Fan, and R Shen. High density DNA methylation array with single CpG site resolution. *Genomics*, 98(4):288–295, 2011.
- [113] Ruth Pidsley, Elena Zotenko, Timothy J Peters, Mitchell G Lawrence, Gail P Risbridger, Peter Molloy, Susan Van Djik, Beverly Muhlhausler, Clare Stirzaker, and Susan J Clark. Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. *Genome Biology*, 17(1):208, 2016.
- [114] Sean Davis and Paul S Meltzer. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. *Bioinformatics*, 23(14):1846–1847, 2007.
- [115] C S Wilhelm-Benartzi, D C Koestler, M R Karagas, J M Flanagan, B C Christensen, K T Kelsey, C J Marsit, E A Houseman, and R Brown. Review of processing and analysis methods for DNA methylation array data. *Br J Cancer*, 109(6):1394–1402, 2013.
- [116] Tiffany J Morris and Stephan Beck. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. *Methods*, 72:3–8, 2015.
- [117] Jie Liu and Kimberly D Siegmund. An evaluation of processing methods for HumanMethylation450 BeadChip data. *BMC Genomics*, 17(1):469, 2016.
- [118] Martin J. Aryee, Andrew E. Jaffe, Hector Corrada-Bravo, Christine Ladd-Acosta, Andrew P. Feinberg, Kasper D. Hansen, and Rafael A. Irizarry. Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics*, 30(10):1363–1369, 2014.
- [119] Timothy J Triche Jr, Daniel J Weisenberger, David Van Den Berg, Peter W Laird, and Kimberly D Siegmund. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. *Nucleic Acids Research*, 41(7):e90, 2013.
- [120] Yi-an Chen, Mathieu Lemire, Sanaa Choufani, Darci T Butcher, Daria Grafodatskaya, Brent W Zanke, Steven Gallinger, Thomas J Hudson, and Rosanna Weksberg. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. *Epigenetics*, 8(2):203–209, 2013.
- [121] Jean-Philippe Fortin and Kasper D. Hansen. minfi guidelines: analysis of 450K data using minfi, 2015.

- [122] P Du, X Zhang, C . C Huang, N Jafari, W A Kibbe, L Hou, and S M Lin. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. *BMC Bioinformatics*, 11:587, 2010.
- [123] Joanna Zhuang, Martin Widswendter, and Andrew E Teschendorff. A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. *BMC Bioinformatics*, 13(1):59, 2012.
- [124] Andrew E Teschendorff, Francesco Marabita, Matthias Lechner, Thomas Bartlett, Jesper Tegner, David Gomez-Cabrero, and Stephan Beck. A Beta-Mixture Quantile Normalisation method for correcting probe design bias in Illumina Infinium 450k DNA methylation data. *Bioinformatics (Oxford, England)*, 29(2):189–196, 2012.
- [125] Sarah Dedeurwaerder, Matthieu Defrance, Emilie Calonne, Hélène Denis, Christos Sotiriou, and François Fuks. Evaluation of the Infinium Methylation 450K technology. *Epigenomics*, 3(6):771–784, 2011.
- [126] Nizar Touleimat and Jörg Tost. Complete pipeline for Infinium® Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. *Epigenomics*, 4(3):325–341, 2012.
- [127] Jovana Maksimovic, Lavinia Gordon, and Alicia Oshlack. SWAN: Subset-quantile Within Array Normalization for Illumina Infinium HumanMethylation450 BeadChips. *Genome Biology*, 13(6):1–12, 2012.
- [128] Andrew E Teschendorff and Shijie C Zheng. Cell-type deconvolution in epigenome-wide association studies: a review and recommendations. *Epigenomics*, 9(5):757–768, 2017.
- [129] Lovisa E Reinius, Nathalie Acevedo, Maaike Joerink, Göran Pershagen, Sven-Erik Dahlén, Dario Greco, Cilla Söderhäll, Annika Scheynius, and Juha Kere. Differential DNA Methylation in Purified Human Blood Cells: Implications for Cell Lineage and Studies on Disease Susceptibility. *PLOS ONE*, 7(7):e41361, 2012.
- [130] Yun Liu, Martin J Aryee, Leonid Padyukov, M Daniele Fallin, Espen Hesselberg, Arni Runarsson, Lovisa Reinius, Nathalie Acevedo, Margaret Taub, Marcus Ronninger, Klementy Shchetynsky, Annika Scheynius, Juha Kere, Lars Alfredsson, Lars Klareskog, Tomas J Ekström, and Andrew P Feinberg. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. *Nature Biotechnology*, 31:142–147, 2013.
- [131] Andrew E Jaffe and Rafael A Irizarry. Accounting for cellular heterogeneity is critical in epigenome-wide association studies. *Genome Biology*, 15(2):R31, 2014.
- [132] Kevin McGregor, Sasha Bernatsky, Ines Colmegna, Marie Hudson, Tomi Pastinen, Aurélie Labbe, and Celia M T Greenwood. An evaluation of methods correcting for cell-type heterogeneity in DNA methylation studies. *Genome Biology*, 17(1):84, 2016.
- [133] Marta Czesnikiewicz-Guzik, Won-Woo Lee, Dapeng Cui, Yuko Hiruma, David L Lamar, Zhi-Zhang Yang, Joseph G Ouslander, Cornelia M Weyand, and Jörg J Goronzy. T cell subset-specific susceptibility to aging. *Clinical Immunology*, 127(1):107–118, 2008.

- [134] Klaudia Kuranda, Jacques Vargaftig, Philippe de la Rochere, Christine Dosquet, Dominique Charron, Florence Bardin, Cecile Tonnelle, Dominique Bonnet, and Michele Goodhardt. Age-related changes in human hematopoietic stem/progenitor cells. *Aging Cell*, 10(3):542–546, 2011.
- [135] Yequn Chen, Yanhong Zhang, Guojun Zhao, Chang Chen, Peixuan Yang, Shu Ye, and Xuerui Tan. Difference in Leukocyte Composition between Women before and after Menopausal Age, and Distinct Sexual Dimorphism. *PLOS ONE*, 11(9):e0162953, 2016.
- [136] Sebastian Seidler, Henning W Zimmermann, Matthias Bartneck, Christian Trautwein, and Frank Tacke. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. *BMC Immunology*, 11(1):30, 2010.
- [137] Angela R Manser and Markus Uhrberg. Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance. *Cancer Immunology, Immunotherapy*, 65(4):417–426, 2016.
- [138] Steve Horvath, Michael Gurven, Morgan E. Levine, Benjamin C. Trumble, Hillard Kaplan, Hooman Allayee, Beate R. Ritz, Brian Chen, Ake T. Lu, Tammy M. Rickabaugh, Beth D. Jamieson, Dianjianyi Sun, Shengxu Li, Wei Chen, Lluis Quintana-Murci, Maud Fagny, Michael S. Kobor, Philip S. Tsao, Alexander P. Reiner, Kerstin L. Edlefsen, Devin Absher, and Themistocles L. Assimes. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome Biology*, 17(1):171, 2016.
- [139] Brian H. Chen, Riccardo E. Marioni, Elena Colicino, Marjolein J. Peters, Cavin K. Ward-Caviness, Pei Chien Tsai, Nicholas S. Roetker, Allan C. Just, Ellen W. Demerath, Weihua Guan, Jan Bressler, Myriam Fornage, Stephanie Studenski, Amy R. Vandiver, Ann Zenobia Moore, Toshiko Tanaka, Douglas P. Kiel, Liming Liang, Pantel Vokonas, Joel Schwartz, Kathryn L. Lunetta, Joanne M. Murabito, Stefania Bandinelli, Dena G. Hernandez, David Melzer, Michael Nalls, Luke C. Pilling, Timothy R. Price, Andrew B. Singleton, Christian Gieger, Rolf Holle, Anja Kretschmer, Florian Kronenberg, Sonja Kunze, Jakob Linseisen, Christine Meisinger, Wolfgang Rathmann, Melanie Waldenberger, Peter M. Visscher, Sonia Shah, Naomi R. Wray, Allan F. McRae, Oscar H. Franco, Albert Hofman, Andri;½ G. Uitterlinden, Devin Absher, Themistocles Assimes, Morgan E. Levine, Ake T. Lu, Philip S. Tsao, Lifang Hou, Jo Ann E. Manson, Cara L. Carty, Andrea Z. LaCroix, Alexander P. Reiner, Tim D. Spector, Andrew P. Feinberg, Daniel Levy, Andrea Baccarelli, Joyce van Meurs, Jordana T. Bell, Annette Peters, Ian J. Deary, James S. Pankow, Luigi Ferrucci, and Steve Horvath. DNA methylation-based measures of biological age: Meta-analysis predicting time to death. *Aging*, 8(9):1844–1865, 2016.
- [140] Alexander J Titus, Rachel M Gallimore, Lucas A Salas, and Brock C Christensen. Cell-type deconvolution from DNA methylation: a review of recent applications. *Human Molecular Genetics*, 26(R2):R216–R224, 2017.
- [141] Andrew E Teschendorff, Charles E Breeze, Shijie C Zheng, and Stephan Beck. A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. *BMC Bioinformatics*, 18(1):105, 2017.

- [142] Andrew E Teschendorff and Caroline L Relton. Statistical and integrative system-level analysis of DNA methylation data. *Nature Reviews Genetics*, 19:129–147, 2018.
- [143] Eugene Andres Houseman, William P Accomando, Devin C Koestler, Brock C Christensen, Carmen J Marsit, Heather H Nelson, John K Wiencke, and Karl T Kelsey. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*, 13:86, 2012.
- [144] Devin C Koestler, Meaghan J Jones, Joseph Usset, Brock C Christensen, Rondi A Butler, Michael S Kobor, John K Wiencke, and Karl T Kelsey. Improving cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). *BMC Bioinformatics*, 17:120, 2016.
- [145] Andrew E. Teschendorff and Shijie C. Zheng. EpiDISH Bioconductor Package, 2017.
- [146] Andrew E. Jaffe. FlowSorted.Blood.450k Bioconductor Package, 2018.
- [147] Aaron M Newman, Chih Long Liu, Michael R Green, Andrew J Gentles, Weiguo Feng, Yue Xu, Chuong D Hoang, Maximilian Diehn, and Ash A Alizadeh. Robust enumeration of cell subsets from tissue expression profiles. *Nature Methods*, 12:453–457, 2015.
- [148] Janko Nikolich-Žugich. The twilight of immunity: emerging concepts in aging of the immune system. *Nature Immunology*, 19(1):10–19, 2018.
- [149] Claudio Franceschi. Inflammaging as a Major Characteristic of Old People: Can It Be Prevented or Cured? *Nutrition Reviews*, 65(s3):S173–S176, 2007.
- [150] Ivan K Chinn, Clare C Blackburn, Nancy R Manley, and Gregory D Sempowski. Changes in primary lymphoid organs with aging. *Seminars in Immunology*, 24(5):309–320, 2012.
- [151] Matthew E Ritchie, Belinda Phipson, Di Wu, Yifang Hu, Charity W Law, Wei Shi, and Gordon K Smyth. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, 43(7):e47, 2015.
- [152] Tianyu Zhu, Shijie C Zheng, Dirk S Paul, Steve Horvath, and Andrew E Teschendorff. Cell and tissue type independent age-associated DNA methylation changes are not rare but common. *Aging*, 10(11):3541–3557, 2018.
- [153] Roderick C Slieker, Maarten van Iterson, René Luijk, Marian Beekman, Daria V Zhernakova, Matthijs H Moed, Hailiang Mei, Michiel van Galen, Patrick Deelen, Marc Jan Bonder, Alexandra Zhernakova, André G Uitterlinden, Ettje F Tigchelaar, Coen D A Stehouwer, Casper G Schalkwijk, Carla J H van der Kallen, Albert Hofman, Diana van Heemst, Eco J de Geus, Jenny van Dongen, Joris Deelen, Leonard H van den Berg, Joyce van Meurs, Rick Jansen, Peter A C ‘t Hoen, Lude Franke, Cisca Wijmenga, Jan H Veldink, Morris A Swertz, Marleen M J van Greevenbroek, Cornelia M van Duijn, Dorret I Boomsma, P Eline Slagboom, Bastiaan T Heijmans, and BIOS Consortium. Age-related accrual of methylomic variability is linked to fundamental ageing mechanisms. *Genome Biology*, 17(1):191, 2016.

- [154] Roderick C Sliker, Caroline L Relton, Tom R Gaunt, P Eline Slagboom, and Bas-tiaan T Heijmans. Age-related DNA methylation changes are tissue-specific with ELOVL2 promoter methylation as exception. *Epigenetics & Chromatin*, 11(1):25, 2018.
- [155] Jenny van Dongen, Michel G Nivard, Gonneke Willemsen, Jouke-Jan Hottenga, Quinta Helmer, Conor V Dolan, Erik A Ehli, Gareth E Davies, Maarten van Iterson, Charles E Breeze, Stephan Beck, BIOS Consortium, Peter A.C.'t Hoen, René Pool, Marleen M J van Greevenbroek, Coen D A Stehouwer, Carla J H van der Kallen, Casper G Schalkwijk, Cisca Wijmenga, Sasha Zhernakova, Ettje F Tigchelaar, Marian Beekman, Joris Deelen, Diana van Heemst, Jan H Veldink, Leonard H van den Berg, Cornelia M van Duijn, Bert A Hofman, André G Uitterlinden, P Mila Jhamai, Michael Verbiest, Marijn Verkerk, Ruud van der Breggen, Jeroen van Rooij, Nico Lakenberg, Hailiang Mei, Jan Bot, Dasha V Zhernakova, Peter van't Hof, Patrick Deelen, Irene Nooren, Matthijs Moed, Martijn Vermaat, René Luijk, Marc Jan Bonder, Freerk van Dijk, Michiel van Galen, Wibowo Arindrarto, Szymon M Kielbasa, Morris A Swertz, Erik W van Zwet, Aaron Isaacs, Lude Franke, H Eka Suchiman, Rick Jansen, Joyce B van Meurs, Bastiaan T Heijmans, P Eline Slagboom, and Dorret I Boomsma. Genetic and environmental influences interact with age and sex in shaping the human methylome. *Nature Communications*, 7:11115, 2016.
- [156] Paolo Garagnani, Maria G Bacalini, Chiara Pirazzini, Davide Gori, Cristina Giuliani, Daniela Mari, Anna M Di Blasio, Davide Gentilini, Giovanni Vitale, Sebastiano Collino, Serge Rezzi, Gastone Castellani, Miriam Capri, Stefano Salvioli, and Claudio Franceschi. Methylation of ELOVL2 gene as a new epigenetic marker of age. *Aging Cell*, 11(6):1132–1134, 2012.
- [157] Renata Zbieć-Piekarska, Magdalena Spólnicka, Tomasz Kupiec, Żanetta Makowska, Anna Spas, Agnieszka Parys-Proszek, Krzysztof Kucharczyk, Rafał Płoski, and Wojciech Branicki. Examination of DNA methylation status of the ELOVL2 marker may be useful for human age prediction in forensic science. *Forensic Science International: Genetics*, 14:161–167, 2015.
- [158] Maria Giulia Bacalini, Joris Deelen, Chiara Pirazzini, Marco De Cecco, Cristina Giuliani, Catia Lanzarini, Francesco Ravaioli, Elena Marasco, Diana Van Heemst, H. Eka D. Suchiman, Roderick Sliker, Enrico Giampieri, Rina Recchioni, Fiorella Marcheselli, Stefano Salvioli, Giovanni Vitale, Fabiola Olivieri, Annemieke M.W. Spijkerman, Martijn E.T. DollCrossed, John M. Sedivy, Gastone Castellani, Claudio Franceschi, Piaternella E. Slagboom, and Paolo Garagnani. Systemic Age-Associated DNA Hypermethylation of ELOVL2 Gene: In Vivo and in Vitro Evidences of a Cell Replication Process. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, 72(8):1015–1023, 2017.
- [159] Shyamalika Gopalan, Oana Carja, Maud Fagny, Etienne Patin, Justin W Myrick, Lisa M McEwen, Sarah M Mah, Michael S Kobor, Alain Froment, Marcus W Feldman, Lluis Quintana-Murci, and Brenna M Henn. Trends in DNA Methylation with Age Replicate Across Diverse Human Populations. *Genetics*, 206(3):1659–1674, 2017.

- [160] G Hannum, J Guinney, L Zhao, L Zhang, G Hughes, and S Sadda. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell*, 49(2):359–367, 2013.
- [161] Maarten van Iterson, Erik W van Zwet, Bastiaan T Heijmans, and the BIOS Consortium. Controlling bias and inflation in epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome Biology*, 18(1):19, 2017.
- [162] Shijie C Zheng, Charles E Breeze, Stephan Beck, and Andrew E Teschendorff. Identification of differentially methylated cell types in epigenome-wide association studies. *Nature Methods*, 15(12):1059–1066, 2018.
- [163] Tina Wang, Brian Tsui, Jason F Kreisberg, Neil A Robertson, Andrew M Gross, Michael Ku Yu, Hannah Carter, Holly M Brown-Borg, Peter D Adams, and Trey Ideker. Epigenetic aging signatures in mice livers are slowed by dwarfism, calorie restriction and rapamycin treatment. *Genome Biology*, 18(1):57, 2017.
- [164] Hehuang Xie, Min Wang, Alexandre De Andrade, Maria De F. Bonaldo, Vasil Galat, Kelly Arndt, Veena Rajaram, Stewart Goldman, Tadanori Tomita, and Marcelo B. Soares. Genome-wide quantitative assessment of variation in DNA methylation patterns. *Nucleic Acids Research*, 39(10):4099–4108, 2011.
- [165] Garrett Jenkinson, Elisabet Pujadas, John Goutsias, and Andrew P Feinberg. Potential energy landscapes identify the information-theoretic nature of the epigenome. *Nature Genetics*, 49:719–729, 2017.
- [166] Steve Horvath. DNAmAge online calculator: <https://dnamage.genetics.ucla.edu/home>, 2013.
- [167] Daniel E Martin-Herranz. demh/epigenetic_aging_clock: Epigenetic ageing clock v1.0.0. GitHub repository: https://github.com/demh/epigenetic_aging_clock/, 2019.
- [168] Olga Troyanskaya, Michael Cantor, Gavin Sherlock, Pat Brown, Trevor Hastie, Robert Tibshirani, David Botstein, and Russ B. Altman. Missing value estimation methods for DNA microarrays. *Bioinformatics*, 17(6):520–525, 2001.
- [169] S Horvath, Y Zhang, P Langfelder, R S Kahn, M P Boks, and K Van Eijk. Aging effects on DNA methylation modules in human brain and blood tissue. *Genome Biol*, 13, 2012.
- [170] Louis Y El Khoury, Tyler Gorrie-Stone, Melissa Smart, Amanda Hughes, Yanchun Bao, Alexandria Andrayas, Joe Burrage, Eilis Hannon, Meena Kumari, Jonathan Mill, and Leonard C Schalkwyk. Properties of the epigenetic clock and age acceleration. *bioRxiv*, page 363143, 2018.
- [171] Riccardo E Marioni, Ian J Deary, Caroline L Relton, Matthew Suderman, Luigi Ferrucci, Brian H Chen, Steve Horvath, Stefania Bandinelli, Stephan Beck, Tiffany Morris, Nancy L Pedersen, and Sara Hägg. Tracking the Epigenetic Clock Across the Human Life Course: A Meta-analysis of Longitudinal Cohort Data. *The Journals of Gerontology: Series A*, 74(1):57–61, 2018.

- [172] Thomas M. Stubbs, Marc Jan Bonder, Anne-Katrien Stark, Felix Krueger, Ferdinand von Meyenn, Oliver Stegle, and Wolf Reik. Multi-tissue DNA methylation age predictor in mouse. *Genome Biology*, 18(1):68, 2017.
- [173] Jeffrey T Leek, Robert B Scharpf, Héctor Corrada Bravo, David Simcha, Benjamin Langmead, W Evan Johnson, Donald Geman, Keith Baggerly, and Rafael A Irizarry. Tackling the widespread and critical impact of batch effects in high-throughput data. *Nature Reviews Genetics*, 11:733–739, 2010.
- [174] Jovana Maksimovic, Alicia Oshlack, Johann A Gagnon-Bartsch, and Terence P Speed. Removing unwanted variation in a differential methylation analysis of Illumina HumanMethylation450 array data. *Nucleic Acids Research*, 43(16):e106–e106, 2015.
- [175] Jean-Philippe Fortin, Aurélie Labbe, Mathieu Lemire, Brent W Zanke, Thomas J Hudson, Elana J Fertig, Celia M T Greenwood, and Kasper D Hansen. Functional normalization of 450k methylation array data improves replication in large cancer studies. *Genome Biology*, 15(11):503, 2014.
- [176] E M Price and Wendy P Robinson. Adjusting for Batch Effects in DNA Methylation Microarray Data, a Lesson Learned , 2018.
- [177] Steve Horvath, Peter Langfelder, Seung Kwak, Jeff Aaronson, Jim Rosinski, Thomas F. Vogt, Marika Eszes, Richard L.M. Faull, Maurice A. Curtis, Henry J. Waldvogel, Oi Wa Choi, Spencer Tung, Harry V. Vinters, Giovanni Coppola, and X. William Yang. Huntington’s disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. *Aging*, 8(7):1485–1512, 2016.
- [178] Steve Horvath. FAQs DNAmAge online calculator: https://horvath.genetics.ucla.edu/html/dnamage/faq.htm#_Toc385147421, 2013.
- [179] Johann A Gagnon-Bartsch and Terence P Speed. Using control genes to correct for unwanted variation in microarray data. *Biostatistics*, 13(3):539–552, 2012.
- [180] Illumina. GenomeStudio® Methylation Module v1.8 User Guide. Technical report, 2010.
- [181] Altuna Akalin. AmpliconBiSeq GitHub repository: findElbow function, 2014.
- [182] Riccardo E Marioni, Sonia Shah, Allan F McRae, Brian H Chen, Elena Colicino, Sarah E Harris, Jude Gibson, Anjali K Henders, Paul Redmond, Simon R Cox, Alison Pattie, Janie Corley, Lee Murphy, Nicholas G Martin, Grant W Montgomery, Andrew P Feinberg, M Daniele Fallin, Michael L Multhaup, Andrew E Jaffe, Roby Joehanes, Joel Schwartz, Allan C Just, Kathryn L Lunetta, Joanne M Murabito, John M Starr, Steve Horvath, Andrea A Baccarelli, Daniel Levy, Peter M Visscher, Naomi R Wray, and Ian J Deary. DNA methylation age of blood predicts all-cause mortality in later life. *Genome Biology*, 16(1):25, 2015.
- [183] Laura Perna, Yan Zhang, Ute Mons, Bernd Holleczek, Kai-Uwe Saum, and Hermann Brenner. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort. *Clinical Epigenetics*, 8(1):64, 2016.

- [184] Marguerite R Irvin, Stella Aslibekyan, Anh Do, Degui Zhi, Bertha Hidalgo, Steven A Claas, Vinodh Srinivasasainagendra, Steve Horvath, Hemant K Tiwari, Devin M Absher, and Donna K Arnett. Metabolic and inflammatory biomarkers are associated with epigenetic aging acceleration estimates in the GOLDN study. *Clinical Epigenetics*, 10(1):56, 2018.
- [185] Zhen Yang, Andrew Wong, Diana Kuh, Dirk S. Paul, Vardhman K. Rakyan, R. David Leslie, Shijie C. Zheng, Martin Widschwendter, Stephan Beck, and Andrew E. Teschendorff. Correlation of an epigenetic mitotic clock with cancer risk. *Genome Biology*, 17(1):205, 2016.
- [186] Isabel Beerman, Christoph Bock, Brian S. Garrison, Zachary D. Smith, Hongcang Gu, Alexander Meissner, and Derrick J. Rossi. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. *Cell Stem Cell*, 12(4):413–425, 2013.
- [187] Ake T Lu, Luting Xue, Elias L Salfati, Brian H Chen, Luigi Ferrucci, Daniel Levy, Roby Joehanes, Joanne M Murabito, Douglas P Kiel, Pei-Chien Tsai, Idil Yet, Jordana T Bell, Massimo Mangino, Toshiko Tanaka, Allan F McRae, Riccardo E Marioni, Peter M Visscher, Naomi R Wray, Ian J Deary, Morgan E Levine, Austin Quach, Themistocles Assimes, Philip S Tsao, Devin Absher, James D Stewart, Yun Li, Alex P Reiner, Lifang Hou, Andrea A Baccarelli, Eric A Whitsel, Abraham Aviv, Alexia Cardona, Felix R Day, Nicholas J Wareham, John R B Perry, Ken K Ong, Kenneth Raj, Kathryn L Lunetta, and Steve Horvath. GWAS of epigenetic aging rates in blood reveals a critical role for TERT. *Nature Communications*, 9(1):387, 2018.
- [188] Mary E. Sehl, Jill E. Henry, Anna Maria Storniolo, Patricia A. Ganz, and Steve Horvath. DNA methylation age is elevated in breast tissue of healthy women. *Breast Cancer Research and Treatment*, 164(1):209–219, 2017.
- [189] Peter M. Visscher, Naomi R. Wray, Qian Zhang, Pamela Sklar, Mark I. McCarthy, Matthew A. Brown, and Jian Yang. 10 Years of GWAS Discovery: Biology, Function, and Translation, 2017.
- [190] Morris L. Eaton. Linear Statistical Models. In *Multivariate Statistics: A Vector Space Approach*, pages 132–158. 2007.
- [191] Simon J. Sheather. *A Modern Approach to Regression with R*. 2009.
- [192] Ake T Lu, Eilis Hannon, Morgan E Levine, Ke Hao, Eileen M Crimmins, Katie Lunnon, Alexey Kozlenkov, Jonathan Mill, Stella Dracheva, and Steve Horvath. Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum. *Nature Communications*, 7:10561, 2016.
- [193] Hans Tomas Bjornsson. The Mendelian disorders of the epigenetic machinery. *Genome Research*, 25(10):1473–1481, 2015.
- [194] Erfan Aref-Eshghi, Laila C Schenkel, Hanxin Lin, Cindy Skinner, Peter Ainsworth, Guillaume Paré, David Rodenhiser, Charles Schwartz, and Bekim Sadikovic. The defining DNA methylation signature of Kabuki syndrome enables functional assessment of genetic variants of unknown clinical significance. *Epigenetics*, 12(11):923–933, 2017.

- [195] Erfan Aref-Eshghi, Eric G Bend, Rebecca L Hood, Laila C Schenkel, Deanna Alexis Carere, Rana Chakrabarti, Sandesh C S Nagamani, Sau Wai Cheung, Philippe M Campeau, Chitra Prasad, Victoria Mok Siu, Lauren Brady, Mark A Tarnopolsky, David J Callen, A Micheil Innes, Susan M White, Wendy S Meschino, Andrew Y Shuen, Guillaume Paré, Dennis E Bulman, Peter J Ainsworth, Hanxin Lin, David I Rodenhiser, Raoul C Hennekam, Kym M Boycott, Charles E Schwartz, and Bekim Sadikovic. BAFopathies' DNA methylation epi-signatures demonstrate diagnostic utility and functional continuum of Coffin–Siris and Nicolaides–Baraitser syndromes. *Nature Communications*, 9(1):4885, 2018.
- [196] Darci T Butcher, Cheryl Cytrynbaum, Andrei L Turinsky, Michelle T Siu, Michal Inbar-Feigenberg, Roberto Mendoza-Londono, David Chitayat, Susan Walker, Jerry Machado, Oana Caluseriu, Lucie Dupuis, Daria Grafodatskaya, William Reardon, Brigitte Gilbert-Dussardier, Alain Verloes, Frederic Bilan, Jeff M Milunsky, Raveen Basran, Blake Papsin, Tracy L Stockley, Stephen W Scherer, Sanaa Choufani, Michael Brudno, and Rosanna Weksberg. CHARGE and Kabuki Syndromes: Gene-Specific DNA Methylation Signatures Identify Epigenetic Mechanisms Linking These Clinically Overlapping Conditions. *The American Journal of Human Genetics*, 100(5):773–788, 2017.
- [197] S Choufani, C Cytrynbaum, B H Y Chung, A L Turinsky, D Grafodatskaya, Y A Chen, A S A Cohen, L Dupuis, D T Butcher, M T Siu, H M Luk, I F M Lo, S T S Lam, O Caluseriu, D J Stavropoulos, W Reardon, R Mendoza-Londono, M Brudno, W T Gibson, D Chitayat, and R Weksberg. NSD1 mutations generate a genome-wide DNA methylation signature. *Nature Communications*, 6:10207, 2015.
- [198] Laila C Schenkel, Charles Schwartz, Cindy Skinner, David I Rodenhiser, Peter J Ainsworth, Guillaume Pare, and Bekim Sadikovic. Clinical Validation of Fragile X Syndrome Screening by DNA Methylation Array. *The Journal of Molecular Diagnostics*, 18(6):834–841, 2016.
- [199] Reid S Alisch, Tao Wang, Pankaj Chopra, Jeannie Visootsak, Karen N Conneely, and Stephen T Warren. Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus. *BMC Medical Genetics*, 14(1):18, 2013.
- [200] Laila C Schenkel, Kristin D Kernohan, Arran McBride, Ditta Reina, Amanda Hodge, Peter J Ainsworth, David I Rodenhiser, Guillaume Pare, Nathalie G Bérubé, Cindy Skinner, Kym M Boycott, Charles Schwartz, and Bekim Sadikovic. Identification of epigenetic signature associated with alpha thalassemia/mental retardation X-linked syndrome. *Epigenetics & Chromatin*, 10(1):10, 2017.
- [201] Rebecca L Hood, Laila C Schenkel, Sarah M Nikkel, Peter J Ainsworth, Guillaume Pare, Kym M Boycott, Dennis E Bulman, and Bekim Sadikovic. The defining DNA methylation signature of Floating-Harbor Syndrome. *Scientific Reports*, 6:38803, 2016.
- [202] Kimberly A Aldinger, Jasmine T Plummer, and Pat Levitt. Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene. *Journal of Neurodevelopmental Disorders*, 5(1):15, 2013.

- [203] Daria Grafodatskaya, Barian H Y Chung, Darci T Butcher, Andrei L Turinsky, Sarah J Goodman, Sana Choufani, Yi-An Chen, Youliang Lou, Chunhua Zhao, Rageen Rajendram, Fatima E Abidi, Cindy Skinner, James Stavropoulos, Carolyn A Bondy, Jill Hamilton, Shoshana Wodak, Stephen W Scherer, Charles E Schwartz, and Rosanna Weksberg. Multilocus loss of DNA methylation in individuals with mutations in the histone H3 Lysine 4 Demethylase KDM5C. *BMC Medical Genomics*, 6(1):1, 2013.
- [204] Kristin D Kernohan, Laila Cigana Schenkel, Lijia Huang, Amanda Smith, Guillaume Pare, Peter Ainsworth, Kym M Boycott, Jodi Warman-Chardon, Bekim Sadikovic, and Care4Rare Canada Consortium. Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy. *Clinical Epigenetics*, 8(1):91, 2016.
- [205] George Leventopoulos, Sophia Kitsiou-Tzeli, Konstantinos Kritikos, Stavroula Psoni, Ariadni Mavrou, Emmanuel Kanavakis, and Helen Fryssira. A Clinical Study of Sotos Syndrome Patients With Review of the Literature. *Pediatric Neurology*, 40(5):357–364, 2009.
- [206] Naohiro Kurotaki, Kiyoshi Imaizumi, Naoki Harada, Mitsuo Masuno, Tatsuro Kon-doh, Toshiro Nagai, Hirofumi Ohashi, Kenji Naritomi, Masato Tsukahara, Yoshio Makita, Tateo Sugimoto, Tohru Sonoda, Tomoko Hasegawa, Yasuaki Chinen, Hiro-aki Tomita, Akira Kinoshita, Tsuyoshi Mizuguchi, Koh-ichiro Yoshiura, Tohru Ohta, Tatsuya Kishino, Yoshimitsu Fukushima, Norio Niikawa, and Naomichi Matsumoto. Haploinsufficiency of NSD1 causes Sotos syndrome. *Nature Genetics*, 30:365–366, 2002.
- [207] John J Cole, Neil A Robertson, Mohammed Iqbal Rather, John P Thomson, Tony McBryan, Duncan Sproul, Tina Wang, Claire Brock, William Clark, Trey Ideker, Richard R Meehan, Richard A Miller, Holly M Brown-Borg, and Peter D Adams. Diverse interventions that extend mouse lifespan suppress shared age-associated epigenetic changes at critical gene regulatory regions. *Genome Biology*, 18(1):58, 2017.
- [208] Lorenzo Rinaldi, Debayan Datta, Judit Serrat, Lluis Morey, Guiomar Solanas, Alexandra Avgustinova, Enrique Blanco, José Ignacio Pons, David Matallanas, Alex Von Kriegsheim, Luciano Di Croce, and Salvador Aznar Benitah. Dnmt3a and Dnmt3b Associate with Enhancers to Regulate Human Epidermal Stem Cell Homeostasis. *Cell Stem Cell*, 19(4):491–501, 2016.
- [209] B E Bernstein, T S Mikkelsen, X Xie, M Kamal, D J Huebert, and J Cuff. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell*, 125(2):315–326, 2006.
- [210] Stephan H Bernhart, Helene Kretzmer, Lesca M Holdt, Frank Jühling, Ole Ammerpohl, Anke K Bergmann, Bernd H Northoff, Gero Doose, Reiner Siebert, Peter F Stadler, and Steve Hoffmann. Changes of bivalent chromatin coincide with increased expression of developmental genes in cancer. *Scientific Reports*, 6:37393, 2016.
- [211] Steve Horvath and Kenneth Raj. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nature Reviews Genetics*, 19(6):371–384, 2018.

- [212] Adam E. Field, Neil A. Robertson, Tina Wang, Aaron Havas, Trey Ideker, and Peter D. Adams. DNA Methylation Clocks in Aging: Categories, Causes, and Consequences. *Molecular Cell*, 71(6):882–895, 2018.
- [213] Eric J Wagner and Phillip B Carpenter. Understanding the language of Lys36 methylation at histone H3. *Nature Reviews Molecular Cell Biology*, 13:115–126, 2012.
- [214] Armelle Luscan, Ingrid Laurendeau, Valérie Malan, Christine Francannet, Sylvie Odent, Fabienne Giuliano, Didier Lacombe, Renaud Touraine, Michel Vidaud, Eric Pasmant, and Valérie Cormier-Daire. Mutations in SETD2 cause a novel overgrowth condition. *Journal of Medical Genetics*, 51(8):512–517, 2014.
- [215] Stephen L McDaniel, Austin J Hepperla, Jie Huang, Raghavar Dronamraju, Alexander T Adams, Vidyadhar G Kulkarni, Ian J Davis, and Brian D Strahl. H3K36 Methylation Regulates Nutrient Stress Response in *Saccharomyces cerevisiae* by Enforcing Transcriptional Fidelity. *Cell Reports*, 19(11):2371–2382, 2017.
- [216] Zhuoyu Ni, Atsushi Ebata, Elham Alipanahiramandi, and Siu Sylvia Lee. Two SET domain containing genes link epigenetic changes and aging in *Caenorhabditis elegans*. *Aging Cell*, 11(2):315–325, 2012.
- [217] Payel Sen, Weiwei Dang, Greg Donahue, Junbiao Dai, Jean Dorsey, Xiaohua Cao, Wei Liu, Kajia Cao, Rocco Perry, Jun Yeop Lee, Brian M. Wasko, Daniel T. Carr, Chong He, Brett Robison, John Wagner, Brian D. Gregory, Matt Kaeberlein, Brian K. Kennedy, Jef D. Boeke, and Shelley L. Berger. H3K36 methylation promotes longevity by enhancing transcriptional fidelity. *Genes and Development*, 29(13):1362–1376, 2015.
- [218] Mintie Pu, Zhuoyu Ni, Minghui Wang, Xiujuan Wang, Jason G. Wood, Stephen L. Helfand, Haiyuan Yu, and Siu Sylvia Lee. Trimethylation of Lys36 on H3 restricts gene expression change during aging and impacts life span. *Genes and Development*, 29(7):718–731, 2015.
- [219] Dirk Schübeler. Function and information content of DNA methylation. *Nature*, 517(7534):321–326, 2015.
- [220] Arunkumar Dhayalan, Arumugam Rajavelu, Philipp Rathert, Raluca Tamas, Renata Z. Jurkowska, Sergey Ragozin, and Albert Jeltsch. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. *Journal of Biological Chemistry*, 285:26114–26120, 2010.
- [221] Tuncay Baubec, Daniele F. Colombo, Christiane Wirbelauer, Juliane Schmidt, Lukas Burger, Arnaud R. Krebs, Altuna Akalin, and Dirk Schübeler. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. *Nature*, 520(7546):243–247, 2015.
- [222] Patricia Heyn, Clare V Logan, Adeline Fluteau, Rachel C Challis, Tatsiana Auchynnikava, Carol-Anne Martin, Joseph A Marsh, Francesca Taglini, Fiona Kilanowski, David A Parry, Valerie Cormier-Daire, Chin-To Fong, Kate Gibson, Vivian Hwa, Lourdes Ibáñez, Stephen P Robertson, Giorgia Sebastiani, Juri Rappaport, Robin C Allshire, Martin A M Reijns, Andrew Dauber, Duncan Sproul, and Andrew P Jackson.

- Gain-of-function DNMT3A mutations cause microcephalic dwarfism and hypermethylation of Polycomb-regulated regions. *Nature Genetics*, 51(1):96–105, 2019.
- [223] Vardhman K. Rakyan, Thomas A. Down, Siarhei Maslau, Toby Andrew, Tsun Po Yang, Huriya Beyan, Pamela Whittaker, Owen T. McCann, Sarah Finer, Ana M. Valdes, R. David Leslie, Panagiotis Deloukas, and Timothy D. Spector. Human aging-associated DNA hypermethylation occurs preferentially at bivalent chromatin domains. *Genome Research*, 20:434–439, 2010.
- [224] Andrew E. Teschendorff, Usha Menon, Aleksandra Gentry-Maharaj, Susan J. Ramus, Daniel J. Weisenberger, Hui Shen, Mihaela Campan, Houtan Noushmehr, Christopher G. Bell, A. Peter Maxwell, David A. Savage, Elisabeth Mueller-Holzner, Christian Marth, Gabrijela Kocjan, Simon A. Gayther, Allison Jones, Stephan Beck, Wolfgang Wagner, Peter W. Laird, Ian J. Jacobs, and Martin Widschwendter. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. *Genome Research*, 20(4):440–446, 2010.
- [225] Wei Xie, Matthew D. Schultz, Ryan Lister, Zhonggang Hou, Nisha Rajagopal, Pradipta Ray, John W. Whitaker, Shulan Tian, R. David Hawkins, Danny Leung, Hongbo Yang, Tao Wang, Ah Young Lee, Scott A. Swanson, Jiuchun Zhang, Yun Zhu, Audrey Kim, Joseph R. Nery, Mark A. Urich, Samantha Kuan, Chia-an Yen, Sarit Klugman, Pengzhi Yu, Kran Suknuntha, Nicholas E. Propson, Huaming Chen, Lee E. Edsall, Ulrich Wagner, Yan Li, Zhen Ye, Ashwinikumar Kulkarni, Zhenyu Xuan, Wen-Yu Chung, Neil C. Chi, Jessica E. Antosiewicz-Bourget, Igor Slukvin, Ron Stewart, Michael Q. Zhang, Wei Wang, James A. Thomson, Joseph R. Ecker, and Bing Ren. Epigenomic Analysis of Multilineage Differentiation of Human Embryonic Stem Cells. *Cell*, 153(5):1134–1148, 2013.
- [226] Hannah K Long, David Sims, Andreas Heger, Neil P Blackledge, Claudia Kutter, Megan L Wright, Frank Grützner, Duncan T Odom, Roger Patient, Chris P Ponting, and Robert J Klose. Epigenetic conservation at gene regulatory elements revealed by non-methylated DNA profiling in seven vertebrates. *eLife*, 2:e00348, 2013.
- [227] Mira Jeong, Deqiang Sun, Min Luo, Yun Huang, Grant A Challen, Benjamin Rodriguez, Xiaotian Zhang, Lukas Chavez, Hui Wang, Rebecca Hannah, Sang-Bae Kim, Liubin Yang, Myunggon Ko, Rui Chen, Berthold Göttgens, Ju-Seog Lee, Preethi Guanaratne, Lucy A Godley, Gretchen J Darlington, Anjana Rao, Wei Li, and Margaret A Goodell. Large conserved domains of low DNA methylation maintained by Dnmt3a. *Nature Genetics*, 46:17–23, 2013.
- [228] Yuanyuan Li, Hui Zheng, Qiuju Wang, Chen Zhou, Lei Wei, Xuehui Liu, Wenhao Zhang, Yu Zhang, Zhenhai Du, Xiaowo Wang, and Wei Xie. Genome-wide analyses reveal a role of Polycomb in promoting hypomethylation of DNA methylation valleys. *Genome Biology*, 19(1):18, 2018.
- [229] Sophie Chantalat, Arnaud Depaux, Patrick Héry, Sophie Barral, Jean Yves Thuret, Stefan Dimitrov, and Matthieu Gérard. Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin. *Genome Research*, 21:1426–1437, 2011.

- [230] Taiping Chen, Naomi Tsujimoto, and En Li. The PWP Domain of Dnmt3a and Dnmt3b Is Required for Directing DNA Methylation to the Major Satellite Repeats at Pericentric Heterochromatin. *Molecular and Cellular Biology*, 24(20):9048–9058, 2004.
- [231] Aaron R Jeffries, Reza Maroofian, Claire G Salter, Barry A Chioza, Harold E Cross, Michael A Patton, I Karen Temple, Deborah Mackay, Faisal I Rezwan, Lise Aksela, Diana Baralle, Tabir Dabir, Matthew Frank Hunter, Arveen Kamath, Ajith Kumar, Ruth Newbury-Ecob, Angelo Selicorni, Amanda Springer, Lionel van Maldergem, Vinod Varghese, Naomi Yachelevich, Katrina Tatton-Brown, Jonathan Mill, Andrew H Crosby, and Emma Baple. Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging. *bioRxiv*, page 477356, 2018.
- [232] Francesco Neri, Stefania Rapelli, Anna Krepelova, Danny Incarnato, Caterina Parlato, Giulia Basile, Mara Maldotti, Francesca Anselmi, and Salvatore Oliviero. Intragenic DNA methylation prevents spurious transcription initiation. *Nature*, 543(7643):72–77, 2017.
- [233] Huilin Huang, Hengyou Weng, Keren Zhou, Tong Wu, Boxuan Simen Zhao, Mingli Sun, Zhenhua Chen, Xiaolan Deng, Gang Xiao, Franziska Auer, Lars Klemm, Huijie Wu, Zhixiang Zuo, Xi Qin, Yunzhu Dong, Yile Zhou, Hanjun Qin, Shu Tao, Juan Du, Jun Liu, Zhike Lu, Hang Yin, Ana Mesquita, Celvie L Yuan, Yueh-Chiang Hu, Wenju Sun, Rui Su, Lei Dong, Chao Shen, Chenying Li, Ying Qing, Xi Jiang, Xiwei Wu, Miao Sun, Jun-Lin Guan, Lianghu Qu, Minjie Wei, Markus Müschen, Gang Huang, Chuan He, Jianhua Yang, and Jianjun Chen. Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. *Nature*, 567(7748):414–419, 2019.
- [234] Kyung-Won Min, Richard W Zealy, Sylvia Davila, Mikhail Fomin, James C Cummings, Daniel Makowsky, Catherine H McDowell, Haley Thigpen, Markus Hafner, Sang-Ho Kwon, Constantin Georgescu, Jonathan D Wren, and Je-Hyun Yoon. Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. *Aging Cell*, 17(3):e12753, 2018.
- [235] Gundula Streubel, Ariane Watson, Sri Ganesh Jammula, Andrea Scelfo, Darren J Fitzpatrick, Giorgio Oliviero, Rachel McCole, Eric Conway, Eleanor Glancy, Gian Luca Negri, Eugene Dillon, Kieran Wynne, Diego Pasini, Nevan J Krogan, Adrian P Bracken, and Gerard Cagney. The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. *Molecular Cell*, 70(2):371–379.e5, 2018.
- [236] Eugene Froimchuk, Younghoon Jang, and Kai Ge. Histone H3 lysine 4 methyltransferase KMT2D. *Gene*, 627:337–342, 2017.
- [237] Payel Sen, Parisha P. Shah, Raffaella Nativio, and Shelley L. Berger. Epigenetic Mechanisms of Longevity and Aging. *Cell*, 166(4):822–839, 2016.
- [238] Zymo Research. EZ DNA methylation-Direct™ Kit. Technical report.
- [239] Illumina. Infinium® HD Assay Methylation Protocol Guide. Technical report, 2015.

- [240] William McLaren, Laurent Gil, Sarah E Hunt, Harpreet Singh Riat, Graham R S Ritchie, Anja Thormann, Paul Flicek, and Fiona Cunningham. The Ensembl Variant Effect Predictor. *Genome Biology*, 17(1):122, 2016.
- [241] Andreas S Richter, Devon P Ryan, Fabian Kilpert, Fidel Ramírez, Steffen Heyne, and Thomas Manke. pyBigWig GitHub Repository.
- [242] Weiwei Zhang, Tim D Spector, Panos Deloukas, Jordana T Bell, and Barbara E Engelhardt. Predicting genome-wide DNA methylation using methylation marks, genomic position, and DNA regulatory elements. *Genome biology*, 16(1):14, 2015.
- [243] Wanding Zhou, Huy Q Dinh, Zachary Ramjan, Daniel J Weisenberger, Charles M Nicolet, Hui Shen, Peter W Laird, and Benjamin P Berman. DNA methylation loss in late-replicating domains is linked to mitotic cell division. *Nature Genetics*, 50(4):591–602, 2018.
- [244] Ryan K Dale, Brent S Pedersen, and Aaron R Quinlan. Pybedtools: a flexible Python library for manipulating genomic datasets and annotations. *Bioinformatics*, 27(24):3423–3424, 2011.
- [245] Adam Frankish, Alexandra Bignell, Andrew Berry, Andrew Yates, Anne Parker, Bianca M Schmitt, Bronwen Aken, Carlos García Girón, Daniel Zerbino, Eloise Stapeleton, Fergal J Martin, Fiona Cunningham, If Barnes, Irina Sycheva, Jane Loveland, Jonathan M Mudge, Jose Manuel Gonzalez, Magali Ruffier, Marie-Marthe Suner, Matthew Hardy, Osagie G Izuogu, Sarah Donaldson, Shamika Mohanan, Thibaut Hourlier, Tiago Grego, Toby Hunt, Paul Flicek, James Wright, Jyoti S Choudhary, Julien Lagarde, Silvia Carbonell Sala, Roderic Guigó, Fernando Pozo, Laura Martínez, Michael L Tress, Tomás Di Domenico, Paul Muir, Barbara Uszczynska-Ratajczak, Benedict Paten, Ian T Fiddes, Joel Armstrong, Mark Diekhans, Tim J P Hubbard, Alexandre Reymond, Anne-Maud Ferreira, Jacqueline Chrast, Rory Johnson, Irwin Jungreis, Manolis Kellis, Baikang Pei, Fabio C P Navarro, Jinuri Xu, Yan Zhang, Mark Gerstein, and Cristina Sisu. GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Research*, 47(D1):D766–D773, 2018.
- [246] C Bock, J Walter, M Paulsen, and T Lengauer. CpG island mapping by epigenome prediction. *PLoS Comput Biol*, 3(6):e110, 2007.
- [247] Daniel E Martin-Herranz, António J. M. Ribeiro, Felix Krueger, Janet M Thornton, Wolf Reik, and Thomas M Stubbs. cuRRBS: simple and robust evaluation of enzyme combinations for reduced representation approaches. *Nucleic Acids Research*, 45(20):11559–11569, 2017.
- [248] NIH Roadmap Epigenomics Mapping Consortium. Roadmap Epigenomics Chromatin State Model: raw data. https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/imputed12marks/jointModel/final/catMat/hg19_chromHMM_imputed25.gz.
- [249] NIH Roadmap Epigenomics Mapping Consortium. Roadmap Epigenomics Chromatin State Model: emission parameters. https://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/imputed12marks/jointModel/final/emissions_25_imputed12marks.png.

- [250] Jay Shendure and Hanlee Ji. Next-generation DNA sequencing. *Nature Biotechnology*, 26:1135, 2008.
- [251] International Human Genome Sequencing Consortium, Eric S Lander, Lauren M Linton, Bruce Birren, Chad Nusbaum, Michael C Zody, Jennifer Baldwin, Keri Devon, Ken Dewar, Michael Doyle, William FitzHugh, Roel Funke, Diane Gage, Katrina Harris, Andrew Heaford, John Howland, Lisa Kann, Jessica Lehoczky, Rosie LeVine, Paul McEwan, Kevin McKernan, James Meldrim, Jill P Mesirov, Cher Miranda, William Morris, Jerome Naylor, Christina Raymond, Mark Rosetti, Ralph Santos, Andrew Sheridan, Carrie Sougnez, Nicole Stange-Thomann, Nikola Stojanovic, Aravind Subramanian, Dudley Wyman, Jane Rogers, John Sulston, Rachael Ainscough, Stephan Beck, David Bentley, John Burton, Christopher Cleo, Nigel Carter, Alan Coulson, Rebecca Deadman, Panos Deloukas, Andrew Dunham, Ian Dunham, Richard Durbin, Lisa French, Darren Grafham, Simon Gregory, Tim Hubbard, Sean Humphray, Adrienne Hunt, Matthew Jones, Christine Lloyd, Amanda McMurray, Lucy Matthews, Simon Mercer, Sarah Milne, James C Mullikin, Andrew Mungall, Robert Plumb, Mark Ross, Ratna Showkeen, Sarah Sims, Robert H Waterston, Richard K Wilson, LaDeana W Hillier, John D McPherson, Marco A Marra, Elaine R Mardis, Lucinda A Fulton, Asif T Chinwalla, Kymberlie H Pepin, Warren R Gish, Stephanie L Chissoe, Michael C Wendl, Kim D Delehaunty, Tracie L Miner, Andrew Delehaunty, Jason B Kramer, Lisa L Cook, Robert S Fulton, Douglas L Johnson, Patrick J Minx, Sandra W Clifton, Trevor Hawkins, Elbert Branscomb, Paul Predki, Paul Richardson, Sarah Wenning, Tom Slezak, Norman Doggett, Jan-Fang Cheng, Anne Olsen, Susan Lucas, Christopher Elkin, Edward Uberbacher, Marvin Frazier, Richard A Gibbs, Donna M Muzny, Steven E Scherer, John B Bouck, Erica J Sodergren, Kim C Worley, Catherine M Rives, James H Gorrell, Michael L Metzker, Susan L Naylor, Raju S Kucherlapati, David L Nelson, George M Weinstock, Yoshiyuki Sakaki, Asao Fujiyama, Masahira Hattori, Tetsushi Yada, Atsushi Toyoda, Takehiko Itoh, Chiharu Kawagoe, Hidemi Watanabe, Yasushi Totoki, Todd Taylor, Jean Weissenbach, Roland Heilig, William Saurin, Francois Artiguenave, Philippe Brottier, Thomas Bruls, Eric Pelletier, Catherine Robert, Patrick Wincker, André Rosenthal, Matthias Platzer, Gerald Nyakatura, Stefan Taudien, Andreas Rump, Douglas R Smith, Lynn Doucette-Stamm, Marc Rubenfield, Keith Weinstock, Hong Mei Lee, JoAnn Dubois, Huanming Yang, Jun Yu, Jian Wang, Guyang Huang, Jun Gu, Leroy Hood, Lee Rowen, Anup Madan, Shizhen Qin, Ronald W Davis, Nancy A Federspiel, A Pia Abola, Michael J Proctor, Bruce A Roe, Feng Chen, Huaqin Pan, Juliane Ramser, Hans Lehrach, Richard Reinhardt, W Richard McCombie, Melissa de la Bastide, Neilay Dedhia, Helmut Blöcker, Klaus Hornischer, Gabriele Nordsiek, Richa Agarwala, L Aravind, Jeffrey A Bailey, Alex Bateman, Serafim Batzoglou, Ewan Birney, Peer Bork, Daniel G Brown, Christopher B Burge, Lorenzo Cerutti, Hsiu-Chuan Chen, Deanna Church, Michele Clamp, Richard R Copley, Tobias Doerks, Sean R Eddy, Evan E Eichler, Terrence S Furey, James Galagan, James G R Gilbert, Cyrus Harmon, Yoshihide Hayashizaki, David Haussler, Henning Hermjakob, Karsten Hokamp, Wonhee Jang, L Steven Johnson, Thomas A Jones, Simon Kasif, Arek Kaspryzk, Scot Kennedy, W James Kent, Paul Kitts, Eugene V Koonin, Ian Korf, David Kulp, Doron Lancet, Todd M Lowe, Aoife McLysaght, Tarjei Mikkelsen, John V Moran, Nicola Mulder, Victor J Pollara, Chris P Ponting, Greg Schuler, Jörg Schultz, Guy Slater, Arian F A Smit, Elia Stupka, Joseph Szustakowski, Danielle Thierry-Mieg, Jean Thierry-Mieg, Lukas Wagner, John Wallis, Raymond Wheeler, Alan Williams, Yuri I Wolf, Kenneth H Wolfe, Shiaw-Pyng Yang,

- Ru-Fang Yeh, Francis Collins, Mark S Guyer, Jane Peterson, Adam Felsenfeld, Kris A Wetterstrand, Richard M Myers, Jeremy Schmutz, Mark Dickson, Jane Grimwood, David R Cox, Maynard V Olson, Rajinder Kaul, Christopher Raymond, Nobuyoshi Shimizu, Kazuhiko Kawasaki, Shinsei Minoshima, Glen A Evans, Maria Athanasiou, Roger Schultz, Aristides Patrinos, and Michael J Morgan. Initial sequencing and analysis of the human genome. *Nature*, 409:860–921, 2001.
- [252] Mouse Genome Sequencing Consortium, Asif T Chinwalla, Lisa L Cook, Kimberly D Delehaunty, Ginger A Fewell, Lucinda A Fulton, Robert S Fulton, Tina A Graves, LaDeana W Hillier, Elaine R Mardis, John D McPherson, Tracie L Miner, William E Nash, Joanne O Nelson, Michael N Nhan, Kymberlie H Pepin, Craig S Pohl, Tracy C Ponce, Brian Schultz, Johanna Thompson, Ewanne Trevaskis, Robert H Waterston, Michael C Wendl, Richard K Wilson, Shiaw-Pyng Yang, Peter An, Eric Berry, Bruce Birren, Toby Bloom, Daniel G Brown, Jonathan Butler, Mark Daly, Robert David, Justin Deri, Sheila Dodge, Karen Foley, Diane Gage, Sante Gnerre, Timothy Holzer, David B Jaffe, Michael Kamal, Elinor K Karlsson, Cristyn Kells, Andrew Kirby, Edward J Kulbokas III, Eric S Lander, Tom Landers, J P Leger, Rosie Levine, Kerstin Lindblad-Toh, Evan Mauceli, John H Mayer, Megan McCarthy, Jim Meldrim, Jim Meldrim, Jill P Mesirov, Robert Nicol, Chad Nusbaum, Steven Seaman, Ted Sharpe, Andrew Sheridan, Jonathan B Singer, Ralph Santos, Brian Spencer, Nicole Stange-Thomann, Jade P Vinson, Claire M Wade, Jamey Wierzbowski, Dudley Wyman, Michael C Zody, Ewan Birney, Nick Goldman, Arkadiusz Kasprzyk, Emmanuel Mongin, Alistair G Rust, Guy Slater, Arne Stabenau, Abel Ureta-Vidal, Simon Whelan, Rachel Ainscough, John Attwood, Jonathon Bailey, Karen Barlow, Stephan Beck, John Burton, Michele Clamp, Christopher Clee, Alan Coulson, James Cuff, Val Curwen, Tim Cutts, Joy Davies, Eduardo Eyras, Darren Grahams, Simon Gregory, Tim Hubbard, Adrienne Hunt, Matthew Jones, Ann Joy, Steven Leonard, Christine Lloyd, Lucy Matthews, Stuart McLaren, Kirsten McLay, Beverley Meredith, James C Mullikin, Zemin Ning, Karen Oliver, Emma Overton-Larty, Robert Plumb, Simon Potter, Michael Quail, Jane Rogers, Carol Scott, Steve Searle, Ratna Shownkeen, Sarah Sims, Melanie Wall, Anthony P West, David Willey, Sophie Williams, Josep F Abril, Roderic Guigó, Genís Parra, Pankaj Agarwal, Richa Agarwala, Deanna M Church, Wratko Hlavina, Donna R Maglott, Victor Sapojnikov, Marina Alexandersson, Lior Pachter, Stylianos E Antonarakis, Emmanouil T Dermitzakis, Alexandre Reymond, Catherine Ucla, Robert Baertsch, Mark Diekhans, Terrence S Furey, Angela Hinrichs, Fan Hsu, Donna Karolchik, W James Kent, Krishna M Roskin, Matthias S Schwartz, Charles Sugnet, Ryan J Weber, Peer Bork, Ivica Letunic, Mikita Suyama, David Torrents, Evgeny M Zdobnov, Marc Botcherby, Stephen D Brown, Robert D Campbell, Ian Jackson, Nicolas Bray, Olivier Couronne, Inna Dubchak, Alex Poliakov, Edward M Rubin, Michael R Brent, Paul Flicek, Evan Keibler, Ian Korf, S Batalov, Carol Bult, Wayne N Frankel, Piero Carninci, Yoshihide Hayashizaki, Jun Kawai, Yasushi Okazaki, Simon Cawley, David Kulp, Raymond Wheeler, Francesca Chiaromonte, Francis S Collins, Adam Felsenfeld, Mark Guyer, Jane Peterson, Kris Wetterstrand, Richard R Copley, Richard Mott, Colin Dewey, Nicholas J Dickens, Richard D Emes, Leo Goodstadt, Chris P Ponting, Eitan Winter, Diane M Dunn, Andrew C von Niederhausern, Robert B Weiss, Sean R Eddy, L Steven Johnson, Thomas A Jones, Laura Elnitski, Diana L Kolbe, Pallavi Eswara, Webb Miller, Michael J O'Connor, Scott Schwartz, Richard A Gibbs, Donna M Muzny, Gustavo Glusman, Arian Smit, Eric D Green, Ross C Hardison, Shan Yang, David Haussler, Axin Hua, Bruce A Roe,

- Raju S Kucherlapati, Kate T Montgomery, Jia Li, Ming Li, Susan Lucas, Bin Ma, W Richard McCombie, Michael Morgan, Pavel Pevzner, Glenn Tesler, Jörg Schultz, Douglas R Smith, John Tromp, Kim C Worley, Eric S Lander, Josep F Abril, Pankaj Agarwal, Marina Alexandersson, Stylianos E Antonarakis, Robert Baertsch, Eric Berry, Ewan Birney, Peer Bork, Nicolas Bray, Michael R Brent, Daniel G Brown, Jonathan Butler, Carol Bult, Francesca Chiaromonte, Asif T Chinwalla, Deanna M Church, Michele Clamp, Francis S Collins, Richard R Copley, Olivier Couronne, Simon Cawley, James Cuff, Val Curwen, Tim Cutts, Mark Daly, Emmanouil T Dermitzakis, Colin Dewey, Nicholas J Dickens, Mark Diekhans, Inna Dubchak, Sean R Eddy, Laura Elnitski, Richard D Emes, Pallavi Eswara, Eduardo Eyras, Adam Felsenfeld, Paul Flicek, Wayne N Frankel, Lucinda A Fulton, Terrence S Furey, Sante Gnerre, Gustavo Glusman, Nick Goldman, Leo Goodstadt, Eric D Green, Simon Gregory, Roderic Guigó, Ross C Hardison, David Haussler, LaDeana W Hillier, Angela Hinrichs, Wratko Hlavina, Fan Hsu, Tim Hubbard, David B Jaffe, Michael Kamal, Donna Karolchik, Elinor K Karlsson, Arkadiusz Kasprzyk, Evan Keibler, W James Kent, Andrew Kirby, Diana L Kolbe, Ian Korf, Edward J Kulkosky III, David Kulp, Eric S Lander, Ivica Letunic, Ming Li, Kerstin Lindblad-Toh, Bin Ma, Donna R Maglott, Evan Mauceli, Jill P Mesirov, Webb Miller, Richard Mott, James C Mullikin, Zemin Ning, Lior Pachter, Genís Parra, Pavel Pevzner, Alex Poliakov, Chris P Ponting, Simon Potter, Alexandre Reymond, Krishna M Roskin, Victor Sapojnikov, Jörg Schultz, Matthias S Schwartz, Scott Schwartz, Steve Searle, Jonathan B Singer, Guy Slater, Arian Smit, Arne Stabenau, Charles Sugnet, Mikita Suyama, Glenn Tesler, David Torrents, John Tromp, Catherine Ucla, Jade P Vinson, Claire M Wade, Ryan J Weber, Raymond Wheeler, Eitan Winter, Shiaw-Pyng Yang, Evgeny M Zdobnov, Robert H Waterston, Simon Whelan, Kim C Worley, and Michael C Zody. Initial sequencing and comparative analysis of the mouse genome. *Nature*, 420:520–562, 2002.
- [253] Nicolas Sierro, James N D Battey, Sonia Ouadi, Nicolas Bakaher, Lucien Bovet, Adrian Willig, Simon Goepfert, Manuel C Peitsch, and Nikolai V Ivanov. The tobacco genome sequence and its comparison with those of tomato and potato. *Nature Communications*, 5:3833, 2014.
- [254] Matteo Fumagalli. Assessing the Effect of Sequencing Depth and Sample Size in Population Genetics Inferences. *PLOS ONE*, 8(11):e79667, 2013.
- [255] Hao Wu, Tianlei Xu, Hao Feng, Li Chen, Ben Li, Bing Yao, Zhaohui Qin, Peng Jin, and Karen N Conneely. Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates. *Nucleic Acids Research*, 43(21):e141–e141, 2015.
- [256] M J Ziller, H Gu, F Mueller, J Donaghey, L T Tsai, and O Kohlbacher. Charting a dynamic DNA methylation landscape of the human genome. *Nature*, 500:477–481, 2013.
- [257] Masako Suzuki and John M Greally. Genome-wide DNA Methylation Analysis Using Massively Parallel Sequencing Technologies. *Seminars in Hematology*, 50(1):70–77, 2013.

- [258] Nongluk Plongthongkum, Dinh H Diep, and Kun Zhang. Advances in the profiling of DNA modifications: cytosine methylation and beyond. *Nat Rev Genet*, 15(10):647–661, 2014.
- [259] Wai-Shin Yong, Fei-Man Hsu, and Pao-Yang Chen. Profiling genome-wide DNA methylation. *Epigenetics & Chromatin*, 9(1):26, 2016.
- [260] S. Kurdyukov and M. Bullock. DNA Methylation Analysis: Choosing the Right Method. *Biology*, 5(1):3, 2016.
- [261] Thadeous J Kacmarczyk, Mame P Fall, Xihui Zhang, Yuan Xin, Yushan Li, Alicia Alonso, and Doron Betel. “Same difference”: comprehensive evaluation of four DNA methylation measurement platforms. *Epigenetics & Chromatin*, 11(1):21, 2018.
- [262] Oluwatosin Taiwo, Gareth A Wilson, Tiffany Morris, Stefanie Seisenberger, Wolf Reik, Daniel Pearce, Stephan Beck, and Lee M Butcher. Methylome analysis using MeDIP-seq with low DNA concentrations. *Nature Protocols*, 7:617–636, 2012.
- [263] Arie B Brinkman, Femke Simmer, Kelong Ma, Anita Kaan, Jingde Zhu, and Hendrik G Stunnenberg. Whole-genome DNA methylation profiling using MethylCap-seq. *Methods*, 52(3):232–236, 2010.
- [264] Edita Kriukienė, Viviane Labrie, Tarang Khare, Giedrė Urbanavičiūtė, Audronė Lapinaitytė, Karolis Koncevičius, Daofeng Li, Ting Wang, Shraddha Pai, Carolyn Ptak, Juozas Gordevičius, Sun-Chong Wang, Artūras Petronis, and Saulius Klimašauskas. DNA unmethylome profiling by covalent capture of CpG sites. *Nature Communications*, 4:2190, 2013.
- [265] Maxim Ivanov, Mart Kals, Marina Kacevska, Andres Metspalu, Magnus Ingelman-Sundberg, and Lili Milani. In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. *Nucleic Acids Research*, 41(6):e72, 2013.
- [266] Fiona Allum, Xiaojian Shao, Frédéric Guénard, Marie-Michelle Simon, Stephan Busche, Maxime Caron, John Lambourne, Julie Lessard, Karolina Tandre, Åsa K Hedman, Tony Kwan, Bing Ge, The Multiple Tissue Human Expression Resource Consortium, Kourosh R Ahmadi, Chrysanthi Ainali, Amy Barrett, Veronique Bataille, Jordana T Bell, Alfonso Buil, Emmanouil T Dermitzakis, Antigone S Dimas, Richard Durbin, Daniel Glass, Neelam Hassanali, Catherine Ingle, David Knowles, Maria Krestyaninova, Cecilia M Lindgren, Christopher E Lowe, Eshwar Meduri, Paola di Meglio, Josine L Min, Stephen B Montgomery, Frank O Nestle, Alexandra C Nica, James Nisbet, Stephen O’Rahilly, Leopold Parts, Simon Potter, Johanna Sandling, Magdalena Sekowska, So-Youn Shin, Kerrin S Small, Nicole Soranzo, Gabriela Surdulescu, Mary E Travers, Loukia Tsaprouni, Sophia Tsoka, Alicja Wilk, Tsun-Po Yang, Krina T Zondervan, Lars Rönnblom, Mark I McCarthy, Panos Deloukas, Todd Richmond, Daniel Burgess, Timothy D Spector, André Tchernof, Simon Marceau, Mark Lathrop, Marie-Claude Vohl, Tomi Pastinen, and Elin Grundberg. Characterization of functional methylomes by next-generation capture sequencing identifies novel disease-associated variants. *Nature Communications*, 6:7211, 2015.

- [267] Warren A Cheung, Xiaojian Shao, Andréanne Morin, Valérie Siroux, Tony Kwan, Bing Ge, Dylan Aïssi, Lu Chen, Louella Vasquez, Fiona Allum, Frédéric Guénard, Emmanuelle Bouzigon, Marie-Michelle Simon, Elodie Boulier, Adriana Redensek, Stephen Watt, Avik Datta, Laura Clarke, Paul Fliceck, Daniel Mead, Dirk S Paul, Stephan Beck, Guillaume Bourque, Mark Lathrop, André Tchernof, Marie-Claude Vohl, Florence Demenais, Isabelle Pin, Kate Downes, Hendrick G Stunnenberg, Nicole Soranzo, Tomi Pastinen, and Elin Grundberg. Functional variation in allelic methylomes underscores a strong genetic contribution and reveals novel epigenetic alterations in the human epigenome. *Genome Biology*, 18(1):50, 2017.
- [268] Emily Hodges, Andrew D. Smith, Jude Kendall, Zhenyu Xuan, Kandasamy Ravi, Michelle Rooks, Michael Q. Zhang, Kenny Ye, Arindam Bhattacharjee, Leonardo Brizuela, W. Richard McCombie, Michael Wigler, Gregory J. Hannon, and James B. Hicks. High definition profiling of mammalian DNA methylation by array capture and single molecule bisulfite sequencing. *Genome Research*, 19:1593–1605, 2009.
- [269] Jie Deng, Robert Shoemaker, Bin Xie, Athurva Gore, Emily M LeProust, Jessica Antosiewicz-Bourget, Dieter Egli, Nimet Maherali, In-Hyun Park, Junying Yu, George Q Daley, Kevin Eggan, Konrad Hochedlinger, James Thomson, Wei Wang, Yuan Gao, and Kun Zhang. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. *Nature Biotechnology*, 27:353–360, 2009.
- [270] Dinh Diep, Nongluk Plongthongkum, Athurva Gore, Ho-Lim Fung, Robert Shoemaker, and Kun Zhang. Library-free methylation sequencing with bisulfite padlock probes. *Nature Methods*, 9:270–272, 2012.
- [271] H. Kiyomi Komori, Sarah A. LaMere, Ali Torkamani, G. Traver Hart, Steve Kotopoulous, Jason Warner, Michael L. Samuels, Jeff Olson, Steven R. Head, Phillip Ordoukhanian, Pauline L. Lee, Darren R. Link, and Daniel R. Salomon. Application of microdroplet PCR for large-scale targeted bisulfite sequencing. *Genome Research*, 21(10):1738–1745, 2011.
- [272] Dirk S. Paul, Paul Guilhamon, Anna Karpathakis, Lee M. Butcher, Christina Thirlwell, Andrew Feber, and Stephan Beck. Assessment of raindrop BS-seq as a method for large-scale, targeted bisulfite sequencing. *Epigenetics*, 9(5):678–684, 2014.
- [273] Diana L Bernstein, Vasumathi Kameswaran, John E Le Lay, Karyn L Sheaffer, and Klaus H Kaestner. The BisPCR2 method for targeted bisulfite sequencing. *Epigenetics & Chromatin*, 8:27, 2015.
- [274] Yao Yang, Robert Sebra, Benjamin S Pullman, Wanqiong Qiao, Inga Peter, Robert J Desnick, C Ronald Geyer, John F DeCoteau, and Stuart A Scott. Quantitative and multiplexed DNA methylation analysis using long-read single-molecule real-time bisulfite sequencing (SMRT-BS). *BMC Genomics*, 16(1):350, 2015.
- [275] Howard Cedar, Adina Solage, Gad Glaser, and Aharon Razin. Direct detection of methylated cytosine in DNA by use of the restriction enzyme MspI. *Nucleic Acids Research*, 6(6):2125–2132, 1979.

- [276] Devora Cohen-Karni, Derrick Xu, Lynne Apone, Alexey Fomenkov, Zhiyi Sun, Paul J Davis, Shannon R Morey Kinney, Megumu Yamada-Mabuchi, Shuang-yong Xu, Theodore Davis, Sriharsa Pradhan, Richard J Roberts, and Yu Zheng. The MspJI family of modification-dependent restriction endonucleases for epigenetic studies. *Proceedings of the National Academy of Sciences*, 108(27):11040–11045, 2011.
- [277] Leonid V Bystrykh. A combinatorial approach to the restriction of a mouse genome. *BMC Research Notes*, 6(1):284, 2013.
- [278] Daniel B Martinez-Arguelles, Sunghoon Lee, and Vassilios Papadopoulos. In silico analysis identifies novel restriction enzyme combinations that expand reduced representation bisulfite sequencing CpG coverage. *BMC research notes*, 7(1):534, 2014.
- [279] Li Yu, Chunhui Liu, Kristi Bennett, Yue-Zhong Wu, Zunyan Dai, Jeff Vandeven, Rene Opavsky, Aparna Raval, Prashant Trikha, Ben Rodriguez, Brian Becknell, Charlene Mao, Stephen Lee, Ramana V Davuluri, Gustavo Leone, Ignatia B Van den Veyver, Michael A Caligiuri, and Christoph Plass. A NotI–EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. *Genomics*, 84(4):647–660, 2004.
- [280] Alexander Meissner, Tarjei S Mikkelsen, Hongcang Gu, Marius Wernig, Jacob Hanna, Andrey Sivachenko, Xiaolan Zhang, Bradley E Bernstein, Chad Nusbaum, David B Jaffe, Andreas Gnirke, Rudolf Jaenisch, and Eric S Lander. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature*, 454(7205):766–70, 2008.
- [281] Patrick Boyle, Kendell Clement, Hongcang Gu, Zachary D Smith, Michael Ziller, Jennifer L Fostel, Laurie Holmes, Jim Meldrim, Fontina Kelley, Andreas Gnirke, and Alexander Meissner. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. *Genome Biology*, 13(10):R92, 2012.
- [282] Alexander Meissner, Andreas Gnirke, George W. Bell, Bernard Ramsahoye, Eric S. Lander, and Rudolf Jaenisch. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. *Nucleic Acids Research*, 33(18):5868–5877, 2005.
- [283] Alexander S Tanas, Marina E Borisova, Ekaterina B Kuznetsova, Viktoria V Rudenko, Kristina O Karandasheva, Marina V Nemtsova, Vera L Izhevskaya, Olga A Simonova, Sergey S Larin, Dmitry V Zaletaev, and Vladimir V Strelnikov. Rapid and affordable genome-wide bisulfite DNA sequencing by XmaI-reduced representation bisulfite sequencing. *Epigenomics*, 9(6):833–847, 2017.
- [284] Yew Kok Lee, Shengnan Jin, Shiwei Duan, Yen Ching Lim, Desmond P Y Ng, Xueqin Michelle Lin, George S H Yeo, and Chunming Ding. Improved reduced representation bisulfite sequencing for epigenomic profiling of clinical samples. *Biological Procedures Online*, 16(1):1, 2014.
- [285] Yen Ching Lim, Sook Yoong Chia, Shengnan Jin, Weiping Han, Chunming Ding, and Lei Sun. Dynamic DNA methylation landscape defines brown and white cell specificity during adipogenesis. *Molecular Metabolism*, 5(10):1033–1041, 2016.

- [286] Xiaojun Huang, Hanlin Lu, Jun-Wen Wang, Liqin Xu, Siyang Liu, Jihua Sun, and Fei Gao. High-throughput sequencing of methylated cytosine enriched by modification-dependent restriction endonuclease MspJI. *BMC Genetics*, 14(1):56, 2013.
- [287] Junwen Wang, Yudong Xia, Lili Li, Desheng Gong, Yu Yao, Huijuan Luo, Hanlin Lu, Na Yi, Honglong Wu, Xiuqing Zhang, Qian Tao, and Fei Gao. Double restriction-enzyme digestion improves the coverage and accuracy of genome-wide CpG methylation profiling by reduced representation bisulfite sequencing. *BMC genomics*, 14:11, 2013.
- [288] Sophie A Kirschner, Oliver Hunewald, Sophie B Mériaux, Regina Brunnhofer, Claude P Muller, and Jonathan D Turner. Focussing reduced representation CpG sequencing through judicious restriction enzyme choice. *Genomics*, 107(4):109–119, 2016.
- [289] Hongcang Gu, Christoph Bock, Tarjei S Mikkelsen, Natalie Jäger, Zachary D Smith, Eleni Tomazou, Andreas Gnirke, Eric S Lander, and Alexander Meissner. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. *Nature methods*, 7(2):133–136, 2010.
- [290] Zachary D. Smith, Hongcang Gu, Christoph Bock, Andreas Gnirke, and Alexander Meissner. High-throughput bisulfite sequencing in mammalian genomes. *Methods*, 48(3):226–232, 2009.
- [291] Carmen M Koch and Wolfgang Wagner. Epigenetic-aging-signature to determine age in different tissues. *Aging*, 3(10):1018–1027, 2011.
- [292] Michael J. Thompson, Karolina Chwiałkowska, Liudmilla Rubbi, Aldons J. Lusis, Richard C. Davis, Anuj Srivastava, Ron Korstanje, Gary A. Churchill, Steve Horvath, and Matteo Pellegrini. A multi-tissue full lifespan epigenetic clock for mice. *Aging*, 10(10):2832–2854, 2018.
- [293] Michael J. Thompson, Bridgett von Holdt, Steve Horvath, and Matteo Pellegrini. An epigenetic aging clock for dogs and wolves. *Aging*, 9(3):1055–1068, 2017.
- [294] Daniel E Martin-Herranz, Erfan Aref-Eshghi, Marc Jan Bonder, Thomas M Stubbs, Oliver Stegle, Bekim Sadikovic, Wolf Reik, and Janet M Thornton. Screening for genes that accelerate the epigenetic ageing clock in humans reveals a role for the H3K36 methyltransferase NSD1. *bioRxiv*, page 545830, 2019.
- [295] Steve Horvath, Junko Oshima, George M. Martin, Ake T. Lu, Austin Quach, Howard Cohen, Sarah Felton, Mieko Matsuyama, Donna Lowe, Sylwia Kabacik, James G. Wilson, Alex P. Reiner, Anna Maierhofer, Julia Flunkert, Abraham Aviv, Lifang Hou, Andrea A. Baccarelli, Yun Li, James D. Stewart, Eric A. Whitsel, Luigi Ferrucci, Shigemi Matsuyama, and Kenneth Raj. Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. *Aging*, 10(7):1758–1775, 2018.
- [296] Courtney W. Hanna, Maria S. Peñaherrera, Heba Saadeh, Simon Andrews, Deborah E. McFadden, Gavin Kelsey, and Wendy P. Robinson. Pervasive polymorphic imprinted methylation in the human placenta. *Genome Research*, 26:756–767, 2016.

- [297] Inês Milagre, Thomas M Stubbs, Michelle R King, Julia Spindel, Fátima Santos, Felix Krueger, Martin Bachman, Anne Segonds-Pichon, Shankar Balasubramanian, Simon R Andrews, Wendy Dean, and Wolf Reik. Gender Differences in Global but Not Targeted Demethylation in iPSC Reprogramming. *Cell Reports*, 18(5):1079–1089, 2017.
- [298] Taiji Kawakatsu, Shao-shan Carol Huang, Florian Jupe, Eriko Sasaki, Robert J Schmitz, Mark A Urich, Rosa Castanon, Joseph R Nery, Cesar Barragan, Yupeng He, Huaming Chen, Manu Dubin, Cheng-Ruei Lee, Congmao Wang, Felix Bemm, Claude Becker, Ryan O’Neil, Ronan C O’Malley, Danjuma X Quarless, Carlos Alonso-Blanco, Jorge Andrade, Claude Becker, Felix Bemm, Joy Bergelson, Karsten Borgwardt, Eunyoung Chae, Todd DeZwaan, Wei Ding, Joseph R Ecker, Moisés Expósito-Alonso, Ashley Farlow, Joffrey Fitz, Xiangchao Gan, Dominik G Grimm, Angela Hancock, Stefan R Henz, Svante Holm, Matthew Horton, Mike Jarsulic, Randall A Kerstetter, Arthur Korte, Pamela Korte, Christa Lanz, Chen-Ruei Lee, Dazhe Meng, Todd P Michael, Richard Mott, Ni Wayan Mulyati, Thomas Nägele, Matthias Nagler, Viktoria Nizhynska, Magnus Nordborg, Polina Novikova, F Xavier Picó, Alexander Platzter, Fernando A Rabanal, Alex Rodriguez, Beth A Rowan, Patrice A Salomé, Karl Schmid, Robert J Schmitz, Ümit Seren, Felice Gianluca Sperone, Mitchell Sudkamp, Hannes Svardal, Matt M Tanzer, Donald Todd, Samuel L Volchenboum, Congmao Wang, George Wang, Xi Wang, Wolfram Weckwerth, Detlef Weigel, Xuefeng Zhou, Nicholas J Schork, Detlef Weigel, Magnus Nordborg, and Joseph R Ecker. Epigenomic Diversity in a Global Collection of *Arabidopsis thaliana* Accessions. *Cell*, 166(2):492–505, 2016.
- [299] Matthew T. Maurano, Hao Wang, Sam John, Anthony Shafer, Theresa Canfield, Kristen Lee, and John A. Stamatoyannopoulos. Role of DNA Methylation in Modulating Transcription Factor Occupancy. *Cell Reports*, 12(7):1184–1195, 2015.
- [300] Galit Lev Maor, Ahuvi Yearim, and Gil Ast. The alternative role of DNA methylation in splicing regulation. *Trends in Genetics*, 31(5):274–280, 2015.
- [301] Silvia Domcke, Anaïs Flore Bardet, Paul Adrian Ginno, Dominik Hartl, Lukas Burger, and Dirk Schübeler. Competition between DNA methylation and transcription factors determines binding of NRF1. *Nature*, 528(7583):575–579, 2015.
- [302] Hume Stroud, Truman Do, Jiamu Du, Xuehua Zhong, Suhua Feng, Lianna Johnson, Dinshaw J Patel, and Steven E Jacobsen. Non-CG methylation patterns shape the epigenetic landscape in *Arabidopsis*. *Nature Structural & Molecular Biology*, 21:64–72, 2013.
- [303] Yan Sun, Rui Hou, Xiaoteng Fu, Changsen Sun, Shi Wang, Chen Wang, Ning Li, Lingling Zhang, and Zhenmin Bao. Genome-Wide Analysis of DNA Methylation in Five Tissues of Zhikong Scallop, *Chlamys farreri*. *PLOS ONE*, 9(1):e86232, 2014.
- [304] Christof Angermueller, Heather J Lee, Wolf Reik, and Oliver Stegle. DeepCpG: accurate prediction of single-cell DNA methylation states using deep learning. *Genome Biology*, 18(1):67, 2017.
- [305] John W Davey and Mark L Blaxter. RADSeq: next-generation population genetics. *Briefings in Functional Genomics*, 9(5-6):416–423, 2011.

- [306] John W Davey, Paul A Hohenlohe, Paul D Etter, Jason Q Boone, Julian M Catchen, and Mark L Blaxter. Genome-wide genetic marker discovery and genotyping using next-generation sequencing. *Nature Reviews Genetics*, 12:499–510, 2011.
- [307] Natalia Naumova, Emily M Smith, Ye Zhan, and Job Dekker. Analysis of long-range chromatin interactions using Chromosome Conformation Capture. *Methods*, 58(3):192–203, 2012.
- [308] Job Dekker, Marc A Marti-Renom, and Leonid A Mirny. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. *Nature Reviews Genetics*, 14:390–403, 2013.
- [309] Richard J Roberts, Tamas Vincze, Janos Posfai, and Dana Macelis. REBASE—restriction enzymes and DNA methyltransferases. *Nucleic Acids Research*, 33(suppl_1):D230–D232, 2005.
- [310] Richard J Roberts, Tamas Vincze, Janos Posfai, and Dana Macelis. REBASE—a database for DNA restriction and modification: enzymes, genes and genomes. *Nucleic Acids Research*, 43(D1):D298–D299, 2015.
- [311] Jennifer Harrow, Adam Frankish, Jose M. Gonzalez, Electra Tapanari, Mark Diekhans, Felix Kokocinski, Bronwen L. Aken, Daniel Barrell, Amonida Zadissa, Stephen Searle, If Barnes, Alexandra Bignell, Veronika Boychenko, Toby Hunt, Mike Kay, Gaurab Mukherjee, Jeena Rajan, Gloria Despacio-Reyes, Gary Saunders, Charles Steward, Rachel Harte, Michael Lin, Cédric Howald, Andrea Tanzer, Thomas Derrien, Jacqueline Chrast, Nathalie Walters, Suganthi Balasubramanian, Baikang Pei, Michael Tress, Jose Manuel Rodriguez, Lakes Ezkurdia, Jeltje Van Baren, Michael Brent, David Haussler, Manolis Kellis, Alfonso Valencia, Alexandre Reymond, Mark Gerstein, Roderic Guigó, and Tim J. Hubbard. GENCODE: The reference human genome annotation for the ENCODE project. *Genome Research*, 22:1760–1774, 2012.
- [312] Leila Taher, Robin P Smith, Mee J Kim, Nadav Ahituv, and Ivan Ovcharenko. Sequence signatures extracted from proximal promoters can be used to predict distal enhancers. *Genome Biology*, 14(10):R117, 2013.
- [313] Aaron R Quinlan and Ira M Hall. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*, 26(6):841–842, 2010.
- [314] Peter J A Cock, Tiago Antao, Jeffrey T. Chang, Brad A. Chapman, Cymon J. Cox, Andrew Dalke, Iddo Friedberg, Thomas Hamelryck, Frank Kauff, Bartek Wilczynski, and Michiel J L De Hoon. Biopython: Freely available Python tools for computational molecular biology and bioinformatics. *Bioinformatics*, 25(11):1422–1423, 2009.
- [315] Daniel E Martin-Herranz, Antonio JM Ribeiro, and Thomas M Stubbs. demh/cuRRBS: cuRRBS V1.0.4, aug 2017.
- [316] Robert M Kuhn, David Haussler, and W James Kent. The UCSC genome browser and associated tools. *Briefings in Bioinformatics*, 14(2):144–161, 2012.

- [317] Anthony Mathelier, Oriol Fornes, David J Arenillas, Chih-yu Chen, Grégoire Denay, Jessica Lee, Wenqiang Shi, Casper Shyr, Ge Tan, Rebecca Worsley-Hunt, Allen W Zhang, François Parcy, Boris Lenhard, Albin Sandelin, and Wyeth W Wasserman. JAS-PAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. *Nucleic Acids Research*, 44(D1):D110–D115, 2015.
- [318] Anaïs F. Bardet, Jonas Steinmann, Sangeeta Bafna, Juergen A. Knoblich, Julia Zeitlinger, and Alexander Stark. Identification of transcription factor binding sites from ChIP-seq data at high resolution. *Bioinformatics*, 29(21):2705–2713, 2013.
- [319] Felix Krueger and Simon R Andrews. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics*, 27(11):1571–1572, 2011.